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GENERAL INTRODUCTION AND OUTLINE OF THE THESIS
General introduction
Obesity is currently a major health problem and is developing into a global epidemic. 
Obesity is classified by the Body Mass Index (BMI) (table 1) and is defined as abnormal 
or excessive fat accumulation which can cause health problems. The World Health Or-
ganisation’s (WHO) latest projections indicate that, globally in 2005, approximately 1.6 
billion adults (age 15+) were overweight, and at least 400 million adults were obese. The 
WHO further predicts that - by 2015- approximately 2.3 billion adults will be overweight 
and more than 700 million will be obese. High body mass index has overtaken tobacco 
smoking as the most costly and detrimental preventable cause of deadly diseases in the 
United States(1).







The prevalence and incidence of asthma has increased over the recent decades(2, 3). 
Besides an improved awareness of the disease, there are several other explanations for 
the increased asthma prevalence, such as decreased exposure to microbial products, 
changes in microbiota, increased exposure to air pollution and tobacco smoke, a change 
in diet and obesity(3). As the incidence and prevalence of obesity have increased con-
currently with the incidence and prevalence of asthma (as shown in Figure 1 for the 
Netherlands), this is suggestive for a possible link between obesity and asthma(4, 5). The 
observation that asthma symptoms decrease after weight loss with either bariatric 
surgery or low caloric diet supports a causal relationship between obesity and asthma(5). 
Moreover, obese patients with persistent asthma have significantly worse asthma-
related quality of life(6), less asthma control(7, 8), more severe disease(9-12), and more 
asthma-related hospital admissions than asthma patients with a normal BMI.  As asthma 
is a heterogeneous disease, with different underlying disease processes, recognizable 
clusters of demographic, clinical and/or pathophysiological characteristics are called 
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Figure 1 Temporal trends of obesity and asthma in the Netherlands
Temporal trends in the prevalence of obesity in adults and asthma in the Netherlands. The dotted line 
represents the prevalence of asthma, while the solid line represents the prevalence of obesity. Asthma year 
prevalence is standardized to population of the Netherlands in 2010 and is index-linked to 1992 (source 
CMR-Nijmegen). Obesity data are standardized to age- and gender distribution of 1981 (source CBS stat-
line, 2013).
Diagnosis of asthma in the morbidly obese
According to the latest Global Initiative for Asthma (GINA) definition of 2014, asthma 
is a heterogeneous disease, usually characterized by chronic airway inflammation. It is 
defined by the history of respiratory symptoms such as wheeze, shortness of breath, 
chest tightness and cough that vary over time and in intensity, together with variable 
expiratory airflow limitation(13).
GINA guidelines advise that asthma diagnosis should be based on both the presence 
of symptoms and objective measurements of variable expiratory airflow limitation(13). 
However, in daily practice the diagnosis of asthma is mainly based on symptoms, and 
spirometry or provocation tests are not always performed(14). Since obese subjects re-
port more dyspnea than non-obese subjects(15, 16), it might be that they get mislabelled 
as asthma (overdiagnosis). Inevitably, any overdiagnosis may lead to inappropriate 
treatment(14), with increased risk of side-effects and increased costs(17).
Many epidemiological studies concerning obesity and asthma have used physician-
diagnosed asthma without confirmation by pulmonary function tests. This implies, as 
discussed earlier, reasonable doubt as to the accuracy of the diagnosis of asthma. Sev-
eral studies report that the diagnosis of asthma could be revisited after extensive testing 
in 30% of physician-diagnosed asthma(18-20), even after stopping with asthma medica-
tion(21). On the other hand, missing the diagnosis of asthma in the obese population 
is also an important aspect. Impaired perception of dyspnea is thought to play a role 
especially in severe asthma(22, 23), and poor perception of airflow obstruction may lead 
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to under-treatment of asthma(24, 25). All the recent studies investigating overdiagnosis of 
asthma in the obese(20, 21, 26) initially used selected subjects with asthma, and therefore 
did not take into account obese patients with so far undetected asthma. Therefore, only 
limited information is available about the underdiagnosis of asthma in the obese.
Bronchial and systemic inflammation in the morbidly obese
Obesity and asthma relationship
The mechanisms underlying the relationship between asthma and obesity are unclear. 
In previous reviews concerning the relationship between obesity and asthma, five hy-
potheses were suggested (figure 2)(27).
 
Figure 2 Explaining the obesity-asthma association
First, the diet of obese people consists of food with less nutritional value, fewer vi-
tamins and more fat. A high amount of fat intake is associated with asthma(28). Mineral 
deficiencies such as zinc- and magnesium deficiencies are associated with asthma and 
bronchial hyperreactivity (BHR)(29). Second, asthma and obesity may share the same 
genetic risk factors. In a large-scale study among 1384 twins, a strong association be-
tween asthma and BMI was found(30). The third hypothesis is that shared co-morbidities 
link these diseases. Obesity is a risk factor for gastro-oesophageal reflux disease (GERD) 
which, in turn, is a risk factor for asthma(31). Another example is Obstructive Sleep Apnoea 
Syndrome (OSAS); the prevalence of OSAS is higher in severe asthma patients as well as 
in obese patients(32). Fourth, obesity may influence lung function parameters. Typically, 
obesity causes a modest reduction in total lung capacity (TLC), and a larger reduction in 
functional residual capacity (FRC) (figure 3)(33).
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 Figure 3. Altered lung function in obesity
Obesity leads to alternations of lung volumes. ERV: expiratory reserve volume; FRC: functional residual ca-
pacity; RV: residual volume; TLC: total lung capacity
The fifth hypothesis suggests that systemic inflammation may lead to asthma by means 
of fat-tissue derived adipokines. Obesity is considered to be a state of chronic low-grade 
systemic inflammation, characterized by an imbalance of pro- and anti-inflammatory 
proteins derived from adipocytes. Fat tissue was traditionally seen as an organ for stor-
age of energy, however, it is now considered to act as an endocrine organ. The fat tissue 
is a source of bioactive peptides and proteins, which are called adipokines(34). Examples 
of adipokines are leptin, adiponectin and resistin. Also interleukin (IL)-6 and TNF-α, 
produced by macrophages in the fat tissue, play a role.
Leptin (Greek leptos, thin) is secreted by fat tissue and causes the feeling of satura-
tion and increases the metabolism. Moreover, leptin influences the T-cell response and 
stimulates the proliferation of T-helper cells, which causes increased production of 
pro-inflammatory cytokines(35). Adiponectin is an insulin-regulating hormone. It also has 
anti-inflammatory effects: it decreases the production of pro-inflammatory cytokines 
and it increases the production of IL-10 and IL-1β. The assumption is that inflammatory 
mediators from the fat tissue enter the systemic circulation, and find their way to the 
lung tissue, where they may cause or intensify airway inflammation(36).
Systemic inflammation in the morbidly obese
The increasing prevalence of obesity may result in development of the metabolic syn-
drome.  Metabolic syndrome is defined by a cluster of cardiometabolic risk factors char-
acterized by abdominal obesity, insulin resistance and chronic systemic inflammation(37).
For components of the metabolic syndrome, such as hypertension(38), type 2 diabetes 
mellitus(39, 40), low-density lipoprotein cholesterol(41) and overall obesity(42) positive as-
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sociations with lung function impairment have been reported. In recent large cohort 
studies it has been shown that there is also a relationship between metabolic syndrome 
and lung function impairment(43-45). Data on the association between lung function 
impairment and the metabolic syndrome in the morbidly obese are limited.
The mechanisms underlying the relationship between the metabolic syndrome and 
impaired lung function are unclear. The relationship might be explained by the chronic 
low-grade systemic inflammation that is associated with obesity. One hypothesis is that 
this low-grade systemic inflammation causes inflammation in the lungs, and hence lung 
function impairment (figure 4).
 
Figure 4 Inflammatory mechanism linking obesity and asthma
Inflammatory mechanisms linking obesity to asthma (adapted from Lugogo(46))
Bronchial inflammation in the morbidly obese
As stated previously, asthma is a chronic inflammatory disorder of the airways. The 
systemic inflammation, known to be present in the morbidly obese, may spill over into 
the lungs, and cause local inflammation in the airways, and thereby asthma. Indeed, 
asthma in the obese has been described as a specific phenotype, with a high symptom 
expression and late onset of symptoms(47, 48). Typical allergic asthma is characterized by 
airway sputum eosinophilia and increased exhaled nitric oxide. Several studies in obese 
patients with asthma have shown an inverse relationship between BMI and exhaled 
nitric oxide and sputum eosinophilia(49-51). Airway neutrophilia has been reported in 
obese asthmatic women as compared to obese controls and lean asthmatics(52). There 
is however, some discrepancy in the literature concerning the nature of bronchial in-
flammation in obese asthmatics.  While some research groups show increased sputum 
neutrophil counts(52, 53), others report no relationship between obesity and neutrophilic 
airway inflammation(50, 51, 54). All aforementioned studies in obese asthmatics investigated 




Bariatric surgery procedures affect weight loss through two mechanisms: malabsorption 
and restriction. In the Sint Franciscus Gasthuis(55) two different bariatric surgery proce-
dures are performed: the gastric sleeve resection and the (Roux-and Y) gastric bypass 
surgery. Sleeve gastrectomy is a partial gastrectomy, in which the majority of the greater 
curvature of the stomach is removed(56), and is thereby a restrictive method. During the 
gastric bypass surgery a small proximal gastric pouch is divided and separated from the 
distal stomach and anastomosed to a Roux limb of small bowel 75 to 150 cm in length(56) 
(figure 5). This is a combination of a restrictive and malabsorptive procedure.
Figure 5 Gastric sleeve resection and gastric bypass surgery
Complications of bariatric surgery
In line with the epidemic of obesity, the number of bariatric surgery procedures being 
performed is increasing every year, with a 22-fold increase between 1996 and 2008(57). 
The postoperative morbidity rate after bariatric surgery is about 5%. In a large cohort 
study it was shown that postoperative pneumonia and respiratory failure, despite being 
infrequent complications of bariatric surgery, account for one fifth of the morbidity. 
Moreover, these complications are also associated with increased mortality(58) and rep-
resent the largest attributable costs of all complications(59). Since the surgery is elective 
and complications are difficult to treat in this group of morbidly obese patients, the 
prevention of complications of bariatric surgery is of great importance. Obesity is found 
to be a risk factor for the development of postoperative pulmonary complications after 
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abdominal surgery(60). Obesity-related co-morbidities – such as asthma(61) -  may predis-
pose obese patients to postoperative complications.
Current guidelines do not indicate pulmonary function testing in patients without 
evidence of pre-existing lung disease who are evaluated for non-thoracic surgical pro-
cedures. However, whether this is also true for morbidly obese is unclear. Spirometry 
could identify patients who are at risk for complications, although this is not the current 
consensus(62). The guidelines state that spirometry is only mandatory in patients who 
are heavy smokers, or have complaints of dyspnea or cough(63). However, there is a poor 
correlation between the presence of symptoms and lung function measurements(64) in 
the general population, but also among the morbidly obese.
Bariatric surgery in the management of asthma
A recent position paper on weight loss interventions in asthma(65) concluded that the 
evidence of benefits from weight reduction on asthma outcomes is weak. They included 
studies with dietary interventions, including the only randomized controlled trial by 
Stenius(66). Besides effect on asthma outcomes, weight loss from dietary interventions 
also have been associated with reduction in markers of systemic inflammation(67, 68). 
However, in the morbidly obese is has been shown that bariatric surgery leads to more 
and persistent weight loss in contrast to dietary weight loss(69). So it is to be expected 
that weight loss by bariatric surgery has a greater and prolonged effect on asthma.
To our knowledge only six prospective studies have been published in which the ef-
fects of bariatric surgery on obese asthmatic patients have been evaluated(70-75). These 
six studies conclude that airway responsiveness, lung volumes and asthma control do 
markedly improve with weight loss following bariatric surgery in severely obese asth-
matic patients. However, the numbers of included subjects were small in all six studies. 
Furthermore, they either lacked (follow-up of ) a non-asthmatic control group of subjects 
with bariatric surgery(70, 71, 73, 75), or they lacked a non-intervention control group(71, 72, 74, 75).
Outline / aim of the thesis
The aim of the thesis is threefold. First, we investigated whether not only overdiagnosis 
but also underdiagnosis of asthma is present in an obese population. Secondly, we 
studied the following research questions:
•	 Is	bronchial	inflammation	present	in	obese	asthmatics?
•	 	Is	 there	 a	 relationship	 between	 bronchial	 inflammation	 in	 obese	 asthmatics	 and	
obesity-associated low-grade systemic inflammation?
Finally, we studied the effect of bariatric surgery on asthma symptoms, lung function 
and bronchial and systemic inflammation.
16 Chapter 1
This thesis consists of three parts. Part A describes in chapter 2 the complex diagnosis 
of asthma in the morbidly obese, and especially focuses on underdiagnosis and over-
diagnosis of asthma in this patient group. Part B investigates bronchial and systemic 
inflammation. It starts in chapter 3 with a review on the association between obesity 
and asthma, where the metabolic syndrome – as state of systemic inflammation -  is 
mentioned as possible explanation for the association between obesity and asthma. In 
chapter 4 systemic inflammation and the metabolic syndrome and impaired lung func-
tion in morbidly obese subjects are discussed. This is followed by chapter 5, in which 
the presence and possible relationship between bronchial and systemic inflammation 
in morbidly obese asthma subjects are discussed. Part C focuses on bariatric surgery, 
first pulmonary function testing and complications of bariatric surgery are discussed 
in chapter 6. In chapter 7 the effect of bariatric surgery on asthma is described. And 
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Underdiagnosis and overdiagnosis of 
asthma in the morbidly obese
Van Huisstede A, Castro Cabezas M, van de Geijn GJ, Mannaerts GH, Njo TL, 




Background: The prevalence of obesity and asthma has increased concurrently over the 
last decades, suggesting a link between obesity and asthma. However, asthma might 
not be adequately diagnosed in this population.
Aim: To investigate whether not only overdiagnosis but also underdiagnosis of asthma 
is present in an obese population.
Methods: Morbidly obese subjects with or without physician-diagnosed asthma were 
recruited from a pre-operative screening programme for bariatric surgery, and were 
characterized using an extensive diagnostic algorithm.
Results: 473 subjects were screened; 220 met inclusion criteria, and 86 agreed to par-
ticipate. Among the 32 participating subjects who had a physician diagnosis of asthma, 
reversible airway obstruction and/or bronchial hyperresponsiveness could only be 
detected in 19 patients (59%, 95%CI [0.41-0.76]), whereas in 13 patients (41%, 95%CI 
[0.24-0.50]) the diagnosis of asthma could not be confirmed (overdiagnosis). In contrast, 
in the remaining 54 patients, 17 (31%, 95% CI [0.20-0.46]) were newly diagnosed with 
asthma (underdiagnosis).
Conclusion: Besides overdiagnosis, there is also substantial underdiagnosis of asthma 
in the morbidly obese. Symptoms could be incorrectly ascribed to either obesity or 
asthma, and therefore also in the morbidly obese the diagnosis of asthma should also 
be based on pulmonary function testing.
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INTRODUCTION
The prevalence and incidence of asthma has increased over the recent decades (1, 2). Be-
sides an improved awareness of the disease, there are several other explanations for the 
increased asthma prevalence, such as air pollution, exposure to tobacco smoke, change 
in diet and obesity (2). Recently, the incidence and prevalence of obesity have increased 
concurrently with the incidence and prevalence of asthma, suggesting a possible link 
between obesity and asthma (3, 4).
International guidelines advise that asthma diagnosis should be based on both the 
presence of symptoms and objective measurements of variable airflow obstruction or 
bronchial hyperresponsiveness (BHR) (1). However, in daily practice spirometry or provo-
cation tests are not always performed, and the diagnosis of asthma is mainly based on 
symptoms (5). Since obese patients report more dyspnea and asthma-like symptoms 
than non-obese patients (6, 7), it might be that they unjustified get labelled as asthma 
(overdiagnosis) without performing adequate diagnostics. Inevitably, any misdiagnosis 
may lead to inappropriate treatment (5), with increased risk of side-effects and increased 
costs (8).
Many epidemiological studies concerning obesity and asthma have used physician-
diagnosed asthma without confirmation by pulmonary function tests. This implies 
reasonable doubt as to the correctness of the diagnosis. Multiple studies report that 
asthma could be excluded after extensive testing in 30% of physician-diagnosed asthma 
(9-11), even after stopping with asthma medication (12). On the other hand, missing the 
diagnosis of asthma in this population is also an important issue. Impaired dyspnea 
perception is especially thought to play a role in severe asthma (13, 14), and poor percep-
tion of airflow obstruction may lead to under- treatment of asthma (15, 16). All the recent 
studies concerning overdiagnosis of asthma in the obese (11, 12, 17), initially used selected 
subjects with asthma, and therefore did not take into account obese patients in which 
asthma was not detected. Therefore, the information about underdiagnosis of asthma 
in the obese is incomplete.
The hypothesis of the present study was that underdiagnosis of asthma is also present 
in the morbidly obese. We therefore used an extensive diagnostic algorithm to investi-
gate whether in addition to overdiagnosis also underdiagnosis of asthma is present in 





The subjects included in this study were patients who underwent pre-operative screen-
ing before bariatric surgery in the Sint Franciscus Gasthuis in Rotterdam, the Netherlands 
from September 2009 to April 2011. Eligibility criteria for bariatric surgery were: age 
between 18 and 60 years old, body mass index (BMI) ≥ 35 kg/m2. We excluded people 
who (a) were older than 50 years of age or; (b) had a history of smoking more than 10 
cigarettes a day, or were currently smoking more than 10 cigarettes a day (with the aim 
to decrease the risk of including subjects with chronic obstructive pulmonary disease 
[COPD]); (c) were taking oral corticosteroid therapy; (d) had an asthma exacerbation four 
weeks before screening; (e) were unable to perform pulmonary function tests; or (f ) had 
pulmonary disease other than asthma.
We aimed for 40 subjects with, and 40 subjects without asthma, as this study is a part 
of a longitudinal study. All subjects underwent baseline physical examinations includ-
ing routine assessment of anthropometry, blood pressure and blood samples. Waist 
circumference was measured directly to the body surface midway between the lower 
rib margin and the ileac crest. Fat free mass and fat weight (in kg and % body weight) 
were measured using bio-electrical impedance analysis (Bodystat 1500, Bodystat Ltd, 
British Isles) (18).
All subjects gave written informed consent and the local ethics committee (Toetsing-
scommissie Wetenschappenlijk Onderzoek Rotterdam e.o.) approved the study protocol 
(Netherlands Trial Register 3204).
Pulmonary function tests
All subjects underwent lung function testing for the presence of reversible airflow 
obstruction as part of the screening protocol before bariatric surgery. Spirometry was 
performed with Vmax spirometer (Vmax SensorMedics Viasys, type Encore 20/22/229/62 
Encore, Cardinal Health, USA) before and after 400 µg of inhaled salbutamol, accord-
ing to the American Thoracic Society / European Respiratory Society guidelines (19). All 
values obtained were related to height, age and gender and expressed as percentage 
of their predicted value (reference ERS 1993(20)). The pulmonary function results are 
prebronchodilator values unless otherwise specified.
All subjects who met the inclusion criteria were invited for a second visit for further 
lung function evaluation. Again, if applicable, subjects were asked not to use long-
acting β-agonists for 48 hours, short-acting β-agonists for 8 hours and antihistamines 
or antileukotriene medication 72 hours before lung function testing. Subjects who were 
using inhaled corticosteroids (ICS), were asked to voluntarily discontinue this. Daily 
symptom diary and daily peak flow rates were used to optimally screen asthma control. 
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Subjects were permitted to use short-acting bronchodilators as rescue medication. 
After six weeks they returned for their second visit, during which exhaled Nitric Oxide 
(FeNO)(Niox mino Aerocrine, Sweden) (21), impulse oscillometry (IOS) (Masterscreen IOS 
system, Erich Jaeger Co., Würzburg, Germany), diffusion capacity (intrabreath method, 
corrected for hemoglobin and alveolar volume) (22) and methacholine provocation test-
ing (five breath dosimeter method) (23, 24) were performed. Bronchial responsiveness to 
methacholine was expressed as the provocative dose of methacholine inducing a 20% 
fall in FEV1 (PD20). A PD20 < 1.8 mg was considered as a positive provocation test. If the 
methacholine provocation test was negative, a second provocation test was performed 
six weeks later. Subjects who refused to stop the ICS, or subjects who had exacerbations 
of asthma symptoms during the 12 weeks of discontinuing their medication, underwent 
provocation testing while using ICS (figure 2a, supplementary files).
Definition of asthma
Asthma was defined according to GINA guidelines (1) as both the presence of symp-
toms and either an increase of ≥12% and 200 ml in FEV1 after salbutamol, or a positive 
provocation test. Physician diagnosis of asthma was scored as a positive reaction to the 
following question “Did a medical doctor ever told you that you have asthma?”. Patients 
with a physician diagnosis of asthma and fulfilling the criteria of asthma were defined 
as having a correct asthma diagnosis. Those without physician diagnosed asthma, but 
who fulfilled the criteria for asthma were defined as underdiagnosed. The subjects with 
physician-diagnosed asthma, but who not fulfilled the criteria of asthma after stopping 
inhaled corticosteroids for more than 6 weeks were defined as overdiagnosed. Patients 
without airway reversibility and a negative provocation test formed the control group 
(figure 2b, supplementary files).
Questionnaires
Asthma symptoms were assessed by the mini Asthma Quality of Life Questionnaire 
(AQLQ) (25) and the Asthma Control Questionnaire (ACQ) (26) to assess asthma complaints. 
The Epworth Sleepiness Scale (27) questionnaire was used to assess OSAS, and the GERD-
Questionnaire for gastro-esophageal reflux disease (GERD) (28). The average of 7 days 
with an activity meter was used to determine the total number of steps taken a day, as 
a measure of activity.
Atopy
Atopic status was assessed with skin-prick tests (SPT) with a battery of common aeroal-
lergens: house-dust mite; dog, cat, and horse dander; Aspergillus fumigatus; mugwort; 
and birch and grass pollen (Vivodiagnost; ALK Benelux BV, Groningen, The Netherlands). 
SPT cutaneous response was compared with a histamine-positive control and a saline 
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solution–negative control. A positive result was defined as at least one response with a 
wheal diameter ≥ 3 mm after 15 minutes. Total IgE and specific plasma IgE were deter-
mined with a solid-phase two-step chemiluminescent immunoassay on the Immulite 
2000 (Siemens, Los Angeles, CA). A positive inhalation screen was defined as at least 
one increased amount of specific IgE for fungus, house-dust mite, cat, dog, grass, birch 
or herbs.
Laboratory
Blood cell counts and 5-part leukocyte differentiation were determined automatically 
using LH750 analyzers (Beckman Coulter Miami, FL, USA). CRP was measured using LX 
20 and DxC analyzers (Beckman Coulter, Miami, FL, USA). Vitamin D was determined by 
RIA or chemiluminescence (LIA) on Liason analyzers (DiaSorin, Stillwater, MN, USA).
Statistical analyses
Underdiagnosis of asthma subjects were consecutively compared with correctly diag-
nosed asthma,  overdiagnosis of asthma and controls. Unless indicated otherwise, all 
data are expressed as median (min-max) for scale variables or percentage for categorical 
variables. Unadjusted between groups comparisons were performed using Mann With-
ney U test, Chi square or Fisher exact test as appropriate. Cohen’s Kappa coefficient was 
calculated as a measure of inter-rater agreement. IgE and FeNO were log transformed for 
statistical purposes. All analyses were performed using SPSS 18.0 software (SPSS Inc., 
Chicago, Illinois, USA). Results were evaluated at 95% confidence interval at a two-sided 
significance threshold of p<0.005 (Bonferroni correction for multiple testing).
RESULTS
Demographics
In total 473 patients were screened. 220 subjects met the inclusion criteria, and 86 sub-
jects agreed to participate in the study. The most frequently reported reasons for refus-
ing participation were “no time for additional appointments due to work” and “distance 
to hospital too far”. The 136 subjects who declined consent did not significantly differ in 
demographic characteristics from the participants (BMI, weight, abdominal circumfer-
ence, age or gender; data not shown) (figure 1).
From the 86 assessed patients, 32 patients had physician-diagnosed asthma. How-
ever, using the diagnostic algorithm, asthma could be excluded based on the absence 
of reversibility in FEV1 or negative provocation test in 13 of these subjects (41%, 
95%CI  [0.24-0.50]) (overdiagnosis). In contrast, when analyzing the 54 patients without 
physician-diagnosed asthma, we found that 17 patients (31%, 95%CI   [0.20-0.46]) had 
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symptoms and a reversible airflow obstruction or airway hyperreactivity (underdiagno-
sis). This way, among the 86 assessed subjects, 36 true asthma patients were diagnosed 
and 50 true controls. Cohen’s Kappa coefficient between physician diagnosed asthma 
and our diagnosis of asthma was 0.251. Table 1 shows the baseline characteristics of 
the four groups. There were no significant differences in demographic characteristics 







Figure 1 Selection of participants and study outcome
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subjects with underdiagnosis of asthma had a significantly larger abdominal circumfer-
ence than the controls.
Symptoms and questionnaires
There were no differences in symptoms between the group with an underdiagnosis of 
asthma and the correctly diagnosed asthma group or the overdiagnosis asthma group 
(table 2). The underdiagnosis group  trended toward having more complaints of wheez-
ing and coughing than the control group. There was also a trend that the asthma control 
questionnaire (ACQ) was better for the underdiagnosis group compared to the correctly 
diagnosed asthma group. The ACQ of the underdiagnosis group was comparable with 
the overdiagnosis group, and significantly better than the controls. The asthma qual-
ity of life questionnaire (AQLQ) was significant worse for the underdiagnosis group, 
compared with the controls, and comparable with the correctly diagnosis asthma and 
overdiagnosis asthma groups.
Medication use
Eleven of the patients with correctly diagnosed asthma were using ICS at the start of 
the study. Three refused to stop the ICS. Of the eight subjects who withheld their ICS, 
two had an increase of asthma symptoms and resumed their ICS. Also, three asthmat-
ics without ICS before the start of the study had an increase in asthma symptoms, and 
started with ICS. In the overdiagnosed subjects, three were using ICS at the start of the 
study, and all agreed to withhold their ICS, without any change in symptoms.
Lung function parameters
A methacholine provocation test was not performed in two of the underdiagnosed 
subjects, because of low FEV1 (n=1) and extreme obesity (BMI 71, n=1), and once in the 
correct diagnosis asthma group because of poor lung function technique. All three, 
however, had reversible airway obstruction (delta FEV1 ≥ 12%). 18 correctly diagnosed 
asthmatics had a positive provocation test, of which 8 also had reversible airway ob-
struction. 11 of the underdiagnosed subjects had a positive provocation test, of which 
only one also had reversible airway obstruction. The diagnosis asthma was only based 
on reversibility, with a negative provocation test in 4 underdiagnosed asthmatics.
There was no difference in lung volumes, FeNO or diffusion capacity between the inves-
tigated groups. Among the parameters of the IOS there was a trend that R5 and Fres were 
higher in the underdiagnosed group compared to the control group (table 3).
Blood parameters
With regard to the laboratory parameters (table 3), there was no difference between the 
investigated groups.
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Allergy, activity and comorbidity
There was no difference in allergy, reflected in either a positive inhalation screen or a 
positive SPT, or rhinitis between the investigated groups (table 3).
To assess the activity of the subjects, a step-counter was used, which showed no sig-
nificant differences between the investigated groups. There were also no differences in 
comorbidities, such as obstructive sleep apnea syndrome (Epworth Sleepiness Scale) or 
reflux (GERD-questionnaire) (both table 3), or the presence of the metabolic syndrome.
DISCUSSION
We found that after discontinuation of inhaled corticosteroids and extensive lung 
function and provocation tests, misdiagnosis of asthma was present in our morbidly 
obese cohort. In addition to confirming previous reports on overdiagnosis of asthma, 
importantly we also found that a substantial proportion of morbidly obese asthma 
patients were underdiagnosed. This indicates that in the morbidly obese, the diagnosis 
of asthma cannot be made on asthma-like symptoms alone, and lung function testing 
is an essential part of the diagnosis of asthma, as confirmed with a low Cohen’s kappa 
coefficient for physicians and our diagnosis of asthma.
This is, to our knowledge, the first study investigating both overdiagnosis and un-
derdiagnosis of asthma in an obese cohort. Furthermore, we have used an extensive 
diagnostic algorithm to confirm or exclude asthma. In addition, we have also looked at 
co-morbidities such as reflux and OSAS, which are abundant in the obese and are known 
to influence asthma. Moreover, also cofactors such as immobility and allergy were taken 
into account.
We confirm previous reports showing that overdiagnosis of asthma is present in the 
morbidly obese (11, 12, 17), although Aaron found that overdiagnosis of asthma was overall 
no more likely to occur among obese individuals than among non-obese individuals. 
However, in studies so far concerning overdiagnosis of asthma, assessment of underdi-
agnosis was not part of these studies. We also found underdiagnosis of asthma in our 
cohort of morbidly obese subjects, a previously overlooked problem.
In the present study symptoms turned out to be unreliable for an adequate diagnosis 
of asthma. Subjects with an overdiagnosis of asthma reported asthma-like symptoms, 
which explain the overdiagnosis. Interestingly, patients who were underdiagnosed for 
asthma also had symptoms. The reason why they did not receive a previous diagnosis 
of asthma is not clear, but may be explained by two factors. First, this discrepancy might 
be due to self-misperception; the patients themselves did not relate their symptoms 
to respiratory disease but rather to obesity and did not contact a physician for these 
complaints. A second possibility could be that they did contact a physician for dyspnea, 































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































but these discomforts were attributed to obesity by the physician (physician mispercep-
tion). Self-misperception of respiratory symptoms is probably the most relevant factor 
(29), and might be partly explained by worse perception of dyspnea. Unfortunately, no 
data were available on previous visits to a physician because of respiratory symptoms.
Interestingly, especially R5 – a marker of both central and distal airways obstruction – 
was particularly high in the underdiagnosed subjects. The underdiagnosed subjects, in 
particular, had a large abdominal circumference in our study. Therefore, central obesity 
may lead to obstruction of the peripheral airways, which may be more related to poor 
perception of dyspnea than proximal airway obstruction. This suggests that it is not the 
amount of fat, but the location of the fat, which influences asthma perceptions, which is 
also supported by a study from Lessard (30). Similar to the symptoms, the inappropriate 
use of inhaled medication was high in the overdiagnosis asthma group. This may result 
in serious side effects and, moreover, contributes to the economic burden of asthma. 
The symptoms could not be explained by a restriction or a low diffusion capacity. There 
was no difference in smoking status, furthermore as result of the exclusion criteria, the 
median number of pack years was nihil, so smoking is unlikely to be a contribution fac-
tor. There was no difference in co-morbidities such as allergy, GERD, OSAS or activity 
between asthmatics and controls, and therefore these factors do not seem to play a role 
in asthma in the obese.
There were few differences between the underdiagnosed and the overdiagnosed 
subjects. However, many of the overdiagnosed subjects had rhinitis, which can cause 
dyspnea perception(31). Furthermore, the overdiagnosed scored low for the AQLQ, espe-
cially in the environment domain, a domain where symptoms related to external stimuli 
are scored. However, by definition, all overdiagnosed had a negative provocation test. 
This reduced QOL in morbidly obese overdiagnosed asthma subjects was also found by 
Scott et al. (11). These data suggest that the discrepancy between pulmonary function 
test and the AQLQ, might in part be explained by rhinitis.
There are several limitations to our study. Only 39% of potentially eligible subjects 
agreed to participate. So a volunteer bias could have influenced the study results. The 
large proportion of declines is most probably due to the fact that this study is a part of a 
longitudinal study. Another effect of this study being a part of another study, is the fact 
that we aimed for 40 subjects with and 40 subjects without asthma and that inclusion 
of the latter group went faster, so subjects were not enrolled in a consecutive order. So 
the prevalence of physician diagnosed asthma in our study cohort is biased, and there-
fore also the prevalence of under- or overdiagnosis of asthma is biased. Importantly, 
however, there were no differences in patient demographics between the subjects who 
declined consent and those who participated. Since a lean control group was not part 
of the study, it is not clear whether underdiagnosis is more prevalent among the obese 
compared to a lean cohort. The selection of subjects willing to undergo bariatric surgery 
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could also have led to a selection bias. And finally, the small group of misdiagnosed 
subjects (either over- or underdiagnosis) could have given us power problems to find 
differences in subgroup analysis.
In summary, both overdiagnosis as well as underdiagnosis of asthma occurs in the 
morbidly obese. A diagnosis of asthma based on symptoms alone is unreliable in the 
morbidly obese, and pulmonary function testing is an essential part of the diagnosis of 
asthma in the morbidly obese. As a result of the most likely high prevalence, potential 
health risk and the high economic burden of misdiagnosis, characterization of these 
patients is important. Further research aiming at the effects of weight reduction on 
quality of life and symptoms, not only in asthmatics but also in the overdiagnosed can 
provide valuable further insights into this interesting problem.
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ABSTRACT
There is substantial evidence that obesity and asthma are related. “Obese asthma” may 
be a unique phenotype of asthma, characterized by decreased lung volumes, greater 
symptoms for a given degree of lung function impairment, destabilization or lack of 
asthma control, lack of eosinophilic inflammation and a different response to controller 
medication.
Whether this relationship between obesity and asthma is causal or represents co-
morbidity due to other factors is unclear. In previous reviews concerning the relationship 
between obesity and asthma, five hypotheses were put forth. One of these hypotheses is 
that a low grade systemic inflammation caused by adipokines from the fat tissue causes 
or enhances bronchial inflammation. In animal models, there is an increasing amount of 
evidence for the role of adipokines derived from fat tissue in the relationship between 
obesity and asthma. The data are conflicting in humans.
Since obesity is a component of the metabolic syndrome and the metabolic syndrome 
is also a form of systemic inflammation, it is to be expected that there is a relationship 
between metabolic syndrome and asthma. The few data that are available show that 
there is no relationship between metabolic syndrome and asthma, but there is one 
between the metabolic syndrome and asthma-like symptoms.
Further research is needed to confirm the relationship between obesity and asthma in 
humans, where a rigorous approach in the diagnosis of asthma is essential.
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INTRODUCTION
Obesity is currently a major health problem and is developing into a global epidemic. 
Obesity is classified by the Body Mass Index (BMI) (table 1) and is defined as abnormal 
or excessive fat accumulation which can cause health problems. The World Health Or-
ganisation’s (WHO) latest projections indicate that, globally in 2005, approximately 1.6 
billion adults (age 15+) were overweight, and at least 400 million adults were obese. 
WHO further predicts that, by 2015, approximately 2.3 billion adults will be overweight 
and more than 700 million will be obese(1).
Because the prevalence of both obesity and asthma have increased in the recent 
years, many studies have examined the possibility of a causal relationship between 
these two conditions(2-5). The fact that asthma improves after weight loss with either 
bariatric surgery or low caloric diet supports the relationship between obesity and 
asthma(6). Moreover, obese patients with persistent asthma have significantly worse 
asthma-related quality of life(7), less asthma control(8, 9), more severe disease(4, 10-12), and 
more asthma-related hospital admissions than asthma patients with a normal BMI.
There are multiple hypotheses that may explain the relationship between obesity and 
asthma. This review will discuss the different hypotheses, and will focus on the systemic 
inflammation, and the possible role of the metabolic syndrome.
Asthma phenotype in obesity
Recent data suggest(13, 14) that obese patients have a different phenotype of asthma, 
characterized by female predominance, late onset of asthma and high symptom expres-
sion.
Classical asthma is characterised by a Th-2 cell mediated allergic airway inflammation. 
The characteristics of airway inflammation in asthma (exhaled nitric oxide (eNO) and 
inflammatory cells in induced sputum) have been investigated in obesity. eNO can be 
seen as a marker of eosinophilic inflammation in the airways. De Winter et al. showed 
that a higher BMI was associated with a higher eNO in healthy patients(15). On the con-
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trary, Kazaks found no significant relationship between exhaled NO and BMI in adult 
asthma patients(16). However, there was no correction for use of corticosteroids.
Sputum eosinophilia is a hallmark of asthma. Several studies have found no - or even 
an inverse - relationship between the number of sputum eosinophils and BMI(17-19). 
Although airway eosinophil accumulation is characteristic for asthma, little is known 
about the influence of obesity on eosinophil migration from bone marrow to the bron-
chial mucosa. Calixto(20) found, in a murine model of asthma, that diet-induced obesity 
enhanced eosinophil trafficking from bone marrow to the airway, but delayed their 
transit through the airway epithelium into the airway lumen.
If the relationship between asthma and obesity could be explained by allergic air-
way inflammation, then one would expect a relationship between obesity and other 
allergic conditions, such as allergic rhinitis or allergic conjunctivitis. Although several 
epidemiologic studies have reported an increased risk of atopy in the overweight and/
or obese(21, 22), others have demonstrated an increased risk of developing asthma in non-
allergic compared to allergic adults(23-25).
In summary, there is a great deal of conflicting data concerning the signs of bronchial 
inflammation in obese asthmatics (eNO, sputum eosinphilia). Data suggest that asthma 
in obese patients is not characterized by a classic Th2 cell driven inflammation, but prob-
ably represents a different phenotype. The inflammatory pattern might be neutrophilic, 
instead of eosinophilic in obese patients with asthma. Allergy is probably not an impor-
tant factor in the relationship between obesity and asthma.
Therapeutic implications
The main goal of asthma treatment is to achieve adequate control of the disease, as 
reflected by minimal symptoms and rescue bronchodilator use. Asthma has been re-
ported to be more difficult to control in obese patients compared to individuals with 
a normal weight(9, 26). Also the improvement of exhaled nitric oxide levels with inhaled 
corticosteroid treatment is smaller in obese asthmatics than in lean asthmatics(27). Is this 
because they do not respond to inhaled corticosteroids? This could be expected when 
one assumes that in obese asthmatics it is a neutrophilic instead of eosinophilic airway 
inflammation. In a recent study by Camargo(28), they found that, compared to subjects 
with normal BMI, the onset to peak FEV1 may require longer treatment exposure in the 
very obese.
Could it be that asthma in obese patients is more difficult to control because obese 
asthmatics have more complaints than lean asthmatics? Although obese asthmatics 
have the same perceptual responses to bronchoconstriction as lean asthmatics, it is 
to be expected that they have more complaints of dyspnoea due to their altered lung 
volumes, as will be discussed later.
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Weight reduction from diet and exercise has been found to improve asthma symp-
toms, but the most striking changes have been reported in morbidly obese asthmatics 
following bariatric surgery(29-34). However, these studies are frequently small and under-
powered, and are often not designed with a primary outcome or rigorous characteriza-
tion of asthma. Although there is still only a small body of evidence in favour of the 
beneficial effect of weight reduction in obese asthmatics, weight reduction does seem 
to be an important aspect of the treatment of these people.
Hypotheses that may explain the relationship between obesity and asthma
Since obese asthmatics might have a non-allergic phenotype of asthma, there must be 
another factor explaining the relationship between obesity and asthma. Although there 
are multiple hypotheses, no causal relationship between obesity and asthma has, as 
yet, been proven. Even though asthma may promote weight gain through increased 
sedentary life style and occasional use of oral corticosteroids, this does not fully explain 
the association of asthma and obesity in the majority of patients. In previous reviews 
concerning the relationship between obesity and asthma, five hypotheses were put 
forth (figure 1).
First, obese people consume food with less nutritional value, fewer vitamins and more 
fat. A high amount of fat intake is associated with asthma(35). Also zinc- and magnesium 
deficiencies are associated with asthma and bronchial hyperreactivity (BHR)(36).
Secondly, obesity and asthma may share the same genetic risk factors. This was dem-
onstrated by a large-scale study among 1384 twins, where a strong association between 
asthma and BMI was found(37).
Co-morbidities, which are a risk factor for asthma as well as obesity, might be the third 
hypothesis. Obesity, for instance, is a risk factor for gastro-oesophageal reflux disease 
(GERD) which, in turn, is a risk factor for asthma(38). The same is true for Obstructive Sleep 
Apnoea Syndrome (OSAS); the prevalence of OSAS is higher in severe asthma patients 
as well as in obese patients(39). A large-scale, questionnaire-based Northern European 
survey showed that after adjustments for possible confounders, obesity and nocturnal 
GERD were found to be independent risk factors for the onset of asthma and respiratory 
symptoms(40).
Fourthly, obesity may alter lung function parameters. Typically, obesity causes 
a modest reduction in total lung capacity (TLC), and a larger reduction in functional 
residual capacity (FRC) (figure 2)(41). The reasons for the reduction in TLC are not known, 
but they are probably due to a mechanical effect of the adipose tissue. A reduction in 
the downward movement of the diaphragm, due to increased abdominal mass is likely 
to decrease TLC by limiting the space for lung expansion on inflation(42). Furthermore, 
obese people have a smaller tidal volume and an increased respiration rate with a de-
creased expiratory reserve volume (ERV)(43). The FEV1/FVC ratio is usually well preserved 
52 Chapter 3
or increased, which implies that the major effect of obesity is on lung volumes, with no 
direct effect on airway obstruction. Furthermore, weight loss significantly improves the 
FRC, TLC and ERV(44).
The decreased lung volume is associated with a decreased diameter of the peripheral 
airways, which leads to tidal breathing at or near closing volume(41). Moreover, Bergeron 
has shown that there is a fat accumulation in the airways in obese patients with less 
defined cartilage ring(45). All this can explain why obese patients often have more 
complaints of dyspnea than subjects with a normal BMI. Salome showed that, although 
obesity reduces lung volumes, it does not alter sensitivity or maximal response to 
methacholine in non-asthmatic subjects(46). Recently, it was also shown that perceptual 
responses to methacholine-induced bronchoconstriction and lung hyperinflation were 
similar in obese and normal-weight asthmatics(47). Thus, obese asthmatics may have 
more complaints of dyspnea, but this may not be directly related to abnormal airway 




Figure 1 Obesity and asthma relationship
The relationship between obesity and asthma is not yet clear. Diet, genetic factors or comorbidities which 
give a higher risk for asthma might also give a higher risk for obesity. Obesity gives a greater abdominal 
mass, which causes altered lung function parameters, which cause dyspnea. Whether or not this dyspnea is 
asthma is questionable. The abdominal mass also causes a dysbalance in inflammatory proteins, in favour 
of the pro-inflammatory proteins. This may lead to a local inflammation, which causes a low grade systemic 
inflammation, which, in turn, causes or enhances a local inflammation of the lung parenchyma.
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The fifth, and last, hypothesis suggests that systemic inflammation by means of fat-
tissue derived adipokines may lead to asthma. The assumption is that inflammatory 
mediators from the fat tissue come into the systemic circulation, and find their way to 
the lung parenchyma, where they may cause or intensify airway inflammation .
Obesity is considered to be a state of chronic low-grade systemic inflammation, 
characterized by a dysbalance of pro- and anti-inflammatory proteins derived from fat 
tissue cells. Fat tissue was traditionally seen as an organ for storage of energy. Recently, 
however, it is considered to act as an endocrine organ. The fat tissue is a source of bioac-
tive peptides, which are called adipokines(48). In 1993, Hotamisligil et al discovered that 
fat cells (adipocytes) in rodents excrete TNF-α. TNF-α is a pro-inflammatory cytokine(49). 
Since then, multiple inflammatory peptides have been discovered which have a rela-
tionship with obesity. Examples of adipokines are leptin, adiponectin and resistin. Also 
interleukin (IL)-6 and TNF-α play a role. They are produced by macrophages in the fat 
tissue.
Leptin (Greek leptos, thin) is excreted by fat tissue and causes the feeling of saturation 
and increases the metabolism. Moreover, leptin influences the T-cell immunity response 
and stimulates the proliferation of T-helper cells, which causes increased production of 
pro-inflammatory cytokines(50). There is an increased leptin production(51, 52) and a rela-
tive leptin resistance in obese patients. A comparison with insulin and insulin resistance 
can be made: here the primary reaction of the body is to increase the production of 
insulin so that the same physical result is achieved. The leptin concentration is not only 
increased in obesity, but also in asthma(53, 54).
Obesity is associated with necrosis of the adipocytes, causing the interstitium to be 
exposed to little fat drops. Macrophages will collect around this necrotizing adipocytes 
and become active. These macrophages will produce TNF-α and IL-6, which will cause 
a decrease in local production of adiponectin(55). Adiponectin is an insulin-regulating 
hormone. It also has anti-inflammatory effects: it decreases the production of pro-
 
Figure 2 Altered lung function in obesity
Obesity leads to alternations of lung vol-
umes. ERV: expiratory reserve volume; 
FRC: functional residual capacity; RV: re-
sidual volume; TLC: total lung capacity
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inflammatory cytokines and it increases the production of IL-10 and IL-1. Plasma adipo-
nectin levels are reversely correlated to BMI(56), but there is no clear relationship between 
adiponectin and asthma(57-60).
Xu et al.(61)have been able to show in a mice model that there is histological evidence 
for a significant infiltration of macrophages in the fat tissue of obese mice. Moreover, 
they also have shown that many inflammatory and specific macrophage genes are 
dramatically upregulated in the fat tissue. This suggests that macrophages in the fat 
tissue play an active role in obesity and macrophage-related inflammation. Weisberg et 
al.(62) showed that the macrophages are responsible for almost all expression of TNF-α 
and IL-6 in the fat tissue. TNF-α is a potent pro-inflammatory cytokine and is involved in 
many processes in the human body, in particular inflammation, cell proliferation, cell dif-
ferentiation, apoptosis and fat metabolism. IL-6 regulates the production of the strong 
pro-inflammatory protein C-reactive protein (CRP).
In summary, in animal models the influence of the different adipokines associated 
with obesity seem to have an effect on the airway inflammation. In humans, however, 
the association is not yet confirmed. Further studies are needed to investigate whether 
a dysbalance in pro and anti-inflammatory cytokines in the systemic circulation may 
induce a change in concentration of the same cytokines in the lung tissue. This may 
result in an increased airway inflammation.
Metabolic syndrome
The fact that asthma improves after weight loss either with bariatric surgery or low caloric 
diet supports the relation between obesity and asthma. Moreover, Cottam found that 
obesity was manifested by a chronic inflammation (including elevation of monocytes 
and eosinophils), which appeared to be reversible within 6 months after bariatric sur-
gery(63). Also, weight loss by low-energy diet was associated with a reduction in markers 
of systemic inflammation(64, 65). So the hypothesis that the relationship between obesity 
and asthma is based on a systemic inflammation seems quite plausible. The metabolic 
syndrome might contribute to this low-grade systemic inflammation.
Recently, the metabolic syndrome has been postulated as a new hypothesis which 
might explain the relationship between obesity and asthma. Obesity, and mainly 
central obesity, is an important component of the metabolic syndrome. The metabolic 
syndrome is a term to cluster type 2 diabetes mellitus, hypertension, dyslipidemia and 
central obesity (table 2).
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Table 2 Metabolic syndrome
Risk factor Objective
Abdominal obesity (waist circumference)
 - male > 102 cm
- female > 88 cm
Triglycerides >1,7 mmol/l or treatment for hypertriglyceraemia
HDL-cholesterol
 - male <1,03 mmol/l, or treatment for low HDL-C
- female < 1,3 mmol/l or treatment for low HDL-C
Blood pressure ≥130/≥85 mmHg, or treatment for hypertension
Blood glucose (plasma) ≥ 6,1 mmol/l, or treatment for hyperglycaemia
Definition of the metabolic syndrome according to NCEP-ATPIII criteria on basis of clinical characteristics. 
Metabolic syndrome when 3 out of 5 characteristics.
Leone found an independent relationship between lung function impairment (FEV1 
or FVC < lower limit of normal) and metabolic syndrome in both sexes, predominantly 
due to abdominal obesity(66). Lee et al(67) found that the metabolic syndrome was as-
sociated with asthma symptoms. The evidence for the relationship between metabolic 
syndrome and asthma is scarce, mainly because it is a new idea. More research is needed 
to make a definitive conclusion.
The metabolic syndrome is a way to group different diseases. If there might be a rela-
tionship between the metabolic syndrome and asthma, there might also be a relationship 
between the separate compounds of the metabolic syndrome and asthma. In a cross-
sectional population-based study, obesity and insulin resistance were associated with 
an increased risk of aeroallergen sensitization and asthma (allergic and non-allergic)(68). 
Thuesen(69) found, in a recent population-based, prospective study among 1443 adults, 
that insuline-resistance is a stronger risk factor for asthma symptoms than obesity. 
Hyperglycemia itself may not be the important factor. Shore et al have demonstrated in 
lean wild-type and leptin receptor-deficient, diabetic, obese mice that administration of 
metformin did not affect ozone-induced airway inflammation(70).
More research is needed to see whether the metabolic syndrome, or it separate 
components, are the “missing link” between obesity and asthma. Also here the same 
remarks as for the fat tissue derived adipokines can be made. If it is so that the metabolic 
syndrome contributes to the low grade systemic inflammation, the question remains 
whether this low grade systemic inflammation has its local effects on the lung paren-




Many of the articles discussed in this review are epidemiologic studies among patients 
with asthma, where asthma is defined as either physician-diagnosed or self-reported. 
Very few studies performed (extensive) lung function tests to confirm the diagnosis of 
asthma. Often the diagnosis is based on symptoms and medication use. The question 
is whether these patients truly have asthma. In a retrospective study among children, 
a strong correlation was found between general practitioner and specialist diagnosed 
asthma, irrespective of BMI(71). In an extensive study among adult patients, the diagnosis 
of asthma was revisited. In 31.8% of the obese, and 28.7% of the non-obese group 
(p=0.46) the diagnosis of asthma was rejected. The percentage of misdiagnosis is the 
same in the obese and non-obese group, so the relationship between asthma and 
obesity cannot be explained by the fact that there is an overdiagnosis of asthma in the 
obese population(72). In a recent study Pakhale et al(73) found a misdiagnosis of asthma 
in up to 30% of patients. They used a rigorous diagnostic testing algorithm to confirm 
the diagnosis of asthma. They found that misdiagnosis of asthma was associated with 
gender, a recent diagnosis, older age and increased FEV1, but not with obesity. Also, 
obese subjects who made urgent healthcare visits for respiratory symptoms were more 
likely to be misdiagnosed with asthma. It is possible that these symptoms could be the 
result of increased effort in breathing associated with obesity, rather than airway inflam-
mation or airway hyperresponsiveness.
Another disadvantage of most studies is that they are based on self-reported weight. 
A BMI based on self-reported height and weight is not accurate for either children or 
adults(74). The weight will be underreported, and the length overreported. There is how-
ever, an algorithm to correct for this.
Some previous studies of the association of adiposity and lung function have used only 
BMI as a marker of obesity, without taking body composition and fat distribution into 
account. The waist circumference - or even better, a MRI-based visceral fat quantification 
-  is possibly a more accurate measure than BMI. The distribution of body fat may be an 
important determinant of lung function, and this may account for the more pronounced 
association between central adiposity and obstructive lung function in men as com-
pared to women(75). Steele et al. performed a study to examine the relationship among 
body fatness, fat distribution, and lung function, adjusted for physical activity, energy 
expenditure and aerobic fitness(76). They found that obesity is inversely associated with 
lung function (FEV1 and FVC) in adults. Central fat distribution, however, appears to have 
a stronger relationship to respiratory mechanics (FEV1) in men than in women. These 
associations were independent of the degree of physical activity in this cohort.
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CONCLUSION
From the literature discussed, it can be concluded that there is a relationship between 
obesity and asthma. “Obese asthma” may be a unique phenotype of asthma, character-
ized by decreased lung volumes, greater symptoms for a given degree of lung function 
impairment, destabilization or lack of asthma control, lack of eosinophilic inflammation 
and a different response to controller medication. Therefore, the clinical evaluation of an 
obese patient with asthma must require a more rigorous and objective approach.
Whether this relationship is really causal or represents parallel co-morbidities is 
unclear. In animal models, there is an increasing amount of evidence for the role of 
adipokines derived from fat tissue in the relationship between obesity and asthma. This 
adipokines cause a low grade systemic inflammation, which might cause or enhance 
bronchial inflammation. The data are conflicting in humans. However, the fact that 
weight loss improves asthma control and normalizes the concentration of adipokines 
in the serum implies that there must be some role for adipokines in the relationship 
between obesity and asthma.
Since obesity is a component of the metabolic syndrome and the metabolic syndrome 
is also a form of systemic inflammation, it is to be expected that there is a relationship 
between metabolic syndrome and asthma. The few data that are available show that 
there is no relationship between metabolic syndrome and asthma, but there is one 
between the metabolic syndrome and asthma-like symptoms.
Further research is needed to confirm the relationship between obesity and asthma in 
humans, where a rigorous approach in the diagnosis of asthma and use of good control 
groups is essential. Intervention-based longitudinal research might find a definitive an-
swer to the question of what the basis of the relationship between obesity and asthma 
could be.
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ABSTRACT
Background: Obesity and asthma are associated. There is a relationship between lung 
function impairment and the metabolic syndrome. Whether this relationship also exists 
in the morbidly obese is still unknown.
Hypothesis: Low grade systemic inflammation associated with the metabolic syndrome 
causes inflammation in the lungs, and hence lung function impairment.
Methods: Cross-sectional study of morbidly obese patients undergoing pre-operative 
screening for bariatric surgery. Metabolic syndrome was assessed according to the 
revised NCEP-ATP III criteria.
Results: 452 patients were included. Patients with the metabolic syndrome (n=293) 
had significantly higher blood monocyte (mean 5.3 versus 4.9, p=0.044) and eosinophil 
percentages (median 1.0 versus 0.8, p=0.002) while the total leukocyte count did not dif-
fer between the groups. The FEV1/FVC ratio was significantly lower in patients with the 
metabolic syndrome (76.7% versus 78.2%, p=0.032). Blood eosinophils were associated 
with FEV1/FVC ratio (adj. B -0.113, p=0.018).
Conclusion: Although the difference in FEV1/FVC ratio between the groups is relatively 
small, in this cross-sectional study, and its clinical relevance may be limited, these data 
indicate that the presence of the metabolic syndrome may influence lung function 
impairment, through the induction of relative eosinophilia.
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INTRODUCTION
Obesity is an increasing worldwide problem that has taken on epidemic proportions(1). 
Cross-sectional studies have shown a positive association between obesity and asthma(2). 
Weight loss in obese asthma patients improved morbidity and lung function(3), however, 
the mechanisms underlying the relationship between asthma and obesity are unclear. It 
is suggested that low grade systemic inflammation associated with obesity plays a role.
The metabolic syndrome is a common metabolic disorder that may result from the 
increasing prevalence of obesity. Metabolic syndrome is a cluster of cardiometabolic risk 
factors characterized by abdominal obesity, insulin resistance and chronic systemic in-
flammation(4). Positive associations with lung function impairment have been reported 
for components of the metabolic syndrome, such as hypertension(5), type diabetes 
mellitus(6, 7), low-density lipoprotein cholesterol(8) and overall obesity(9). In recent large 
cohort studies it has been shown that there is also a relationship between lung function 
impairment and the metabolic syndrome(10-12). However, all aforementioned studies 
included overweight as well as normal weight subjects and were therefore not specifi-
cally targeted to examine these issues in the morbidly obese. Data on the association 
between lung function impairment and the metabolic syndrome in the morbidly obese 
are limited.
The mechanisms underlying the relationship between impaired lung function and the 
metabolic syndrome are unclear. The chronic low-grade systemic inflammation that is 
associated with obesity might explain this relationship. Our hypothesis is that this low-
grade systemic inflammation causes inflammation in the lungs, and hence lung function 
impairment.
We therefore performed a study to investigate (1) the association between lung func-
tion and the metabolic syndrome in morbidly obese subjects, and (2) to determine the 
effect of systemic inflammation on the relationship between lung function impairment 
and the metabolic syndrome.
METHODS
Study population
The subjects included in this study were consecutive patients who underwent pre-
operative screening for bariatric surgery in the Sint Franciscus Gasthuis in Rotterdam, 
the Netherlands, between October 2009 and May 2011. Eligibility criteria for bariatric 
surgery were: age between 18 and 60 years, either body mass index (BMI) ≥ 40 kg/m2 or 
≥ 35 kg/m2 combined with the presence of comorbidity e.g. diabetes mellitus, hyperten-
sion or proven obstructive sleep apnea syndrome (OSAS). Subjects underwent baseline 
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physical examinations that included routine assessment of anthropometry, blood pres-
sure, pulmonary function and blood samples.
Height and weight were measured wearing light clothes and no shoes. Body mass 
index was calculated as weight (in kg) divided by height (in m) squared. Abdominal 
circumference was measured directly to the body surface midway between the lower 
rib margin and the ileac crest.
The Epworth Sleepiness Scale questionnaire(13) was used to assess OSAS, and the 
GERD-Questionnaire(14) for gastro-esophageal reflux disease (GERD).
All subjects gave informed consent and the local ethics committee (Toetsingscom-
missie Wetenschappenlijk Onderzoek Rotterdam e.o, trialnumber NL25637.101.08) 
approved the study protocol (Netherlands Trial Register number NTR3204).
Definition of the metabolic syndrome
Metabolic syndrome was diagnosed according to the National Cholesterol Education 
Program’s Adult Treatment Panel III report (NCEP ATP-III) criteria when ≥3 of the follow-
ing 5 risk factors were present: abdominal obesity, an elevated level of serum triglycer-
ides, low serum level of high-density lipoprotein cholesterol (HDL-C), elevated blood 
pressure, and high serum glucose level or treatment for any of these disorders(4).
Pulmonary function tests
Spirometry was performed with Vmax spirometer (Vmax SensorMedics Viasys, type 
Encore 20/22/229/62  Encore, Cardinal Health, USA) before and after 400 µg of inhaled 
salbutamol, with subjects in a sitting position and nose clips in place according to 
the American Thoracic Society / European Respiratory Society statement(15). All values 
obtained were related to height, age and gender and expressed as percentage of their 
predicted value (reference ERS 1993). The pulmonary function results are prebroncho-
dilator values unless specifically noted. Exhaled Nitric Oxide (FeNO) was measured with 
Niox mino (Aerocrine, Sweden) and expressed in parts per billion (ppb).
Clinical chemistry
Blood was taken by venapuncture during routine pre-operative screening. Laboratory 
measurements were performed according to standard procedures by our department of 
Clinical Chemistry. Plasma-cholesterol, HDL-cholesterol, glucose, triglycerides and CRP 
were measured using LX 20 and DxC analyzers (Beckman Coulter, Miami, FL, USA). LDL-
cholesterol was calculated using the Friedewald formula. Total IgE and specific plasma 
IgE were determined with a solid-phase two-step chemiluminescent immunoassay on 
the Immulite 2000 (Siemens, Los Angeles, CA). A positive inhalation screen was defined 
as at least one increased amount of specific IgE  against one of the following allergens; 
Aspergillus fumigatus, house-dust mite, cat, dog, grass, birch or herbs. Blood cell counts 
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and 5-part leukocyte differentiation were determined automatically using LH750 ana-
lyzers (Beckman Coulter). HbA1C was determined using a Tosoh G8 HLC-723 analyzer 
(Tosoh Bioscience, Tokyo, Japan). Insulin was measured using radio immunoassay (RIA) 
DSL1600 (Diagnostic Systems Laboratories, Webster, Tx, USA). Vitamin D was determined 
by RIA or chemiluminescence (LIA) on  Liason analyzers (DiaSorin, Stillwater, MN, USA).
Statistical analyses
Unadjusted between-group comparisons were performed using Student’s t test or the 
Chi-square test, where appropriate, and Mann Whitney U test for nonparametric com-
parisons (eosinophils). CRP, IgE, insulin, lipoprotein-a and vitamin B6 were not normally 
distributed (standard error of kurtosis and skewness below -3 or above 3), and were 
therefore log-transformed. Univariate linear regression was used to evaluate associa-
tions between continuous variables.  Backward linear regression analysis was used to 
investigate which component of the metabolic syndrome is related to the FEV1/FVC 
ratio. Variables associated with FEV1/FVC ratio in univariate analysis at a p-value of <0.1 
were examined in the multiple linear regression analysis. Since the FEV1/FVC ratio as 
percentage predicted is already corrected for height, age and gender we did not add 
these variables to the model. As eosinophils and abdominal circumference were cor-
related, we selected only eosinophils to prevent collinearity. We omitted OSAS because 
of the large proportion of missing data. All analyses were performed using SPSS 18.0 
software (SPSS Inc., Chicago, Illinois, USA). Results were evaluated at 95% confidence 
interval at a two-sided p<0.05.
RESULTS
Subjects
452 subjects were included in the study (97 males and 355 females). 293 subjects (64.8%) 
fulfilled the criteria for metabolic syndrome. Table 1 shows the general characteristics 
of the study population. Patients with the metabolic syndrome were significantly older 
(mean 43 years), were less often female (73.7%), and had a larger abdominal circum-
ference in centimeters (mean 134.3 cm) compared to patients without the metabolic 
syndrome (mean 37 years, 87.4% and mean 126.8 cm, respectively).
Metabolic syndrome and blood parameters
Patients with the metabolic syndrome did not have a higher total leukocyte count or 
neutrophil percentage in the peripheral blood (p=0.253), but they did have a signifi-
cantly higher percentage of eosinophils (p=0.002) and monocytes (p=0.044) compared 
to patients without the metabolic syndrome (Table 2). Other parameters of systemic 
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inflammation such as CRP, Complement C3 and Complement C4 did not show signifi-
cant differences between the two groups (Table 2). There was no correlation between 
BMI and eosinophils. We did find a low, but significant correlation between eosinophils 
and abdominal circumference (Spearman correlation coefficient 0.270, p<0.001), and 
CRP and abdominal circumference (Spearman correlation coefficient 0.146, p=0.010).
Metabolic syndrome and pulmonary function tests
The subjects with the metabolic syndrome showed a significantly lower FEV1/FVC ratio 
– a measure for bronchial obstruction - compared to the group without the metabolic 
syndrome (76.7% and 78.2% respectively, p=0.032), while no difference was observed 
regarding FEV1 or FVC (Table 3). Although there was no significant difference in FEF25-75 
between subjects with and without the metabolic syndrome, the FEF75 was significant 
lower in the metabolic syndrome group (p=0.036). Log transformed FeNO – a measure for 
bronchial inflammation -  showed no difference between the two groups. There was no 
correlation between BMI and FeNO, and abdominal circumference and FeNO.
Table 1 General characteristics of the population included in the study





Age (years) 37 ± 11 43 ± 10 <0.0011
BMI (kg/m2) 45.4 ± 6.7 46.0 ± 6.5 0.395
Gender (% female) 87.4% 73.7% 0.0012
Ethnicity (% Caucasian) 80.5% 85.0% 0.222
Smoking
0.152
 %never smoked, 49% 40%
 %stopped smoking, 29% 32%
 %smokes 22% 28%
Pack years 3 6.0 ± 11.2 9.9 ± 14.8 0.003
Abdominal circumference (cm) 126.8 ± 14 134.3 ± 16 <0.001
Systolic blood pressure (mmHg) 136.4 ± 17.9 145.98 ± 16.6 <0.001
Diastolic blood pressure (mmHg) 83.6 ± 11.8 87.83 ± 10.1 <0.001
Comorbidities
 Diabetes mellitus 3.8% 30.3% <0.001
 Hypertension 18.9% 42.8% <0.001
 Hypercholesterolemia 1.9% 21.7% <0.001
 Self reported asthma 19.6% 21.0% 0.723
 Use of inhaled corticosteroids 3.8% 5.5% 0.413
1 Data presented as mean ± standard deviation, p-value for Student’s t test
2 Data presented as percentage, p-value for Chi-square test
3 Data were log transformed for statistical analysis
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Subgroup analysis – self reported asthma
There was no difference in the prevalence of self reported asthma between subjects 
with or without the metabolic syndrome (21.0% versus 19.6% respectively, p=0.723). 
In a subgroup analysis of subjects with self reported asthma, we found no significant 
difference in the use of inhaled corticosteroids, body mass index, pack years, FEV1 (% 
predicted), FEV1/FVC (% predicted), FeNO, blood eosinophils or CRP between subjects 
with or without the metabolic syndrome (data not shown).
Subgroup analysis – reversibility
In a subgroup analysis of subjects with and without reversibility (ΔFEV1≥12%), we found 
that only 50% of subjects with reversibility (n=30) had self reported asthma. Although 
subjects with reversibility did use more often inhaled corticosteroids (13.3% versus 
4.4%, p=0.032), there was no significant difference in FeNO, blood eosinophils or CRP 
between subjects with and without the metabolic syndrome.
Table 2 Comparison of blood parameters between subjects with and without metabolic syndrome





Leukocytes (109/L) 8.6 ± 2.3 8.9 ± 2.1 0.2531
 Neutrophils (%) 70.1 ± 8.6 68.9 ± 9.1 0.186
 Lymphocytes (%) 23.7 ± 7.1 23.8 ± 7.0 0.844
 Monocytes (%) 4.9 ± 1.8 5.3 ± 1.9 0.044
 Eosinophils (%) 0.82 (0.05-1.07) 1.00 (0.45-1.85) 0.0022
CRP (mg/L) 3 9.6 ± 7.4 9.5 ± 8.0 0.865
Cholesterol (mmol/l) 5.2 ± 1.0 5.1 ± 1.1 0.198
HDL- cholesterol (mmol/l) 1.3 ± 0.3 1.1 ± 0.2 <0.001
LDL- cholesterol (mmol/l) 3.5 ± 0.9 3.3 ± 1.1 0.108
Triglyceride (mmol/l) 1.0 ± 0.4 1.6 ± 1.0 <0.001
Glucose (mmol/l) 6.3 ± 1.3 8.2 ± 3.9 <0.001
HbA1C (%) 5.52± 0.4 6.4 ± 1.5 <0.001
Insulin (mE/L) 3 56.2 ± 58.1 75.0 ± 79.4 <0.001
Vitamin D (nmol/L) 39.5 ± 22.9 38.5 ± 17.7 0.661
IgE (kU/L) 3 213.5 ± 479.9 197.8 ± 391.3 0.141
Positive inhalation screen 46.2% 44.0% 0.694
1 Data presented as mean ± standard deviation, p-value for Student’s t-test
2 Data presented as median (1st-3rd quartiles), p-value for Mann-Whitney U test
3 Data were log transformed for statistical analysis
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Variables related with FEV1/FVC ratio
Since the FEV1/FVC ratio was the only variable of spirometric function tests which was 
different between subjects with and without the metabolic syndrome, and our hypoth-
esis was that the metabolic syndrome causes a lower FEV1/FVC ratio – and not the other 
way around - we investigated which variables were related to the FEV1/FVC ratio.
There was an association between the peripheral blood eosinophils percentage and 
the FEV1/FVC ratio (univariate linear regression coefficient= -0.806, p=0.006). Abdominal 
circumference and OSAS (Eppworth Sleepiness Scale (ESS)) were significantly related to 
the FEV1/FVC ratio (univariate linear regression analysis), whereas BMI, GERD, CRP and 
monocytes were not significantly related to the FEV1/FVC ratio (table 4). Missing values 
of ESS were not correlated to other variables.
Since the metabolic syndrome was associated with the FEV1/FVC ratio, we investigated 
which of the components of the metabolic syndrome contributed to this relationship. 
Only hypertension was significantly related to FEV1/FVC ratio (regression coefficient = 
-1.612, p=0.038 in backward linear regression analysis) (Table 5).
Multiple regression analysis
After correction for the use of inhaled corticosteroids, and the number of pack years, we 
found an association between blood eosinophils and the FEV1/FVC ratio (adj. B -0.113, 
p=0.018) (table 6).
DISCUSSION
This study shows that obese patients with the metabolic syndrome have a higher propor-
tion of blood monocytes and eosinophils and a lower FEV1/FVC ratio, indicating airway 
Table 3 Pulmonary function test of subjects with and without metabolic syndrome
No metabolic syndrome (n=159) Metabolic syndrome (n=293) p Value
FEV1 (% predicted) 93.0 ± 13.9 91.2 ± 14.5 0.2063
FVC (% predicted) 100.6 ± 14.0 98.5 ± 14.7 0.206
FEV1/FVC 78.2 ± 6.9 76.7 ± 6.4 0.032
FEF25-75 (% predicted) 77.4 ± 24.0 73.9 ± 23.3 0.152
Reversibility FEV1 >12% 6% 7% 0.5232
FeNO (ppb) 1 19.3 ± 22.4 17.6 ± 12.6 0.541
1 Data were log transformed before comparison
2 Data presented as percentage, p-value for Chi-square analysis,
3 Data presented as mean ± standard deviation, p values for Student T-test
FEV1, forced expired volume in 1 second; FVC, forced vital capacity; FEF25-75, forced expiratory flow 25%-75%; 
FeNO, fractional expiratory nitric oxide; TLC, total lung capacity.
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obstruction, than obese patients without the metabolic syndrome. Blood eosinophils 
(%) in morbidly obese subjects were related to FEV1/FVC, whereas monocytes were not. 
After adjustment for multiple variables, the relationship between FEV1/FVC ratio and 
eosinophils remained intact. Although the differences are small, it strengthens our hy-
Table 4 Univariate linear regression analysis of FEV1/FVC
Regression coefficient Standard Error p Value2
Monocytes (%) -0.079 0.162 0.626
Eosinophils (%) -0.806 0.290 0.006
CRP (mg/mL) 0.075 0.045 0.098
Abdominal circumference (cm) -0.058 0.021 0.006
Body mass index (kg/m2) 0.041 0.047 0.387
OSAS (Eppworth Sleepiness Scale)1 0.311 0.141 0.029
GERD (GERD questionnaire) 0.068 0.157 0.667
1 Missing values n=148
2 Data presented as linear regression coefficient, p-value for simple linear regression analysis
GERD, Gastro Esophageal Reflux Disease; OSAS, Obstructive Sleep Apnea Syndrome
Table 5 Univariate regression analysis of relation of components of metabolic syndrome and FEV1/FVC ratio
Regression coefficient Standard error p Value1
Abdominal circumference NA
Hypertriglycemia -1.119 0.739 0.130
Low serum HDL- cholesterol 0.712 0.686 0.300
Hypertension -1.612 0.774 0.038
High serum glucose -0.010 0.753 0.989
1 Data presented as linear regression coefficient, p-value for linear regression analysis
Abdominal circumference is not applicable, because all patients fulfill the criteria for abdominal circumfer-
ence according to the NCEP-ATP III criteria for metabolic syndrome
Table 6 Multiple regression analysis FEV1/FVC ratio
Whole group
(n=408)
(Adj R2 = 0.074)
Regression coefficient 95% CI p-Value
Eosinophils (%) -0.113 -1.247- -0.118 0.018
Use of inhalationcorticosteroids -0.025 -3.635-2.122 0.606
Pack years -0.259 -0.162- -0.076 <0.001
Variables associated with FEV1/FVC ratio in univariate analysis at a p-value of <0.1 were examined in the 
multiple linear regression analysis. Since the FEV1/FVC ratio as percentage predicted is already corrected for 
height, age and gender we did not add this variables to the model. As eosinophils and abdominal circum-
ference are correlated, we selected only one variable to prevent co-linearity. We omitted OSAS because of 
the large proportion of missing data.
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pothesis that the presence of the metabolic syndrome could play a role in lung function 
impairment, through the induction of systemic inflammation, in particular mediated by 
blood eosinophils. Whether this also leads to asthma on the long term still remains to 
be elucidated.
To our knowledge this is the first study concerning lung function and the metabolic 
syndrome in a cohort of only morbidly obese subjects. Secondly, comorbid conditions 
associated with obesity such as OSAS and GERD were taken into account in the cur-
rent study. Thirdly, adiposity was not only assessed with BMI, but also with abdominal 
circumference. Although one would expect that all our subjects have the metabolic 
syndrome, we found a 65% prevalence of the metabolic syndrome in our group, which 
corresponds with 60% of the morbidly obese in the NHANES III cohort(16).
Various studies have shown that obesity causes a modest reduction in total lung ca-
pacity (TLC), and a larger reduction in functional residual capacity (FRC)(17).  However, we 
were unable to perform a TLC measurement in all subjects to rule out a restrictive pat-
tern. The FEV1/FVC ratio is usually well preserved in obese subjects, or even increased. 
This could explain the high mean FEV1/FVC ratio in our subjects, and therefore we have 
used the FEV1/FVC ratio as a continuous variable and did not use a cutoff value of 70% 
predicted. Furthermore, in contrast to the FEV1/FVC, the FEV1 is influenced by BMI, hence 
our focus on the FEV1/FVC ratio.
The prevalence of self-reported asthma was similar in the two groups. We did not 
perform methacholine-provocation tests, so a definitive diagnosis of asthma was often 
not possible. Since misdiagnosis of asthma is a relevant issue, also in the obese(18), we felt 
more comfortable using objective parameters instead of a presumed diagnosis.
Since the metabolic syndrome was associated with the FEV1/FVC ratio in univariate 
analysis, we investigated which of the components of the metabolic syndrome contrib-
uted to this relationship. Hypertension was the only component that was significantly 
associated with a reduced FEV1/FVC ratio after multiple backward regression analysis. 
Hypertension may have the strongest association with systemic inflammation, as pro-
posed by Irace et al.(19). We could also confirm the results of Leone et al.(10) showing that 
there is indeed a relationship between abdominal circumference (in cm) and the FEV1/
FVC ratio. Interestingly we found a correlation between blood eosinophil percentage 
and abdominal circumference, were we found no correlation between blood eosinophil 
percentage and BMI, indicating that it is mainly the place of the fat that matters. This 
suggests that the increased abdominal circumference of subjects with the metabolic 
syndrome causes the relative eosinophilia.
Obesity is a state of chronic low grade systemic inflammation. Leukocyte count is 
considered a marker of systemic inflammation. Several epidemiological studies have 
already noted a relationship between some components of metabolic syndrome and 
leukocytes(20, 21). Several studies showed an increased eosinophil percentage in obe-
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sity(22) or in the metabolic syndrome(20, 21). C-reactive protein (CRP) is a traditional marker 
of inflammation, and is well correlated with BMI(23). Even though our study found no 
difference in CRP between the two groups - we did not use high-sensitivity CRP mea-
surements - monocyte and eosinophils percentage in the blood were higher in those 
with the metabolic syndrome. Our study suggests that increased numbers or circulating 
eosinophils could be a specific manifestation of the systemic inflammation associated 
with the metabolic syndrome.
The question remains why there is relative eosinophilia in the obese. Traditionally, 
eosinophils are related to allergic diseases, asthma and parasitic infections. The fat tis-
sue is a source of adipokines, which are considered to play a role in the low-grade 
systemic inflammation in obesity(24). Leptin –mainly produced by adipose tissue- is a 
pro-inflammatory agent. Serum leptin is markedly increased in obese humans, corre-
lating to BMI(25), it activates eosinophils(26) and increases their survival(27). Serum leptin 
levels are elevated in adults of normal weight with impaired lung function(28). Eotaxin, 
is an eosinophil-specific chemokine that is increased in obesity(29). Adipocytes produce 
more eotaxin when stimulated by leptin(30). Plasma adiponectin - an anti-inflammatory 
hormone - is reversely correlated to BMI(31). The leptin/adiponectin ratio is a marker 
of insulin resistance(32) and the metabolic syndrome(33). Thus, both leptin and possibly 
eotaxin could contribute to relative eosinophilia in the obese. Unfortunately, we do 
not have data on leptin, adiponectine and eotaxin to further support their role in the 
observed eosinophilia.
Another question is whether this relative eosinophilia in the peripheral blood also has 
local effects on the bronchial tissue, and causes or enhances the bronchial inflammation 
as seen in asthma. Asthma-like symptoms are common in patients with the metabolic 
syndrome, and their pulmonary function is impaired(34, 35). Although we did find dif-
ferences in pulmonary function between subjects with and without the metabolic 
syndrome, there was no difference in prevalence of self-reported asthma between the 
two groups. This is however unreliable in the morbidly obese(18). The characteristics of 
airway inflammation in asthma (exhaled nitric oxide (eNO) and inflammatory cells in 
induced sputum) have been investigated in obesity and are still subject to debate. De 
Winter – de Groot et al. showed that a higher BMI was associated with a higher eNO 
in healthy patients(36). Several studies have found no –or even an inverse– relationship 
between the number of sputum eosinophils and BMI(37). We found no difference in eNO 
between subjects with and without the metabolic syndrome. Induced sputum or bron-
chial biopsies could have helped to solve this question, but were unfeasible in this study. 
Since there was no difference in the use of inhaled corticosteroids, this could not have 
influenced our results of eNO.
Our study includes several limitations. We did not measure TLC values, so we were 
not able to firmly assess a restrictive lung function pattern. Also, we did not perform 
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methacholine-provocation tests, so a definite diagnosis of asthma was often not pos-
sible. The FEV1/FVC ratio however, is easy to measure and widely used in clinical practice. 
Although the differences in FEV1/FVC and eosinophils between subjects with and with-
out the metabolic syndrome were small, the difference was significant despite the fact 
that our study groups consisted of unselected subjects. There probably is a selection-
bias since we only included patients who were willing to undergo bariatric surgery. It 
is widely known that most of the subjects who undergo bariatric surgery are female. 
This explains the female predominance among our subjects. Furthermore, we did not 
measure adipocytokines or high sensitivity-CRP. We did not include a non-obese control 
group as comparison for low grade inflammation, and we cannot fully exclude that 
smoking might have contributed  to a state of low-grade inflammation. However, we 
corrected for smoking in the multiple regression analysis. Finally, we realize that a cross-
sectional association between metabolic syndrome and lung function cannot establish 
causality. However, Naveed et al.(12) have recently shown that the metabolic syndrome 
predicts a steeper FEV1 decline over time, suggesting that the systemic inflammation 
produced by metabolic syndrome may impact the progression to abnormal lung func-
tion in a longitudinally followed cohort.
In summary, our study shows that there is a small, but statistical significant, difference 
in eosinophils and FEV1/FVC between subjects with and without the metabolic syn-
drome. After correction for other variables, an association between blood eosinophils 
and FEV1/FVC remained. Although the differences we have found were relatively small, 
it might support our hypothesis that the presence of the metabolic syndrome may 
influence lung function impairment, through the induction of systemic inflammation, 
in particular mediated by blood eosinophils. Further research with a firm diagnosis of 
asthma and assessment of peripheral airway inflammation is necessary. Moreover, in 
order to establish causality between the metabolic syndrome and lung function impair-
ment, longitudinal studies in morbidly obese patients before and after bariatric surgery 
are needed.
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To the editor
Asthma in the obese has been described as a specific phenotype, with a late onset and 
high symptom expression(1). However, the nature of bronchial inflammation in obese 
subjects with asthma is not fully understood.  In contrast to eosinophilic airway inflam-
mation in lean asthmatics, a predominance of airway neutrophilia has been reported 
in obese asthmatic women(2). Some groups reported increased sputum neutrophil 
counts(2, 3),  whereas others found no increase of neutrophilic inflammation in obese 
asthma patients(4, 5).
All aforementioned studies in obese asthmatics investigated induced sputum or 
brush biopsies(6) which may not fully reflect tissue inflammation. Thus far, only one 
study has described  the analysis of bronchial biopsies in obese asthmatics, showing 
increased eosinophil counts in patients with severe asthma and obesity as compared to 
lean asthmatics(7). However, that study did not include an obese control group, nor were 
other cell populations investigated such as airway neutrophils. To our knowledge, there 
are no data on bronchial biopsies from morbidly obese patients with mild-to-moderate 
asthma compared to morbidly obese control subjects without asthma.
We performed a cross-sectional study in 27 morbidly obese patients with asthma, 
defined according to GINA guidelines(8) and 43 morbidly obese control subjects under-
going bariatric surgery. Some of the results of this study have been previously reported 
in the form of an abstract(9).
This study is part of a larger study, the results of which have been reported else-
where(10). Subjects were between 18 and 50 years of age, with a BMI above 35 kg/m2, 
and were excluded if they smoked more than 10 cigarettes per day or had smoked more 
than 10 pack years. The study was approved by the local ethics committee (Netherlands 
Trial Register 3204), and all subjects gave written informed consent. Lung function tests, 
asthma control, asthma quality of life, comorbidities, parameters of systemic inflamma-
tion and cell counts of bronchial biopsies were compared between obese patients with 
asthma and obese control patients.
A total of 86 patients were included(10), of whom 70 patients (table 1) had bronchial 
biopsies with acceptable quality for further analysis. When comparing the obese pa-
tients with asthma and obese control groups, no differences were detectable in several 
parameters assessed in peripheral blood, except for the neutrophil count and levels of 
serum IL-6 which were both slightly, but significantly, increased in the morbidly obese 
asthma group compared to the morbidly obese control group (table 1). We found no 
other significant differences between these groups concerning markers of systemic 
inflammation (IL-8, hs-CRP, TNFα, GM-CSF, leptin or adiponectin).
When assessing bronchial biopsies, there were no significant differences in submu-
cosal cell counts of eosinophils, neutrophils, mast cells, macrophages, B-cells, CD4+ or 
CD3+ T-cells (figure 1 A – G). CD8+ T-cells were significantly lower in the asthma group 
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Gender (%female) 77.8% 81.4% 0.764
Ethnicity (%non-Caucasian) 18.5% 11.6% 0.493
Age (years) 33 (19-48) 38 (19-50) 0.623
Weight (kg) 127.1 (101-202) 126.0 (94-199) 0.850
Body Mass index (kg/m2) 44.59 (38.4-63.8) 43.35 (36.9-60.0) 0.326
Abdominal circumference (cm) 130 (112-165) 128 (98-200) 0.985
Bio-impedance
 Fat free Mass 58.2 (50.1-100.5) 62.3 (48.0-83.9) 0.248
 Fat weight (%) 50.9 (37.6-70.4) 51.1 (31.1-59.7) 0.878
 Fat weight (kg) 65.4 (44.5-134.4) 63.0 (33.9-100) 0.396
Smoking status 0.058
 % never smoked 55.6% 72.1%
 % stopped smoking 14.8% 18.6%
 % current smoker 29.6% 9.3%
Pack years 0 (0-10) 0 (0-10) 0.246
Asthma
Asthma Control Questionnaire1 1.1 (0.4-2.9) 0.3 (0-2.9) 0.001
Asthma Quality of Life Questionnaire 2 5.8 (3.7-6.8) 6.6 (3.7-7.0) 0.007
Medication use at inclusion study
 Short acting bronchodilator 48.1% 23.3% 0.039
 Long acting bronchodilator 3.7% 2.3% 1.000
 Antileukotrienes 0% 2.3% 1.000
 B2 sympaticomimetica/ ICS 22.2% 7.0% 0.070
 Inhaled corticosteroids 22.2% 7.0% 0.079
 Antihistamines 25.9% 11.6% 0.192
 Nasal corticosteroids 14.8% 11.6% 0.726
Atopy
Atopy 3 70.4% 41.9% 0.027
IgE (kU/L) ** 205 (5-1838) 59 (1.4-761) 0.049
Comorbidities
Epworth Sleepiness Scale 2 (0-8) 2 (0-15) 0.670
GERD-questionnaire 6 (4-12) 7 (2-14) 0.524
Steps a day 5107 (2156-12176) 5158 (2061-11705) 0.766
Metabolic syndrome 51.9% 51.2% 1.000
Lung function
Spirometry
 FEV1, pre(% predicted) 88 (66-119) 97 (73-125) 0.023
 FEV1, post (% predicted) 95 (74-118) 101 (75-129) 0.141
 FVC, pre (% predicted) 97 (75-126) 102 (79-144) 0.623
 FEV1/FVC, pre (%) 76 (63-86) 81 (66-93) 0.010
 RV, post (% predicted) * 68 (39-126) 75 (33-118) 0.757
 ERV, post (% predicted) * 45 (24-78) 47 (11-66) 0.682
 TLC, post (% predicted) * 95 (80-106) 94 (76-114) 0.822
 FRC, post (% predicted) * 60 (47-95) 61 (41-88) 0.925
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 RV/TLC, post (%) * 22 (10-41) 25 (12-86) 0.249
Reversibility FEV1 10 (-6-20) 3 (-7-11) 0.001
FeNO (ppb) ** 16 (5-45) 16 (7-53) 0.934
Diffusion capacity (% predicted) 95 (69-130) 96 (69-134 1.000
PD20 (mg) 0.33 (0.04-1.8) > 1.8
IOS
 R5 (kPa/sec) 0.70 (0.42-1.39) 0.56 (0.32-0.85) 0.003
 R20 (kPa/sec) 0.45 (0.27-1.03) 0.42 (0.19-0.68) 0.623
 R5-R20 0.26 (0.06-0.66) 0.15 (0.03-0.28) <0.001
 X5 (kPa/sec) -0.26 (-0.87- -0.12) -0.20 (-0.41- -0.08) 0.061
 Fres (Hz) 22.67 (10.5-29.0) 17.95 (8.4-23.2) <0.001
Laboratory4
 Cholesterol (mmol/L) 4.7 (3.4-7.4) 5.0 (2.3-6.9) 0.972
 HDL-cholesterol (mmol/L) 1.1 (0.7-2.3) 1.1 (0.7-2.1) 0.910
 LDL-cholesterol (mmol/L) 2.9 (1.6-5.1) 3.0 (0.7-4.8) 0.920
 Triglyceride (mmol/L) 1.7 (0.6-3.3) 1.4 (0.4-5.1) 0.326
 Glucose (mmol/L) 5.6 (4.6-9.5) 5.6 (4.0-27.1) 0.910
 Vitamin D (nmol/L) 40.5 (11-127) 40.0 (10-62) 0.877
Peripheral blood count
 Leukocytes (109 /L) 8.7 (5.3-13.1) 7.2 (5.2-11.9) 0.141
 Neutrophils (%) 61 (45-72) 59 (46-70) 0.049
 Lymphocytes (%) 28 (17-45) 32 (20-47) 0.141
 Monocytes (%) 0.5 (0.4-1.5) 0.5 (0.3-0.9) 0.141
 Eosinophils (%) 2 (0-6) 2 (0-8) 0.942
 Basophils (%) 0 (0-1) 0 (0-2) 0.850
 HS-CRP (pg/ml) 36.0 (4.3-142.0) 31.5 (3.7-120.4) 0.732
 IL-6 (pg/ml) 0.72 (0.61-3.78) 0.70 (0.7-13.3) 0.020
 IL-8 (pg/ml) 3.86 (1.79-13.46) 3.84 (1.86-9.12) 0.877
 TNF-alfa (pg/ml) 0.8 (0.8-1.3) 0.8 (0.8-1.0) 0.910
 GM-CSF (pg/ml) 0.61 (0.61-3.78) 0.61 (0.61-8.44) 0.275
 Leptin (ng/ml) 68 (18-100) 70 (11-100) 0.877
 Adiponectin (pg/ml) 12.0 (4.5-22.0) 14.1 (0.06-28.9) 0.251
Data are presented as median (min-max)
* Because of weight limitations (<150 kg) of body box different numbers; asthma = 18, control = 30
** Log transformed for statistical purposes
1 Scores of the asthma control questionnaire range from 0 to 6, with lower scores indicating better asthma 
control
2 Scores of the AQLQ range from 1 to 7, with higher scores indicating better asthma-specific quality of life
3 Defined as either one positive reaction to the skin-prick test or one positive reaction to specific IgE inhala-
tion screen
4 Non-fasting blood sample
Diffusion capacity,  kCO; ERV, expiratory reserve volume; FeNO, exhaled nitric oxide; FEV1, forced expiratory 
volume in 1 second; FRC, functional residual capacity; FVC, forced vital capacity; ICS, inhaled corticosteroid; 
PD20, provocative dose of methacholine inducing a 20% fall in FEV1; RV, residual volume; TLC, total lung 
capacity
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compared to the controls (median 682 versus 1017, p=0.014; figure 1H). There was no 
difference in CD4/CD8 ratio or in reticular basement membrane (RBM) thickness be-
tween the two groups (figure 1I-J).
In contrast, a subgroup analysis showed that asthmatics with uncontrolled asthma 
(Asthma Control Questionnaire score >1.5) compared to obese control had signifi-
cantly higher levels of IL-6 (median 0.89 vs. 0.70 pg/ml, p<0.001) and lower adiponectin 
(median 9.2 vs. 14.1 ng/ml, p=0.014), whereas we found no differences in cell counts 
in bronchial biopsies.  Further subgroup analysis (ICS use at time of biopsy, females, 
high IgE, large abdominal circumference, childhood-onset versus adult onset asthma, 
smoking) showed no differences between obese control patients and obese patients 
with asthma regarding all parameters representing bronchial or systemic inflammation.
We found no significant correlations between clinical parameters (lung function 
parameters [FEV1, FEV1/FVC, provocative dose of methacholine inducing a 20% fall in 
FEV1, and fractional exhaled nitric oxide] or symptoms (Asthma Control Questionnaire or 
Asthma Quality of Life Questionnaire) and bronchial or systemic inflammation.
In contrast to previous reports(2, 7), the present results show neither eosinophilic nor 
neutrophilic inflammation in the group of morbidly obese asthmatics. In contrast to De-
sai and colleagues(7), who analyzed exclusively patients with severe asthma, we included 
only patients with mild-to-moderate asthma. Furthermore, the median body mass index 
was significantly higher in our study (44 kg/m2) compared to Desai’s study (36 kg/m2).
In addition, we also investigated other cell types in the bronchial submucosa, such as 
mast cells, macrophages, B-cells, CD3+, and CD4+ and positive T-cells, and again found 
no differences between the asthma and the control group. Moreover, we also measured 
the reticular basement membrane thickness, as a marker of airway remodeling(11), and 
found no difference between obese asthmatics and obese control patients. These data 
suggest that asthma in this cohort is not driven by a classical Th2-mediated mechanism 
and probably needs to be regarded as a distinct phenotype of the disease that is not 
related to significant inflammatory responses in the airways. It needs to be noted that 
we did not assess innate immune cells such as innate lymphoid cells, natural killer cells 
and dendritic cells in our analysis, and therefore cannot exclude the possibility that dif-
ferences existed in these cells between the asthma and control groups.
Sutherland and colleagues(12) previously demonstrated that asthma phenotypes are 
not homogenous in obese individuals. However, in the present study, we found no dif-
ferences in lung function, symptoms, or inflammation parameters when analyzing dif-
ferent subgroups such as subjects with a larger abdominal circumference, age of onset 
of asthma, high IgE or use of inhaled corticosteroids. We cannot exclude the possibility 
that morbidly obese mild to moderate asthma patients constitute an obese asthma 
phenotype that is characterized by the absence of bronchial inflammation.


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 1 Bronchial submucosal cell counts and reticular basement membrane thickness
Bronchial submucosal cell count in obese subjects with and without asthma (a) eosinophils (p=1.000) 
(asthma n=27, control n=43), (b) neutrophils (p=0.141), (c) mast cells, (d) macrophages (p=0.326), (e) B-cells 
(p=0.141), (f ) CD4+ T cells (p=1.000), (g) CD3+ T cells (p=0.326), (h) CD8+ T cells (p=0.014), (i) reticular base-
ment membrane thickness (p=0.874) (asthma n=15, control n=18),  (j) CD4 / CD8 ratio  (k) Photomicrograph 
of a bronchial biopsy from an obese subject with asthma showing stained eosinophils.
The horizontal bar is the median.
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Several hypotheses may explain the relationship between obesity and asthma, such 
as co-morbidities (Gastroesophageal reflux disease, obstructive sleep apnea syndrome) 
or the metabolic syndrome(13) for which we found no differences between obese pa-
tients with asthma and obese control patients. Body composition in the obese, however, 
might cause asthmatic symptoms and lung function impairment(14), and in particular, 
the significant difference in impulse oscillometry (R5-R20) suggests  an
abnormality in the lung periphery, which is in line with recently reported data(15).
The strength of our study is the inclusion of an obese control group of subjects with-
out asthma. Furthermore, the diagnosis of asthma was performed strictly according to 
the Global Initiative for Asthma guidelines, and was not based on a doctor diagnosis in 
which  symptoms play a major role, which has been shown to be incorrect(16). Nonethe-
less, there are some limitations to our study. First, we did not include a lean asthma or 
lean control group. Furthermore, we used a heterogeneous asthma group with a major-
ity of subjects with mild to moderate disease and relatively few symptoms, in contrast to 
other studies that investigated more severe obese patients with asthma.
In summary, despite evidence for systemic inflammation, which seemed to be related 
to the level of asthma control, there was no evidence for bronchial inflammation, char-
acterized by increased numbers of eosinophils or neutrophils. Further research aiming 
at the effects of weight reduction on inflammation, symptoms, lung function and quality 
of life in the morbidly obese may provide valuable further insights in the pathogenesis 
and treatment of asthma in that population.
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Pulmonary function testing and 
complications of laparoscopic 
bariatric surgery
van Huisstede A, Biter LU, Luitwieler R, Castro Cabezas M, Mannaerts G, 




Background: Obesity is associated with respiratory symptoms and impaired pulmonary 
function, which could increase the risk of complications after bariatric surgery.
Aim: To assess the relationship between pulmonary function parameters before, and the 
risk of complications after, laparoscopic bariatric surgery.
Methods: This prospective study included patients (age 18-60, BMI >35 kg/m2), who 
were eligible for bariatric surgery. Spirometry was performed in all patients. Complica-
tions up to 30 days after bariatric surgery were recorded.
Results: 485 patients were included (304 laparoscopic sleeve gastrectomy, 181 
laparoscopic gastric bypass). There were 53 complications (8 pulmonary, 27 surgical, 
14 infectious, 4 other) in 50 patients (10%). There were 35 re-admissions (7.2%), and 
17 re-laparoscopies (3.5%). Subjects with and without complications did not differ 
significantly with respect to demographics, weight, BMI, abdominal circumference or 
fat percentage. Subjects with complications had a significantly lower mean FEV1 (mean 
86.9% predicted) and FVC (95.6% predicted) compared to patients without complica-
tions (95.9% predicted, p=0.005, and 100.1% predicted, p=0.045, respectively). After 
adjustment for age, gender, BMI and smoking, abnormal spirometry value remained the 
single predictive covariable of postoperative complications; FEV1/FVC<70% adj. OR 3.1 
(95%CI 1.4-6.8, p=0.006) and ΔFEV1≥12% adj. OR 2.9 (95%CI 1.3-6.6, p=0.010).
Conclusion: The risk of pulmonary complications after laparoscopic bariatric surgery 
is low. However, subjects with abnormal spirometry test results have a threefold risk 
of complications after laparoscopic bariatric surgery. Preoperative pulmonary function 
testing might be useful to predict the risk of complications of laparoscopic bariatric 
surgery.
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INTRODUCTION
Obesity is becoming a world-wide epidemic. In 2008, the WHO estimated that one out 
of ten persons of the world’s adult population was obese(1). Accordingly, the number of 
bariatric surgery procedures being performed is increasing every year, with a 22-fold 
increase between 1996 and 2008(2). The postoperative morbidity rate after bariatric 
surgery is about 5%. Gupta showed in a large cohort study that postoperative pneumo-
nia and respiratory failure, despite being infrequent complications of bariatric surgery, 
account for one fifth of the morbidity. Moreover, these complications are also associated 
with increased mortality(3) and represent largest attributable costs of all complications(4). 
The prevention of complications of bariatric surgery is of great importance, especially 
since the operation is elective and complications are difficult to treat in this group of 
morbidly obese patients. Obesity is found to be a risk factor for the development of 
postoperative pulmonary complications after abdominal surgery(5). Obesity-related 
co-morbidities may predispose obese patients to postoperative complications, as illus-
trated by the observation that asthma is 50% more prevalent among obese subjects(6) 
and obese asthma patients have worse asthma control(7), which might predispose them 
to postoperative complications.
Current guidelines do not indicate pulmonary function testing in patients without 
evidence of pre-existing lung disease who are evaluated for non-thoracic surgical 
procedures. It is, however, questionable whether this also holds true for the morbidly 
obese. Spirometry could identify patients who are at risk for complications, although 
this is not the current consensus(8). Spirometry is mandatory in patients who are heavy 
smokers, or have complaints of dyspnea or cough(9). However, there is a poor correlation 
between lung function measurements and the presence of symptoms(10), also among 
the morbidly obese.
Hamoui has shown  that pulmonary function parameters prior to open bariatric 
surgery are predictive for complications after bariatric surgery(11). However, bariatric 
surgery has developed during the last decade into a laparoscopic procedure which 
is considered to be a safer treatment than open surgery(12). Laparoscopic procedures 
are typically associated with less postoperative pain, decreased opioid use, and earlier 
mobilization when compared with open procedures(13). However, the prognostic added 
value of pulmonary function testing before laparoscopic bariatric surgery is unknown.
Since laparoscopic procedures are now standard, and little is known about the 
value of pulmonary function tests before laparoscopic bariatric surgery, we performed 
a prospective study to compare the predictive relationship between lung function 
parameters before laparoscopic bariatric surgery and the postoperative 30 days risk of 
complications, taking co-morbidities, demographic, and anthropomorphic features into 
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account. We hypothesized that abnormal lung function test results before surgery could 
identify patients at risk for complications of bariatric surgery.
MATERIALS AND METHODS
Study population
The subjects included in this study were consecutive patients who underwent a pre-
operative screening program for bariatric surgery in the Sint Franciscus Gasthuis in Rot-
terdam, The Netherlands, between October 2009 and November 2011. Eligibility criteria 
for bariatric surgery were: age between 18 and 60 years, body mass index (BMI) either 
≥ 40 kg/m2 or ≥ 35 kg/m2 combined with the presence of comorbidity such as diabetes 
mellitus, hypertension or proven obstructive sleep apnea syndrome (OSAS). Prior to 
surgery, subjects underwent  physical examinations that included routine assessment 
of anthropometry and pulmonary function. Height and weight were measured wearing 
light clothes and no shoes. Body mass index was calculated as weight (in kg) divided 
by height (in m squared). Abdominal circumference was measured directly to the body 
surface midway between the lower rib margin and the ileac crest. Fat free mass and fat 
weight (in kg and % body weight) were measured using electrical impedance analysis 
(Bodystat 1500, Bodystat Ltd, British Isles)(14). The presence of comorbidities was defined 
as follows: diabetes mellitus, hypertension or hyperlipidemia all by the use of medica-
tion, the presence of the metabolic syndrome according to the NCEP-ATP-III criteria(15), 
the diagnosis of asthma and COPD after consultation with a pulmonologist and pulmo-
nary function tests, as described below. The Epworth Sleepiness Scale(16) questionnaire 
was used to assess OSAS, and the GERD-Questionnaire(17) for gastro-esophageal reflux 
disease (GERD).
All participating subjects gave informed consent. The local ethics committee (Toetsing-
scommissie Wetenschappenlijk Onderzoek Rotterdam e.o, trial number NL25637.101.08) 
approved the study protocol (Netherlands Trial Register number NTR3204).
Pulmonary function tests
Spirometry was performed with Vmax spirometer (Vmax SensorMedics Viasys, type 
Encore 20/22/229/62 Encore, Cardinal Health, USA) before and after 400 µg of inhaled 
salbutamol, with subjects in a sitting position and nose clips in place according to 
the American Thoracic Society / European Respiratory Society statement(18). All values 
obtained were related to height, age and gender and expressed as percentage of their 
predicted value (reference ERS 1993). The pulmonary function test results are shown 
as prebronchodilator values unless otherwise indicated. The degree of reversibility in 
FEV1, which indicates a diagnosis of asthma is generally accepted as ≥12% and 200 ml 
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from the pre-bronchodilator value (ΔFEV1≥12%)(19). Because many lung diseases may 
result in reduced FEV1, a useful assessment of airflow limitation is the ratio of FEV1 to 
FVC. The FEV1/FVC ratio is normally greater than 70%. Total Lung Capacity could only be 
measured if subjects were <150 kg. Exhaled nitric oxide (FeNO) was measured with Niox 
mino (Aerocrine, Sweden) and expressed in parts per billion (ppb)(20).
Bariatric surgery
All operations were laparoscopic, either sleeve gastrectomy(21) or Roux-en Y gastric 
bypass. Routine anesthesia was applied with desflurane and remifentanil. Both proce-
dures were performed with the patient in a semi-reclining position (anti-Trendelenburg 
position) with the legs in split upward position (French position). All patients routinely 
received prophylaxis against deep venous thrombosis with pneumatic compression 
stocking and subcutaneous low molecular weight heparin during two weeks. Periop-
erative antibiotics (cefazoline 2 gram) were also routinely given. Patients were normally 
discharged the second day after surgery.
Complications
The cumulative 30-days postoperative complications were obtained from the patient 
charts and divided into pulmonary, surgical, infectious or other by a surgeon and a 
pulmonologist. The reasons for either  hospital readmission or the problem found at 
relaparoscopy were scored as complications, but  readmission or  relaparoscopy itself 
were not scored as separate complications.
Statistical analyses
Analysis was not restricted to pulmonary problems, but included all complications. Pa-
tients were divided into groups with and without complications. Unadjusted between-
group comparisons were performed using Student’s t test or the Chi-square test (or 
Fisher’s Exact test, where appropriate) and the Mann Whitney U test for nonparametric 
comparisons. Multiple logistic regression analysis (entered) was used to assess the 
relationship between preoperative factors and the risk of postoperative complications 
adjusted for other co-variables. Baseline variables associated with complications in 
univariate analysis at a p-value of <0.1 were examined in the logistic regression analysis. 
Age, sex, BMI and smoking status were added to the regression analysis. Since FEV1 and 
FVC are associated, we used three different regression models which all contained one 
of the pulmonary function parameters. All analyses were performed using SPSS 18.0 




485 patients were included (mean BMI 45.4 kg/m2, M:F 100:385). There were in total 53 
complications in 50 patients (10.3%) after bariatric surgery (as specified in table 1). There 
were 35 re-admissions (7.2%), of which seven patients were found to have no complica-
tions. Relaparoscopy was performed in 16 cases, relaparotomy in one case (total 3.5%). 
All of these subjects were found to have a complication (9 hematoma, 1 spleen injury, 
1 anastomosis leakage, 3 anastomosis stenosis, 2 small bowel injuries, 1 abscess).  No 
deaths occurred.
Baseline characteristics did not differ between subjects with or without complications 
(table 2), especially not in BMI, abdominal circumference or fat mass. The superobese 
patients (BMI>50 kg/m2, n=104) did not have more complications than the subjects 
with BMI <50 kg/m2 (n=381) (10.6% versus 10.2%, p=0.92). There was no difference 
in pre-existing comorbidities, e.g. asthma, diabetes, reflux (assessed with GERD-Q) or 
sleep apnea syndrome (assessed with ESS). There were no differences either in opera-
Table 1 Postoperative complications
Frequency
Pulmonary complications 8 (1.6%)
 Pneumonia 5
 Pulmonary embolism 1
 Pneumothorax 1
 Lung abscess 1
Surgical complications 27 (5.6%)
 Hematoma (intra-abdominal) 10
 Spleen injury 3
 Anastomotic leak 2
 Anastomotic stenosis 3
 Requirement for blood transfusion 4
 Small bowel injury 2
 Abscess (deep) 1
 Stenosis (endoscopic dilatation) 1
 Hypovolemic shock 1
Infectious complications 14 (2.9%)
 Urinary tract infection 4
 Abdominal wall infection 8
 Unknown 2
Other complications 4 (0.8%)
 Dehydration 3
 Intensive Care admission for  hyperglycaemia 1
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tion technique used (sleeve gastrectomy or gastric bypass) or in American Society of 
Anesthesiologists (ASA) scoring between groups with or without complications. There 
was a trend towards longer operation duration in subjects with complications, and the 
median length of hospital stay was significantly longer in subjects with complications 
(table 2).
Subjects with complications had a significantly lower FEV1 compared to subjects with-
out complications (table 3). Subjects with complications more often had airflow revers-
ibility (increase in FEV1 after bronchodilatation of at least 12%) and airway obstruction 
(FEV1/FVC < 70% predicted), compared to subjects without complications. There was no 
difference in TLC or FeNO between subjects with or without complications.
Abnormal spirometry requiring an intervention by means of additional medication, 
increased medication dose or pre-operative steroid course occurred more often in sub-
jects with complications (26%) than in subjects without complications (14%, p=0.026). 
Subjects with a medication advice did not have longer operation duration or length of 
hospital stay.








Age (years) 41.6 ± 11.1 40.7 ± 10.8 0.603
Weight (kg) 131.0 ± 22.4 136.1 ± 28.5 0.229
Body Mass Index (kg/m2) 45.3 ± 6.2 46.5 ± 6.6 0.196
Abdominal circumference (cm) 131.6 ± 14.9 133.1 ± 17.0 0.536
Bioimpedance
 Fat Free Mass (kg) 63.78 ± 11.2 66.4 ± 14.4 0.164
 Fat (%) 50.5 ± 7.0 51.4 ± 6.9 0.425
 Fat (kg) 66.9 ± 16.3 71.2 ± 18.9 0.117
Gender (% female) 79.5% 78.0% 0.799
Ethnicity (% Caucasian) 84.6% 86.0% 0.475
Smoking status 0.758
 % Never 42% 46%
 % Former 33% 28%
 % Active 25% 26%
Pack years * 2.2 (0-12.5) 2.2 (0-14) 0.754
Comorbidity
 Asthma 23.0% 28.0% 0.429
 COPD 3.2% 2.0% 0.999
 Diabetes mellitus 32.0% 33.3% 0.856
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Table 3 Pulmonary function tests
N Subjects without complications Subjects with complications p Value
FEV1 (% predicted) 485 92.9 ± 14.3 86.9 ± 13.5 0.005
FEV1 < 80% predicted 485 17.1% 28.0% 0.057
FVC (% predicted) 485 100.1 ± 14.9 95.7 ± 13.0 0.045
FVC < 80% predicted 485 9.0% 10.0% 0.813
FEV1/FVC (% predicted) 485 79.2 ± 5.9 77.7 ± 7.8 0.111
RV (% predicted, post) 212 76.9 ± 20.4 76.5 ± 14.3 0.941
FRC (% predicted, post) 212 66.0 ± 13.2 66.1 ± 12.3 0.993
TLC (% predicted, post) 212 94.8 ± 11.2 95.2 ± 8.4 0.889
Reversibility FEV1 (%) 485 4.3 ± 4.9 5.5 ± 7.7 0.315
FeNO (ppb) * 225 14.5 (9.0-22.0) 17.0 (9.5-23.5) 0.676
ΔFEV1 ≥ 12% 485 7.2% 18.4% 0.007
FEV1/FVC < 70% predicted 485 8.1% 20.0% 0.006
Unless stated otherwise, data presented as mean ± standard deviation or %
* Data presented as median (IQR)
FeNO, exhaled nitric oxide; FEV1, Forced expiratory volume in one second; FRC, Functional Respiratory Ca-
pacity; FVC, Forced vital capacity; RV, Residual volume; TLC, Total Lung Capacity








 Hypertension 74.4% 68.8% 0.396
 Hypercholesterolemia 35.8% 43.8% 0.281
 Metabolic syndrome 64.6% 64.6% 0.993
 Epworth Sleepiness Scale (OSAS) * 3 (2-4) 3 (1-4) 0.870
 GERD-questionnaire 6.9 ± 2.3 6.4 ± 1.9 0.455
Surgery
 Operation (% sleeve gastrectomy) 63% 58% 0.470
 Operation duration (minutes) 92.4 ± 40.4 102.9 ± 37.2 0.080
 Admission (days)* 4 (3-4) 5 (4-7.25) <0.001
 ASA scoring 0.835
  1 (%) 0.2% 0%
  2 (%) 36.8% 34.1%
  3 (%) 60.5% 61.4%
  4 (%) 2.4% 4.5%
Unless stated otherwise, data presented as mean ± standard deviation or %
* Data presented as median (IQR)
ASA score, American Society of Anesthesiologists score;  GERD, gastro-esophageal reflux disease; OSAS, 
obstructive sleep apnea syndrome


























































































































































































































































































































































































































































































































































































Table 4 displays the results of three separate logistic regression analyses, after adjust-
ment for age, sex, BMI and smoking status. Since FEV1 and FVC are correlated, we used 
three different models which all contained one of the pulmonary function parameters. 
Airway reversibility (ΔFEV1≥12%) and airway obstruction (FEV1/FVC<70%) remained 
significant predictors of complications.
DISCUSSION
This study demonstrates that morbidly obese subjects with abnormal preoperative spi-
rometric results, -- more specifically, airway obstruction (FEV1/FVC < 70% predicted) (adj 
OR 3.1) or airflow reversibility (increase of FEV1 ≥12%) (adj. OR 2.9) -- are more likely to 
develop postoperative complications after undergoing laparoscopic bariatric surgery.
To our knowledge, this is the first study which has investigated the association between 
preoperative pulmonary function testing and complications after laparoscopic bariatric 
surgery. Previous studies have investigated complications in open procedures(10) or both 
open and laparoscopic(22). Furthermore, this study has also included sleeve gastrectomy, 
a rather new surgical technique as a standalone procedure. This study has used a large 
group of subjects, who were all well characterized.
The American Society for Metabolic and Bariatric Center of Excellence facilities re-
port mentioned a 5% readmission rate and a 2% reoperation rate(23), which compares 
well with our rates (7% and 3.5% respectively). Also, our complication rate of 10% is 
comparable to other studies (3 to 24%). Surgical experience may have influenced the 
complication rates. Some studies suggest that leakage is more likely to occur when the 
surgeon is less experienced(24). In the present study, procedures were performed by an 
experienced team in which each surgeon had carried out over 200 procedures. Further-
more, the highly standardized treatment protocol applied in our hospital, such as routine 
prophylaxis against deep venous thrombosis with pneumatic compression stocking and 
administration of subcutaneous heparin, probably also prevented complications.
There is considerable debate regarding the role of preoperative pulmonary function 
testing for risk stratification. It has been suggested that the test simply confirms the 
clinical impression of disease severity in most cases, adding little to the clinical esti-
mation of risk of complications(25). Consequently, most patients with an abnormal spi-
rometry test result would also have been identified on the basis of history and physical 
examination. Several critical remarks can be made. First, lung function measurements 
and the presence of symptoms are poorly associated(10). Second, all studies on the added 
value of preoperative spirometry were conducted in a general population, and not in 
the specific morbidly obese patient group undergoing bariatric surgery, as described 
here. Since the morbidly obese can be seen as a distinct group with a different physiol-
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ogy, it is questionable whether results from the general population also apply to the 
obese. One exception is Gonzalez et al. who investigated the role of pulmonary function 
testing specifically in the morbidly obese. They found that a FEV1 <80% of predicted 
increased the likelihood of complicated postoperative management after Roux-en-Y 
gastric bypass(21). They combined open and laparoscopic operations, whereas we only 
used the laparoscopic technique. Although the current study does not support the data 
by Gonzalez et al, a similar trend was found here (OR 1.9, p=0.07, table 4). However, our 
study found that FEV1/FVC <70% (airflow obstruction) and ΔFEV1>12% (airflow revers-
ibility) increased the likelihood of complicated bariatric surgery.
Airflow reversibility and airflow obstruction are hallmarks of asthma. Valid compari-
sons with other studies are limited. Other publications on the risk of complications of 
bariatric surgery did not include asthma(3), or state that well controlled asthma is not 
a risk factor(8). Although the diagnosis of asthma is usually based on the presence of 
characteristic symptoms, in the morbidly obese, these symptoms are often unreliable(26). 
It is known that asthma is overdiagnosed by 30% when self-reported asthma is used(27). 
The European Respiratory Society state in the Global Initiative for Asthma guidelines, 
that the measurement of reversibility of lung function abnormalities greatly enhance 
diagnostic confidence, and it also recommends that patients with asthma undergo pre-
operative evaluation to assess asthma control(18). We advocate that spirometry should be 
part of pre-operative evaluation before bariatric surgery for the following three reasons. 
First of all, this is because asthma is 50% more prevalent among obese subjects(6), and 
obesity is an important risk factor for severe asthma(7). Secondly, the diagnosis of asthma 
is more complicated in obese subjects than in lean subjects. Finally, our results show 
that spirometric tests can identify the patients at risk for complications.
Interestingly, our study has shown that spirometry is not only useful in predicting 
pulmonary complications, but it might predict all complications of bariatric surgery. This 
it is in line with previous findings that FEV1 is associated with mortality(28-30). FEV1 could 
possibly be a marker of general health or fitness. So abnormal spirometry does not only 
indicate obstructive pulmonary disease, but might also indicate poor general health. In 
contrast to spirometry, the American Society of Anesthesiologists physical status scale 
(ASA) appeared to be insensitive for predicting complications in this study.
Another study suggested that the super obese (BMI > 50 kg/m2) are more prone to 
complications of bariatric surgery(31). This study did not find this relationship in our 
cohort, despite the fact that 21% had a BMI > 50 kg/m2. Furthermore, this study found 
no difference in mean BMI, body fat percentage or abdominal circumference between 
the subjects with and without complications. Therefore, this  study does not support 
that differences in fat distribution influence the risk of complications of bariatric surgery.
Cawley and co-workers in a large cohort study showed that subjects with obesity 
related co-morbidities prior to bariatric surgery were at significantly elevated risk of 
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post-surgery complications(32). In contrast, in our cohort pre-surgical obesity-related 
co-morbidities such as diabetes mellitus, hypertension, hyperlipidemia, GERD or OSAS 
were unrelated to complications. This might be an effect of the extensive pre-surgical 
screening -- and if indicated treatment -- for co-morbidities as is standard in our hospi-
tal(33).
There are several limitations. First of all, complications were obtained from the patient 
charts, and may have been subject to underreporting. Secondly, we did not perform 
methacholine provocation tests, implying that a definite diagnosis of asthma could not 
always be reached. Finally, we did not perform a randomized study, so we cannot state 
anything on the surplus value of spirometry. Furthermore, the extensive pre-surgical 
screening program as incorporated in our hospital could have reduced the incidence of 
complications. The low numbers of pulmonary complications in our study did not allow 
for specific subgroup comparisons.
As symptoms are often unreliable in the morbidly obese, pulmonary function tests 
should routinely be part of the preoperative risk assessment. We have shown that 
subjects with complications within 30 days of bariatric surgery more often have airflow 
reversibility or airflow obstruction. Generally laparoscopic bariatric surgery is safe, but 
randomized prospective studies are needed to investigate whether abnormal pulmo-
nary functions tests could indeed serve as a guide in patient selection and optimization 
of the preoperative medical condition of patients undergoing bariatric surgery, which 
could lead to additional improvement in the outcomes after bariatric surgery.
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Effect of bariatric surgery on asthma 
control, lung function and bronchial 
and systemic inflammation in 
morbidly obese subjects with asthma
Van Huisstede A, Rudolphus A, Castro Cabezas M, Biter LU, Van de Geijn GJ,  




Background: The pathogenesis of asthma in obese subjects is poorly understood and 
has been described as a specific phenotype in these patients. Weight loss improves 
asthma control and lung function. Whether this improvement is the result of better 
mechanical properties of the airways or decreased systemic and bronchial inflammation 
remains unclear.
Methods: A longitudinal study in obese patients with asthma (bariatric surgery and 
asthma group (BS+A), n=27) and obese control (bariatric surgery without asthma group 
(BS-A), n=39) subjects undergoing bariatric surgery, and obese patients with asthma 
without intervention (no bariatric surgery and asthma group (NBS+A), n=12). Lung func-
tion, asthma control, cellular infiltrates in bronchial biopsies and circulating markers of 
systemic inflammation were measured during follow up at 3, 6 and 12 months.
Results: Bariatric surgery resulted in a profound weight loss at 12 months. In the BS+A 
group as well as the BS-A group FEV1, functional residual capacity, total lung capacity 
improved, whereas FEV1/FVC only improved in the BS-A group. In addition, Asthma Con-
trol Questionnaire (ACQ), Asthma Quality of Life Questionnaire, inhaled corticosteroid 
use and PD20 improved in BS+A, whereas in the NBS+A group only ACQ improved. Small 
airway function R5-R20 improved in both surgery groups, however the change in the 
BS+A group was greater, resulting in a comparable R5-R20 between BS+A and BS-A at 12 
month follow-up. Besides improvement of systemic inflammation (hs-CRP, adiponectin 
and leptin) after BS, only a decrease in mast cell numbers was detectable in the BS+A 
group.
Conclusions: Bariatric surgery improved small airway function, decreased systemic 
inflammation and number of mast cells in the airways. These effects could explain the 
improvement of asthma control, quality of life and lung function. Therefore bariatric 
surgery, in addition to all other positive effects, also improves asthma in subjects with 
morbid obesity.
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INTRODUCTION
Asthma prevalence has increased over the recent decades(1, 2), concurrently with the 
prevalence of obesity, suggesting a possible link between obesity and asthma(3). In a 
prospective study on the relationship between obesity and asthma, obese patients ap-
peared to have a 2.6 times elevated risk of developing asthma(4). In addition, obesity is 
associated with increased severity of asthma. Obese patients with asthma have worse 
asthma control(5) and respond less to standard therapy compared with lean patients 
with asthma(6).
A recent position paper on weight loss interventions in asthma(7) concluded that the 
evidence for benefits from weight reduction on asthma outcomes is weak. Unfortu-
nately, only studies with dietary weight loss were included, and a sustained effect of 
weight loss through lifestyle changes is small. In contrast, bariatric surgery leads to a 
more pronounced and persistent weight loss in subjects who are morbidly obese(8). 
Therefore, weight loss by bariatric surgery may have more profound effects on asthma.
Asthma in the patients who are obese has been described as a specific phenotype, 
with high symptom expression and late onset of symptoms(9). Whether bronchial inflam-
mation in obese subjects with asthma is characterised by eosinophilic or neutrophilic 
inflammation, or both, is a matter of debate in the literature. Different methods were 
used to (indirectly) measure bronchial inflammation. So far, only two studies have 
reported on the analysis of bronchial biopsies in obese subjects with asthma(10, 11), in 
which, especially in those who are morbidly obese, little inflammation was detectable in 
the airways. Although previous studies have shown that bariatric surgery does improve 
asthma control, lung function and systemic inflammation(12-18), the effect on bronchial 
inflammation is unknown. Previous studies were conducted in small groups and either 
lacked follow up of a control group (12, 13, 15), or they lacked a non-intervention control 
group(13, 14, 16-18). To our knowledge, this is the first study analysing bronchial biopsies be-
fore and after bariatric surgery. We hypothesised that bariatric surgery and weight loss 
would result in improved bronchial obstruction, and reduced systemic and bronchial 
inflammation. To test this, we performed a cohort study to evaluate the impact of weight 
loss by bariatric surgery on asthma control, lung function and bronchial and systemic 
inflammation after 12-month follow-up. Baseline data (including subjects without 12 




This study is part of a larger study, of which results have been reported before(11, 19) 
Inclusion and exclusion criteria of this study are described in the online supplementary 
material. In summary, subjects were between 18 and 50 years old, had a body mass 
index (BMI) above 35 kg/m2, and were excluded if they smoked more than 10 cigarettes 
per day or had smoked more than 10 pack years.
The local ethics committee (Toetsingscommissie Wetenschappenlijk Onderzoek 
Rotterdam e.o.) approved the study protocol (Netherlands Trial Register 3204), and all 
subjects gave written informed consent.
The subjects in this study were divided into three groups: a group of morbidly obese 
subjects with asthma scheduled for bariatric surgery (BS+A), a group of morbidly obese 
subjects without asthma also scheduled for bariatric surgery (BS-A), and a group of 
obese subjects with asthma not undergoing bariatric surgery (NBS+A). The first two 
groups were patients who applied for bariatric surgery in the Sint Franciscus Gasthuis; 
the third group was a control group included from our outpatient clinic.
The primary endpoint of the study was the change of FEV1/FVC at 12 month follow-up. 
Secondary endpoints were other lung function parameters, asthma symptoms (asthma 
control, asthma-related quality of life, medication use), change of comorbidities (ob-
structive sleep apnoea syndrome (OSAS), gastro-oesophageal reflux disease) airway 
inflammation and systemic inflammation at 3, 6 and 12-month follow-up. Only subjects 
with a follow-up at 12 months were analysed. Baseline data (including subjects without 
12-month follow-up) were published previously(11).
Definition of asthma
Asthma was defined according to Global Initiative for Asthma (GINA) guidelines(1) as 
both the presence of symptoms and either an increase of ≥12% and 200 mL in FEV1 
after salbutamol, or a positive provocation test (methacholine PD20 <1.8 mg). Patients 
without airway reversibility and a negative provocation test formed the control group.
Descriptions of pulmonary function tests (spirometry(20, 21), exhaled nitric oxide(22), 
impulse oscillometry, diffusion capacity(23) and methacholine provocation testing(24, 25)) 
can be found in the online supplementary material, along with descriptions of the ques-
tionnaires used (Asthma Quality of Life Questionnaire (AQLQ)(26) and Asthma Control 
Questionnaire (ACQ)(27)), comorbidities (obstructive sleep apnoea syndrome (OSAS)(28), 
gastro-oesophageal reflux disease(29) and metabolic syndrome(30)), atopy definitions, labo-
ratory measurements and the formula used for the percentage excess weight loss (%EWL).
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Bronchial biopsies and immunohistochemistry
Peripheral bronchial biopsies were taken prior to laparoscopic bariatric surgery (either 
sleeve gastrectomy or Roux-and-Y gastric bypass), after routine anaesthesia with desflu-
rane and remifentanil, directly after intubation(11). Twelve months after bariatric surgery 
bronchial biopsies were taken during cosmetic surgery or during an out-patient visit. 
Bronchoscopy was performed according to the British Thoracic Society guidelines(31) 
using a flexible fibre optic bronchoscope (Olympus). Four biopsies were taken from 
the segmental carina from the right middle and lower lobe using a forceps (Boston 
Scientific, Radial Jaw 3). The 4 µm sections from paraffin-embedded bronchial biopsies 
were stained for EG2 (eosinophils), neutrophil elastase (neutrophils), AA1 (mast cells), 
CD68 (macrophages), CD20 (B cells), CD8, CD4 and CD3 (T cells), or negative control, 
and enumerated as cells per square millimetre submucosa on digitalised images. The 
smallest 10% of selected surfaces of biopsies were not used for analysis. The mean cell 
count of an individual was the mean of two to four biopsies. The observer was blinded 
with regard to the patient’s number and clinical status during selection, processing and 
analysis of the biopsy samples. Baseline data were published previously(11).
Power calculation and statistical analysis
The group size was powered on the expected change in FEV1/FVC ratio after bariatric 
surgery. Based on a pilot study and published data we assumed that in the BS+A group 
the FEV1/FVC ratio would increase from 72% to 75% (SD ± 6). The increase of 3% rep-
resents an effect size of 0.5. To find a difference in the group with obesity and asthma 
before and after operation with an α error of 5% and a power of 80%, we needed at least 
27 participants per group. With an expected drop-out of 25% over 1-year follow-up we 
aimed at 40 patients per subgroup.
For the comparison between the three groups at baseline, the independent samples 
median test for scaled data or the Chi-square or Fisher exact test  were used. For all groups, 
baseline data were compared with 12-month follow-up data, using a non-parametric 
test (related-samples Wilcoxon signed rank test). Unless indicated otherwise, all data 
are expressed as median (min-max) for paired data for scale variables or percentage for 
categorical variables. Spearman correlation coefficient (R) was calculated. All analyses 
were performed using SPSS V.21.0 software (SPSS Inc., Chicago, Illinois, USA). Given the 
exploratory nature of this study, we did not control for multiple comparisons. Results 
were evaluated at 95% CI at a two-sided significance threshold of p<0.05.
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RESULTS
A total of 101 patients were included in the initial study(11). At 12-month follow-up data 
were available for 78 subjects, which were included in the present analysis. In table 1 
(and online supplementary table S1B) the baseline subject characteristics are shown 
(27 BS+A, 39 BS-A and 12 NBS+A). There were no significant differences in demographic 
characteristics between the groups, with the exception of BMI.
Table 1 Demographics of the study population
NBS+A BS+A BS-A p Value
Number
Baseline 12 27 39
3-month follow-up 11 26 33
6-month follow-up 11 21 34
12-month follow-up 12 27 39
Gender (%female) 91.7% 74.1 82.1 0.494
Ethnicity (%non-Caucasian) 25.0% 14.8% 15.4% 0.714
Age (years) 33 (20-45) 36 (19-48) 39 (18-50) 0.440
Weight (kg) 103 (82-132) 130 (101-202) 126 (94-199) 0.044
Body mass index (kg/m2) 35.6 (30.9-53.9) 45.1 (38.4-63.8) 43.1 (35.6-58.6) 0.015
Abdominal circumference (cm) 119 (102-155) 133 (112-165) 127 (103-200) 0.016
Smoking status 0.178
 % never smoked 75.0% 55.6% 71.8%
 % stopped smoking 16.7% 11.1% 17.9%
 % current smoker 8.3% 33.3% 10.3%
Pack years 0 (0-0) 0 (0-10) 0 (0-10) 0.311
Asthma
Asthma Control Questionnaire1 1.7 (0.3-2.6) 1.1 (0.4-2.9) 0.3 (0-2.9) <0.001
Asthma Quality of Life Questionnaire 2 5.4 (3.5-6.7) 5.6 (3.7-6.8) 6.5 (3.7-7.0) 0.007
Lung function
Spirometry
 FEV1, pre(% predicted) 88 (45-106) 86 (66-119) 97 (73-125) 0.009
 FEV1, post (% predicted) 95 (49-106) 93 (75-118) 101 (75-129) 0.079
 FVC, pre (% predicted) 102 (64-118) 97 (75-126) 106 (77-144) 0.575
 FVC, post (% predicted) 107 (62-120) 99 (74-126) 107 (78-141) 0.754
 FEV1/FVC, pre (%) 79 (61-90) 76 (63-92) 81 (66-93) 0.096
 FEV1/FVC, post (%) 82 (69-91) 79 (67-94) 84 (68-94) 0.215
 RV, post (% predicted) * 79.5 (74-92) 74 (39-126) 74 (47-118) 0.567
 TLC, post (% predicted) * 92.5 (77-109) 98 (83-106) 95 (75-114) 0.826
 FRC, post (% predicted) * 68 (54-90) 62 (40-95) 64 (41-88) 0.554
 RV/TLC, post (%) * 26.5 (20-36) 22 (10-41) 24 (12-41) 0.146
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Weight loss
Sixty-three percent of the BS+A and 69% of the BS-A group underwent gastric sleeve 
resection; the remaining subjects underwent gastric bypass surgery. BMI and abdominal 
circumference decreased in both bariatric surgery groups, and remained stable in the 
non-intervention group (figure 1A, B). Although the %EWL was significantly lower in the 
BS+A group compared with the BS-A group (median 73% vs 84% respectively, p=0.045), 
the BMI did not differ between the BS+A and BS-A group at baseline or at 12-month 
follow-up.
Effect of weight loss on lung function tests
Figure 2 and table 2 show the results of the follow-up of lung function. Twelve months 
after bariatric surgery FEV1/FVC and residual volume (RV) improved only in the BS-A 
group, whereas FEV1 (post), functional residual capacity (FRC), and total lung capacity 
(TLC) improved in both BS-A and BS+A groups. These results can be better explained 
by a reduction in lung restriction than by  a reduction in lung obstruction. RV/TLC, 
representing hyperinflation, did not change in any of the groups. FEV1/FVC, RV, FEV1, 
Table 1 Demographics of the study population (continued)
NBS+A BS+A BS-A p Value
Number
Reversibility FEV1 7 (-12-22) 9 (-6-20) 4 (-7 -11) 0.012
FeNO (ppb) 17 (7-96) 16 (5-45) 16 (7-53) 0.870
Diffusion capacity, kCo (% predicted) 98 (70-116) 97 (69-133) 95 (69-134) 0.890
PD20 (mg) 0.31 (0.04-1.8) 0.37 (0.04-1.8) 1.8 (1.8-1.8)
IOS
 R5 (kPa/sec) 0.58 (0.24-1.11) 0.69 (0.41-1.39) 0.57 (0.17-0.97) 0.022
 R20 (kPa/sec) 0.44 (0.20-0.65) 0.45 (0.27-1.03) 0.43 (0.18-0.68) 0.841
 R5-R20 (kPa/sec) 0.18 (0.04-0.62) 0.25 (0.06-0.66) 0.17 (-0.1-0.48) 0.001
 X5 (kPa/sec) -0.16 (-0.67 to  -0.1) -0.26 (0.87 to -0.12) -0.21 (-0.43 to -0.10) 0.138
 Fres (Hz) 17.3 (9.2-30.4) 22.6 (10.7-28.9) 18.5 (8.4-28.7) 0.001
Data are presented as median (min-max)
1 Scores of the Asthma Control Questionnaire range from 0 to 6, with lower scores indicating better asthma 
control
2 Scores of the Asthma Quality of Life Questionnaire range from 1 to 7, with higher scores indicating better 
asthma-specific quality of life
* Because of weight limitations for the body box (<150 kg), full spirometry could not be performed in all 
subjects; numbers for these parameters: NBS+A =4, BS+A = 15, BS-A = 30
BS+A, bariatric surgery and asthma group; BS-A, bariatric surgery without asthma group; FeNO, exhaled 
nitric oxide; FRC, functional residual capacity; IOS, impulse oscillometry; NBS+A,  no bariatric surgery and 
asthma group; PD20, provocative dose of methacholine inducing a 20% fall in FEV1; RV, residual volume; TLC, 
total lung capacity
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FRC and TLC did not change in the NBS+A group, confirming that the improvement in 
restrictive lung function was due to weight loss.  There was no significant change in 
diffusion capacity or exhaled nitric oxide (FeNO) in any of the groups.
Impulse oscillometry, and especially R5-R20 as a measure of small airway function, 
showed a significant improvement in both bariatric groups (figure 2-C). At baseline the 
BS+A group had a significantly higher R5-R20 as compared with the BS-A group (p<0.001). 
At 12-month follow-up the R5-R20 of the BS+A group was comparable to the BS-A group. 
We found a correlation between BMI and R5-R20 (R=0.518, p<0.001), and abdominal 
circumference and R5-R20 (R=0.415, p<0.001). Also between ACQ and R5-R20 (R=0.498, 

















































































































































































































































































































Figure 1 Effect of weight loss on asthma control
NBS+A, no bariatric surgery and asthma group (circles); BS+A, bariatric surgery  and asthma group (squares); 
BS-A = bariatric surgery without asthma group (triangles). Only p-values for comparison between baseline 
and 12-month follow-up were calculated; only significant p-values are shown (*).
Scores of the Asthma Control Questionnaire (ACQ) range from 0 to 6, with lower scores indicating better 
asthma control. Scores of the Asthma Quality of Life Questionnaire (AQLQ) range from 1 to 7, with higher 
scores indicating better asthma-specific quality of life. FU, follow-up. 




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In the BS+A group, 24 subjects had a positive provocation test at baseline (PD20 < 1.8 
mg). At 3, 6 and 12-month follow-up of these 24 subjects, 11 (of 24), 9 (of 20) and 13 
(of 25) subjects had a negative provocation test, respectively. Median values increased 
significantly (figure 2-D and table 2).  In the NBS+A group the PD20 did not increase 
significantly. No correlation was found between PD20 and BMI, however we did found a 













































































































































































































































































































Figure 2 Effect of weight loss on lung function
NBS+A,  no bariatric surgery and asthma group (circles); BS+A, bariatric surgery and asthma group (squares); 
BS-A,  bariatric surgery without asthma group (triangles).  Only p-values for comparison between baseline 
and 12-month follow-up were calculated, only significant p-values are shown (*)
(A) FEV1 BS+A median 97 – 106 % predicted, p=0.001; BS-A median 86 - 95 % predicted, p< 0.001; (B) FEV1/
FVC BS-A 84 - 87%, p<0.001; (C) R5-R20 BS+A 0.25 - 0.07 kPa/sec, p<0.001; BS-A 0.17 - 0.07 kPa/sec; p<0.001. 
While there was at baseline a significant difference in R5-R20 between BS+A and BS-A group (p<0.001), at 
12-month follow-up there was no significant difference (p=0.919); (D) PD20 BS+A median 0.22 - 1.46 mg, 
p=0.001.
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Effect of weight loss on asthma control
The ACQ improved statistically and was clinically significant (Δ>0.5) in both asthma 
groups (NBS+A and BS+A) at 12-month follow-up (figure 1-C). The improvement in ACQ 
in the BS-A group was also statistically significant, but not clinically significant.
The AQLQ did not improve in the NBS+A group, but it did improve in the BS+A group 
(statistically and clinically significant (Δ>0.5)) at 12-month follow-up, and also in the 
BS-A group (figure 1-D).
Medication use
In the BS+A group 10 subjects used inhaled corticosteroids (ICS) at inclusion in the 
study, of which 8 subjects agreed to stop for at least 6 weeks before provocation testing. 
Because of symptoms, one subject restarted ICS, and three subjects who did not use ICS 
before inclusion in the study were prescribed ICS because of progression of symptoms. 
So, a total of six subjects used ICS  at baseline, with a median budesonide equivalence 
dose of 600 µg/day. At 12-month follow-up, ICS was prescribed to six subjects, however 
only four subjects used the ICS, with a median budesonide equivalence of 600 µg/ day.
In the NBS+A group all 12 subjects used ICS at baseline, and in follow-up all subjects 
remained on ICS: the median budesonide equivalence dose remained stable (baseline 
800 µg, 3 months 400 µg and 12 months 800 µg).
Comorbidities and activity
There were no significant changes in the Epworth Sleepiness Scale or Gastro-oesopha-
geal Reflux Disease questionnaire in any group at any follow-up time point (3, 6 or 12 
months) (data not shown). Daily activity as assessed by the number of steps a day did 
improve significantly in both bariatric surgery groups at 12-month follow-up (BS+A: me-
dian 4946 to 8312, p=0.030; BS-A: median 5224 to 8094, p= 0.005), and did not improve 
in the NBS+A group.
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Figure 3 Correlation analysis of asthma control, small airway function and body mass index
Baseline data and 12-month follow-up data were used to calculate correlations. ACQ, Asthma Control Ques-
tionnaire.
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Effect of weight loss on bronchial and systemic inflammation
Interleukine (IL)-6, IL-8, tumor necrosis factor (TNF)-α and granulocyte macrophage 
colony-stimulating factor (GM-CSF), markers of systemic inflammation, did not change 
at follow-up in any of the groups, although the levels of IL-6, TNFα and GM-CSF were at 
the lower limit of detection. Other markers of systemic inflammation, such as high-sen-
sitivity C-reactive protein (hs-CRP), leptin and adiponectin, were significantly changed 
at 12-month follow-up in both the BS+A, and BS-A groups, and did not change in the 
NBS+A group (table 3).
At 12-month follow-up, bronchial biopsies were collected from  24 subjects (8 BS+A, 
14 BS-A). Submucosal cell counts of eosinophils (EG2), neutrophils (NE), B cells (CD20), 
macrophages (CD68), CD4+ T-cells or CD8+ T cells did not change at 12-month follow-
up in either the BS+A or BS-A group (figure 4, and online supplementary table S4). In 
contrast, mast cells (AA1) decreased significantly at 12-month follow-up in the BS+A 
group  (median 118-61 cells/mm2, p=0.036), whereas CD3+ T cells decreased significantly 
at 12-month follow-up only in the BS-A group (median 884 - 558 cells/mm2, p=0.015).
Subgroup analysis
When we divided the BS+A group into subjects who at baseline had a positive provo-
cation test, and at 12-month follow-up either a positive (non-responder) or negative 
(responder) provocation test, we found no differences between the two groups. In a 
subgroup analysis of patients with low immunoglobulin E (IgE) (‘TH2-low’, IgE <100, n=6) 
versus high IgE (‘TH2-high’, n=12), we found that the PD20 only improved in the IgE-high 
group at 12-month follow-up (median 0.19 - 1.59 mg, p=0.003), and not in the IgE-low 
group (median 0.53 - 0.99 mg). We found no differences in change in R5-R20.
DISCUSSION
In the present study bariatric surgery of morbidly obese patients with asthma was found 
to result in a significant improvement in small airway function (R5-R20) and airway hyper-
responsiveness (PD20 methacholine), as well as asthma control and markers of bronchial 
(mast cell counts) and systemic inflammation. In contrast, there was no change in FEV1/
FVC.
There was no significant improvement in our primary endpoint FEV1/FVC, a marker of 
airway obstruction, in the BS+A group. However, in the BS-A group, there was a statisti-
cally significant increased FEV1/FVC, showing that weight loss affects airway diameter to 
some extent in patients without asthma. As the power of this study should be adequate, 
we might conclude that weight loss does not influence obstruction of the larger airways 
in asthma subjects. In line with previous reports(13, 15), we found that weight loss induces 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 4 Submucosal cell counts of bronchial biopsies, before and 12 months after bariatric surgery
Bronchial submucosal cell count in morbidly obese subjects before and 12 months after bariatric surgery, 
with (BS+A, n=8, squares) and without asthma (BS-A, n=14, circles). P Values were calculated for the com-
parison between baseline and 12-month follow-up (12M FU) within each group, only significant p values 
are shown (*). Horizontal line represents median.
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an increase not only in TLC, but also FRC in both bariatric surgery groups suggesting 
that the weight loss improves the relative restrictive lung function. Remarkably, the RV 
in the BS+A group did not change after bariatric surgery, whereas it did in the BS-A 
group. This could be because the RV at baseline was already relatively high in the BS+A 
group, so further improvement was unlikely. Perhaps the BS+A group had peripheral 
airway obstruction before bariatric surgery due to different fat distribution compared 
with the BS-A group, since the abdominal circumference is higher in the BS+A group. 
However, the RV/TLC ratio was the same in both bariatric groups, making a difference in 
obstruction less likely.
The main improvement in lung function was in R5-R20, a marker of small airway function. 
Whereas at baseline the R5-R20 in the BS+A group was significantly worse compared with 
the BS-A group, 12 months after bariatric surgery, there was no longer a significant dif-
ference between the two groups. This remained when only non-smokers were analysed 
(data not shown). Our data are in line with Al-Alwan et al., who recently demonstrated 
that obese subjects with asthma have more collapsible peripheral airways than obese 
subjects without asthma(16), suggesting that altered lung mechanics play a role in the 
relationship between obesity and asthma. In addition to a correlation between R5-R20 
and BMI, we also found a correlation between R5-R20 and ACQ, suggesting that increased 
R5-R20 might explain the high symptom expression in obese subjects with asthma. Dixon 
et al. have shown previously that bariatric surgery was more beneficial to subjects with 
normal IgE levels (TH2-low) in contrast to TH2-high subjects(13),  especially for  small airway 
function(18). In contrast, the present study could not find a relation between IgE levels 
and small airway function, and only found a relation in the high IgE group and bronchial 
hyperresponsiveness. Besides a difference in BMI between Dixon and our study (51 and 
45 kg/m2), the IgE level of our ‘TH2 high’ group was higher, and the ratio of number of 
subjects in the low versus high group was different in our study compared with Dixon.
Whereas other studies have shown only a reduction in bronchial hyperreactivity 
12 months after bariatric surgery(13, 15), in some of our patients the PD20 methacholine 
became negative, despite the decreased use of ICS in the 12-month follow-up. This 
was in contrast to the NBS+A subjects, in whom we did not succeed to taper off the 
ICS. Whether they truly needed ICS is questionable. We found a negative correlation 
between R5-R20 and PD20, suggesting that the increased peripheral airway resistance is 
associated with more severe bronchial hyperreactivity.
One hypothesis explaining the relationship between obesity and asthma is the con-
cept of spill over of systemic inflammation caused by obesity, to the lungs, resulting 
in bronchial inflammation. Although others have demonstrated that obese subjects 
with asthma have more neutrophilic inflammation compared with lean subjects with 
asthma(32, 33), we have previously shown that there is no difference in neutrophil (or 
eosinophil) cell counts in bronchial biopsies between morbidly obese subjects with 
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asthma and morbidly obese controls(11). As we found no differences in cell counts at 
baseline, we expected no change in any cell count after bariatric surgery. However, our 
results demonstrate that in subjects with asthma, mast cell counts in bronchial biopsies 
taken 12 months after bariatric surgery decreased significantly compared with baseline. 
This decrease in mast cells might reflect a better asthma control. This decrease in mast 
cells could in part explain the improved asthma control, because mast cells contribute 
to inflammation and tissue remodelling in asthma. As the study was powered to detect 
changes in the primary endpoint FEV1/FVC it could be that the number of patients inves-
tigated was not enough to detect subtle changes in bronchial inflammatory cells. Still 
none of the comparisons in cells counts showed a trend of being statistically different. 
Moreover, we found no differences in demographics between the group with follow-up 
bronchoscopy and those without (data not shown).
In line with previous reports(34), we found that systemic inflammation (hs-CRP, leptin 
and adiponectin in serum) decreased after bariatric surgery. These data suggest that a 
reduction in systemic inflammation may result in reduction in local airway inflamma-
tion in subjects with asthma. However, the improvement after weight loss of especially 
the small airway function, and the correlation between small airway function and ACQ 
reflects that bariatric surgery also improves the mechanical properties of the lungs.  The 
observation that some obese patients develop asthma and other obese subjects do not 
has led to several hypotheses. Our data are in line with the suggestion made by Dixon 
et al(16), that obese subjects with asthma  may be predisposed to the effect of obesity on 
small airways, which is supported by their data obtained by computational remodelling 
of airway wall stiffness and thickness, predicting a relationship between airway hyper-
responsiveness and BMI(35).
The strengths of our study are that we included an obese control group of subjects 
without asthma, as well as a control group of obese subjects with asthma without bar-
iatric surgery. In addition, the group size in our study was larger than previous studies, 
and we not only performed data collection at 12 months but also at 3 and 6 months of 
follow-up. Furthermore, the diagnosis of asthma was performed strictly according to 
the GINA guidelines as a doctor diagnosis of asthma in which symptoms play a major 
role has previously been shown to be not suitable for diagnosing asthma in patients 
with obesity(19, 36). Finally, participation was good and only few dropped out during the 
12-month follow-up.
There are also some limitations to our study. First of all, we did not include a lean 
asthma group. Second, our obese asthma group without bariatric surgery is not fully 
comparable to both bariatric surgery groups due to differences in recruitment strategy. 
As a result, for example, the BMI is lower and this is because the frequency of patients 
with morbid obesity and asthma is low in our outpatient clinic is because the frequency 
of patients with morbid obesity and asthma is low in our out-patient clinic. As a second 
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bronchoscopy was optional, a bias is possible. Finally, bronchial biopsies were taken 
centrally, and therefore are not optimally suited to establish a possible relationship with 
peripheral airway function.
In summary, this is the first study that examined a wide variety of clinical, physiologi-
cal, systemic and bronchial mucosal inflammatory parameters before and after bariatric 
surgery in morbidly obese subjects with asthma and morbidly obese control subjects. 
Although we found no improvement in our primary endpoint FEV1/FVC, we did find im-
provement in asthma control, quality of life, medication use and PD20 methacholine. The 
significant improvement of R5-R20 (peripheral airway function) after bariatric surgery, 
which was associated with BMI, ACQ and PD20, suggests that peripheral airways play a 
major role in the relationship between obesity and asthma. Finally, bariatric surgery also 
decreased markers of systemic inflammation, and mast cell counts in central bronchial 
submucosa of obese subject with asthma. Collectively these findings emphasise that 
weight loss as achieved by bariatric surgery should be a cornerstone in the treatment 
of morbidly obese patients with asthma. Further research regarding the role of small 
airways in obese asthma is needed.
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The subjects included in this study were patients who underwent pre-operative screen-
ing before bariatric surgery in the Sint Franciscus Gasthuis in Rotterdam, the Netherlands 
from September 2009 to April 2011. Eligibility criteria for bariatric surgery were: age 
between 18 and 60 years old, body mass index (BMI) ≥ 35 kg/m2. We excluded people 
who (a) were older than 50 years of age or; (b) had a history of smoking more than 10 
cigarettes a day, or were currently smoking more than 10 cigarettes a day (with the aim 
to decrease the risk of including subjects with chronic obstructive pulmonary disease 
[COPD]); (c) were taking oral corticosteroid therapy; (d) had an asthma exacerbation four 
weeks before screening; (e) were unable to perform pulmonary function tests; or (f ) had 
pulmonary disease other than asthma.
All subjects underwent baseline physical examinations including routine assessment 
of anthropometry and blood pressure and collection of blood samples. Waist circumfer-
ence was measured directly to the body surface midway between the lower rib margin 
and the ileac crest. Fat free mass and fat weight (in kg and % body weight) were mea-
sured using bio-electrical impedance analysis (Bodystat 1500, Bodystat Ltd, British Isles).
Percentage excess weight loss (%EWL) was calculated as: (BMI baseline  – BMI 12 
months follow up) / (BMI baseline – 25) * 100.
Pulmonary function tests
Spirometry was performed with Vmax spirometer (Vmax SensorMedics Viasys, type 
Encore 20/22/229/62 Encore, Cardinal Health, USA) before and after 400 µg of inhaled 
salbutamol, according to the American Thoracic Society / European Respiratory Society 
guidelines(20, 21).  Static lung volumes were measured by body plethysmography, directly 
after the spirometry. If applicable, subjects were asked not to use longacting β2-agonists 
for 48 h, short-acting β2-agonists for 8 h and anti-histamines or anti-leukotriene medica-
tion 72 h before lung function testing. Subjects who were using inhaled corticosteroids 
(ICS), were asked to discontinue them until bariatric surgery. Daily symptom diary and 
daily peak flow rates were used to screen asthma control. Subjects were permitted to 
use short-acting bronchodilators as rescue medication. After six weeks they returned for 
their second visit, during which exhaled Nitric Oxide (FeNO)(Niox mino Aerocrine, Swe-
den)(22), impulse oscillometry (IOS) (Masterscreen IOS system, Erich Jaeger Co., Würzburg, 
Germany), diffusion capacity (intrabreath method, corrected for hemoglobin and alveo-
lar volume)(23) and methacholine provocation testing (five breath dosimeter method)
(24, 25) were performed. Bronchial responsiveness to methacholine was expressed as the 
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provocative dose of methacholine inducing a 20% fall in FEV1 (PD20). A PD20 < 1.8 mg 
was considered as a positive provocation test. If the methacholine provocation test was 
negative, a second provocation test was performed six weeks later. If the methacholine 
provocation test was negative, a second provocation test was performed six weeks later. 
The use of ICS was allowed during follow up.
At 3 and 6 month follow-up FEV1 was measured by methacholine provocation testing. 
At 12-month follow-up two visits were scheduled. During the first visit, spirometry and 
body plethysmography were performed. During the second visit, FeNO, IOS, diffusion 
capacity and methacholine provocation testing were performed.
Questionnaires and comorbidities
Based on questionnaires the subjects with asthma were grouped into child onset of 
asthma if they have had the diagnosis asthma before the age of 18, and adult onset of 
asthma from 18 years or older. Asthma symptoms were assessed by the mini Asthma 
Quality of Life Questionnaire (AQLQ)(26) and the Asthma Control Questionnaire (ACQ)
(27) to assess asthma complaints. An delta of 0.5 in either AQLQ or ACQ was considered 
clinically significant. The Epworth Sleepiness Scale(28) questionnaire was used to as-
sess OSAS, and the GERD-Questionnaire for gastro-esophageal reflux disease (GERD)
(29). The average of 7 days data collected with an activity meter was used to determine 
the total number of steps taken a day, as a measure of activity. Metabolic syndrome 
was diagnosed according to the National Cholesterol Education Program’s Adult Treat-
ment Panel III report (NCEP ATP-III) criteria when ≥3 of the following 5 risk factors were 
present: abdominal obesity, an elevated level of serum triglycerides, low serum level of 
high-density lipoprotein cholesterol (HDL-C), elevated blood pressure, and high serum 
glucose level or treatment for any of these disorders(30).
Atopy
Atopy was defined as either a positive skin-prick test (SPT) or a positive serum inhalation 
screen. The skin-prick tests (SPT) consisted of a battery of common aeroallergens: house-
dust mite; dog, cat, and horse dander; Aspergillus fumigatus; mugwort; and birch and 
grass pollen (Vivodiagnost; ALK Benelux BV, Groningen, The Netherlands). A positive SPT 
was defined as at least one reaction to the aforementioned allergens as compared to the 
histamine positive control and saline solution-negative control. Total IgE and specific 
serum IgE were determined with a solid-phase two-step chemiluminescent immunoas-
say on the Immulite 2000 (Siemens, Los Angeles, CA). A positive serum inhalation screen 
was defined as at least one increased amount of specific IgE for fungus, house-dust mite, 
cat, dog, grass, birch or herbs.
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Laboratory
Laboratory measurements were performed according to standard procedures by our 
Department of Clinical Chemistry. Plasma-cholesterol, HDL-cholesterol, glucose, and 
triglycerides, were measured using LX-20 and DxC analyzers (Beckman Coulter, Miami, 
FL, USA). LDL-cholesterol was calculated using the Friedewald formula. Blood cell counts 
and 5-part leukocyte differentiation were determined automatically using LH750 or 
DxH800 analyzers (Beckman Coulter). Vitamin D was determined by radioimmunoas-
say or chemiluminescence (LIA) on Liason analyzers (DiaSorin, Stillwater, MN, USA). 
Serum markers of systemic inflammation were assessed using the Meso Scale Discovery 
Platform (Meso Scale Discovery, Gaitherburg, MD), for IL-6, IL-8, high-sensitivity (hs)-CRP, 
TNFα, GM-CSF, leptin and adiponectin. Lower limit or upper limit of detection were 
respectively 0.7-2500 pg/ml, 0.6-2500 pg/ml, 0.05-142 ng/ml, 0.8-2500 pg/ml, 0.61-2500 
pg/ml, 0.2-100 ng/ml and 0.064-1000 ng/ml. All values which were below or above the 
lower or upper limit of detection of the assay, were arbitrarily set at these limits.
RESULTS
In the BS+A group median BMI decreased from 45.1 kg/m2 to 35.9 kg/m2 at 3-month 
follow-up, 33.0 kg/m2 at 6-month follow-up and 30.2 kg/m2 at 12-month follow-up 
(p<0.001 for all comparisons). In the BS-A group median BMI decreased from 43.1 kg/
m2 to 36.0 kg/m2 at 3-month follow-up, 32.3 kg/m2 at 6-month follow-up and 29.0 kg/m2 
at 12-months follow-up (p<0.001 for all comparisons). The BMI was stable in the NBS+A 
group (35.6 kg/m2 at baseline, 35.3 kg/m2 at 3-month follow-up, 35.6 kg/m2 at 6-month 
follow-up and 36.2 kg/m2 at 12-month follow-up).
Also the median abdominal circumference improved in the BS+A group (133 cm base-
line, 99cm 12-month follow-up; p<0.001) as well as in the BS-A group (127 cm baseline, 
93 cm 12-month follow-up; p<0.001), but not in the NBS+A group (119 cm baseline, 113 
cm 12-month follow-up).
AQLQ improved clinically and statistically significantly at 12-month follow-up as 
compared to baseline for the BS+A group (median 5.6 to 6.7, p= 0.002), and BS-A group 
(median 6.3 to 6.9, p<0.001). There was no significant improvement in the NBS+A group 
(median 5.5 to 5.8, p=0.075). ACQ improved clinically and statistically significantly at 
12-month follow-up as compared to baseline for BS+A group (median 1.2 to 0.4, p= 
0.001), and the NBS+A group (1.7 to 1.0, p= 0.012), and only statistically significantly in 
the BS-A group (median 0.3 to 0.0, p= 0.001). While there was a significant difference 
between BS+A and BS-A group at baseline (p=0.001), there was no difference between 
these group at 12-month follow-up (p=0.057).
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Table S1 B Demographics of the study population
NBS+A BS+A BS-A p Value
Bio-impedance
 Fat free Mass 56.3 (42.9-7-9) 61.2 (47.8-100.5) 62.0 (47.2-74.7) 0.103
 Fat weight (%) 43.5 (24.5-59.5) 50.9 (37.6-70.4) 50.6 (31.1-59.1) 0.124
 Fat weight (kg) 45.1 (27.6-79.0) 68.1 (44.5-134.4) 62.3 (32.0-100.0) 0.046
Asthma
Medication use at inclusion study
 Short acting bronchodilator 35.7% 41.4% 25.0% 0.367
 Long acting bronchodilator 14.3% 3.4% 2.3% 0.153
 Antileukotrienes 35.7% 0% 2.3% <0.001
 B2 sympaticomimetica/ ICS 71.4% 20.7% 6.8% <0.001
 Inhaled corticosteroids 21.4% 17.2% 6.8% 0.227
 Antihistamines 23.1% 24.1% 13.6% 0.447
  Nasal corticosteroids 71.4% 17.2% 11.4% <0.001
Age of onset of asthma (% as child) 75% 33%
Atopy
Positive inhalation screen Not done 69.2% 42.4% 0.049
Skin prick test (% ≥1 positive wheal) 78.6% 55.2% 31.8% 0.005
IgE (kU/L) 90.7 (5.8-2026.0) 213 (5.0-2329) 52 (1.4-761.0) 0.041
Comorbidities
Epworth Sleepiness Scale 2 (0-16) 2 (0-8) 2 (0-9) 0.964
GERD-questionnaire 6 (4-12) 6 (4-12) 6 (2-14) 0.296
Steps a day 7191 (3307-9587) 4964 (2021-12176) 4613 (2061-10083) 0.155
Metabolic syndrome 27.3% 59.3% 53.8% 0.206
Laboratory1
 Cholesterol (mmol/L) 4.3 (2.9-5.8) 4.7 (3.4-7.4) 5.0 (3.0-6.9) 0.570
 HDL-cholesterol (mmol/L) 1.1 (0.8-1.7) 1.1 (0.7-2.3) 1.2 (0.7-2.1) 0.725
 LDL-cholesterol (mmol/L) 2.7 (1.0-3.6) 2.9 (1.8-5.1) 3.0 (1.6-4.8) 0.634
 Triglyceride (mmol/L) 1.2 (0.8-2.4) 1.7 (0.6-3.3) 1.4 (0.5-5.1) 0.080
 Glucose (mmol/L) 5.2 (4.2-9.4) 5.6 (4.6-9.5) 5.9 (4.0-27.1) 0.029
Peripheral blood count
 Leukocytes (109 /L) 9.2 (4.6-12.3) 8.7 (5.3-13.1) 7.2 (4.6-11.9) 0.057
 Neutrophils (%) 59 (37-79) 61 (45-72) 59 (46-70) 0.144
 Lymphocytes (%) 31 (15-48) 28 (15-45) 31 (20-47) 0.282
 Monocytes (%) 7 (4-14) 7 (5-13) 6 (4-13) 0.837
 Eosinophils (%) 2 (0-7) 2 (0-9) 2 (0-6) 0.965
 Basophils (%) 0 (0-1) 0 (0-1) 0 (0-2) 0.814
Data are presented as median (min-max)
1 non fasting blood
BS+A, bariatric surgery and asthma group; BS-A, bariatric surgery without asthma group; ICS, inhaled corti-
costeroid; NBS+A, no bariatric surgery and asthma group
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Table S4 Submucosal cell counts of bronchial biopsies, before and 12 months after bariatric surgery
BS+A BS-A
Baseline 12-month FU p Value Baseline 12-month FU p Value
Eosinophils (EG2) 3.0 (0.04-20.2) 1.4 (0.04-133.2) 0.889 1.3 (0.03-27.1) 2.5 (0.04-42.7) 0.826
Neutrophils (NE) 54 (11-273) 111 (24-361) 0.208 47 (0.1-139) 71 (3-228) 0.221
Mast cells (AA1) 118 (75-236) 61 (6-248) 0.036 152 (84-262) 145 (24-213) 0.125
Macrophages (CD68) 271 (67-520) 151 (65-373) 0.161 191 (7-531) 208 (58-569) 0.570
B cells (CD20) 28 (5-243) 45 (0.1-82) 1.000 36 (0.1-402) 26 (0.1-205) 0.570
T cells (CD8) 945 (321-2304) 566 (55-965) 0.050 1040 (0.2-2377) 493 (94-2641) 0.053
T cells (CD4) 510 (24-2393) 241 (6-1013) 0.161 434 (0.07-1136) 186 (0.04-719) 0.211
T cells (CD3) 1000 (161-3433) 732 (164-1165) 0.401 844 (459-2193) 559 (43-1753) 0.015
Bronchial submucosal cell count in morbidly obese subjects before and 12 months after bariatric surgery, 
with (BS+A, n=8) and without asthma (BS-A, n=14). p Values were calculated for the comparison between 











SUMMARY AND GENERAL DISCUSSION
Obesity has historically been viewed as a sign of wealth and prosperity. However, obe-
sity is not a medical disorder that started with the industrial revolution, since already 
Hippocrates wrote that “Corpulence is not only a disease itself, but the harbinger of oth-
ers”(1). The current epidemic of obesity has revealed various co-morbidities associated 
with obesity. Asthma is one these co-morbidities which are associated with obesity, and 
is the focus of the research described in the present thesis. The main topic of this thesis 
is whether the relationship between obesity and asthma is causal or that obesity and 
asthma are two co-incidental diseases in the same person.
Main findings
In chapter 2 we have shown that both overdiagnosis as well as underdiagnosis of 
asthma occur in the morbidly obese. A diagnosis of asthma based on symptoms alone is 
unreliable in the morbidly obese, and pulmonary function testing is an essential part of 
the diagnosis of asthma in the morbidly obese(2).
As overdiagnosis of asthma cannot fully explain the interplay between obesity and 
asthma, we explored other explanations. In chapter 3 all possible known explanations 
were discussed. As a new explanation the metabolic syndrome was suggested(3). To 
investigate whether the metabolic syndrome might explain the relationship between 
obesity and asthma, we explored in chapter 4 the relationship between airflow obstruc-
tion (FEV1/FVC) – an essential component of the diagnosis of asthma – and the metabolic 
syndrome. This study showed a small, but statistically significant, difference in eosino-
phils and FEV1/FVC between subjects with and without the metabolic syndrome(4). After 
correction for other variables, an association between blood eosinophils and FEV1/FVC 
remained. Although the differences we have found were relatively small, it might sup-
port our hypothesis that the presence of the metabolic syndrome may influence lung 
function impairment, through the induction of systemic inflammation, in particular, 
mediated by blood eosinophils.
We therefore investigated in chapter 5 characteristics of bronchial biopsies from mor-
bidly obese asthma patients and morbidly obese controls. We were surprised to find that 
despite evidence for systemic inflammation, which seemed to be related to the level of 
asthma control, there was no evidence for bronchial inflammation in the morbidly obese 
as shown e.g. by the absence of increased numbers of eosinophils or neutrophils(5).
Bariatric surgery is considered a definitive solution for morbid obesity, as weight loss 
is permanent in contrast to dieting, which is most often a temporary solution. In chapter 
6  we have shown that subjects with complications within 30 days of bariatric surgery 
more often have airflow reversibility or airflow obstruction(6). Therefore, as symptoms 
indicative of airway disease are often unreliable in the morbidly obese – as already 
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discussed in chapter 2 - , pulmonary function tests should routinely be part of the pre-
operative risk assessment.
In chapter 7 we extensively looked at both clinical, physiological, systemic and bron-
chial mucosal inflammatory parameters before and after bariatric surgery in morbidly 
obese asthma subjects and morbidly obese control subjects. Although we found no 
improvement in our primary endpoint FEV1/FVC, we did find improvement in asthma 
control, quality of life, medication use and PD20 methacholine. The significant improve-
ment of R5-R20 (peripheral airway function) after bariatric surgery, which was associated 
with BMI, ACQ and PD20, suggests that peripheral airways play a major role in the rela-
tionship between obesity and asthma. Finally, bariatric surgery also decreased markers 
of systemic inflammation, and mast cell counts in bronchial submucosa of obese asthma 
subjects. Collectively these findings emphasize that weight loss as achieved by bariatric 
surgery should be a cornerstone in the treatment of morbidly obese asthma patients.
Based on my main findings, this discussion is subdivided into three main topics. First, I 
will discuss the pitfalls concerning the diagnosis of asthma, especially in the morbidly 
obese. Then, I will describe bronchial and systemic inflammation in the morbidly obese. 
Thereafter I will address bariatric surgery in the morbidly obese, and will especially focus 
on the therapeutic effect of bariatric surgery in morbidly obese asthma patients.
Diagnosis of asthma in the morbidly obese
The first step to investigate the possible causal relationship between asthma and 
obesity, is to be sure that the diagnosis of asthma is correct. According to the latest 
Global Initiative for Asthma (GINA) definition of 2014, asthma is a heterogeneous dis-
ease, usually characterized by chronic airway inflammation. It is defined by the history 
of respiratory symptoms such as wheeze, shortness of breath, chest tightness and cough 
that vary over time and in intensity, together with variable expiratory airflow limita-
tion(7). Although the GINA guidelines are clear in stating that besides symptoms, also 
objective measurements of variable expiratory airflow limitation are necessary for the 
diagnosis of asthma - implying that lung function testing is mandatory for the diagnosis 
of asthma - in daily practice the diagnosis of asthma is often made only on the basis 
of symptoms(8). Especially within the morbidly obese population, this symptom-based 
approach has been proven to be of limited value. Morbidly obese do often have dyspnea 
and the diagnostic challenge is to distinguish dyspnea resulting from overweight and 
dyspnea due to asthma. In chapter 2 we have shown that both overdiagnosis as well as 
underdiagnosis of asthma occur in the morbidly obese. A diagnosis of asthma based on 
symptoms alone is unreliable in the morbidly obese patient population, and pulmonary 




To our knowledge, this is the first study that not only focuses on overdiagnosis but 
also on underdiagnosis of asthma in this patient population. Underdiagnosis of asthma 
can lead to undertreatment, increased morbidity and eventually possible death. On 
the other hand, overdiagnosis leads to overtreatment with possible risk of side-effects 
of the inhaled corticosteroids and high health costs. It can be argued that the use of 
inhaled corticosteroids (ICS) can influence the results of the provocation test(9), however 
stopping of ICS use is a possibility to correct for this. Many clinicians are reluctant to do 
this, but we have shown that it can be done in most morbidly obese (asthmatic) patients 
without complications (ref; unpublished observations).
Many of the population-based studies use a physician-diagnosis of asthma. The ques-
tion thus arises, whether this physician diagnosis of asthma is correct, especially in the 
morbidly obese. However, as a result of the inclusion method of our study in chapter 2, 
we cannot make any statement on the frequency of underdiagnosis or overdiagnosis 
in the total morbidly obese population. So, it is still unclear whether overdiagnosis of 
asthma truly explains the relationship between obesity and asthma. Further research in 
a cross-sectional study in the general population in which all subjects undergo spirom-
etry and bronchial provocation testing could answer this question.
Bronchial and systemic inflammation in the morbidly obese
As overdiagnosis of asthma cannot fully explain the interplay between obesity and 
asthma, we explored other explanations. In chapter 3 all possible known explanations 
are discussed.
 “Obese asthma” may be a unique phenotype of asthma, characterized by decreased 
lung volumes, greater symptoms for a given degree of lung function impairment, de-
stabilization or lack of asthma control, lack of eosinophilic inflammation and a different 
response to controller medication. Therefore, the clinical evaluation of an obese patient 
with asthma must require a more rigorous and objective approach. Whether this rela-
tionship is really causal or represents parallel co-morbidities is unclear. In animal models, 
there is an increasing amount of evidence for the role of adipokines derived from fat 
tissue in the relationship between obesity and asthma. These adipokines cause a low 
grade systemic inflammation, which might cause or enhance bronchial inflammation. 
The data are conflicting in humans. However, the fact that weight loss improves asthma 
control and normalizes the concentration of adipokines in the circulation implies that 
there must be some role for adipokines in the relationship between obesity and asthma.
A hypothesis not discussed in chapter 3, is the effect of gut microbiota on asthma 
and obesity. The modern dietary pattern with reduced fiber content is associated with 
changes in gut microbiota biodiversity, which is a risk factor for allergy and obesity(10). 
The gut microbiota and the microbiome (collective genetic material of gut microbiota) 
are important in normal immune development. A disruption of the gut microbiota 
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increases immune and metabolic dysregulation, and increases the risk of obesity and 
asthma. The changing gut microbiota is linked to inflammation through increased CRP, 
TNFα and IL-6(11). The hygiene hypothesis states that excessive cleaning and reduced 
pathogen exposure contribute to inadequate immune responses(12). A link can be seen 
with the gut microbiota which can be influenced by diet and antibiotics use, and some 
state that the hygiene theory should be rewritten into the “microflora hypothesis”(13). 
This hypothesis postulated that disturbances in gut microbiota lead to underdeveloped 
microbiota, which impair proper maturation of the immune system leading to allergic 
hypersensivity and asthma. But also obesity is influenced by altered gut microbiota. In 
obese subjects the gut barrier is altered leading to higher plasma lipopolysaccharide 
levels which trigger low grade inflammation and insulin resistance(14). Because the 
notion that gut microbiota affects obesity and asthma is a recent insight, we have not 
performed any research on this subject yet.
Another explanation how obesity can influence asthma is the metabolic syndrome 
(mentioned in chapter 3). Since obesity is a component of the metabolic syndrome and 
the metabolic syndrome also includes systemic inflammation, it is to be expected that 
there is a relationship between metabolic syndrome and asthma. The few data that are 
available show that there is no relationship between metabolic syndrome and asthma, 
but there is one between the metabolic syndrome and asthma-like symptoms.
To investigate whether the metabolic syndrome might explain the relationship be-
tween obesity and asthma, we explored in chapter 4 the relationship between airflow 
obstruction (FEV1/FVC) – an essential component of the diagnosis of asthma – and the 
metabolic syndrome. This study showed a small, but statistically significant, difference 
in eosinophils and FEV1/FVC between subjects with and without the metabolic syn-
drome(4). After correction for other variables, an association between blood eosinophils 
and FEV1/FVC remained. Although the differences we have found were relatively small, 
it might support our hypothesis that the presence of the metabolic syndrome may 
influence lung function impairment, through the induction of systemic inflammation, in 
particular, mediated by blood eosinophils.
Insulin resistance, another part of the metabolic syndrome, might also help to explain 
the relationship between obesity and asthma. Hyperinsulinemia may lead to changes 
in the lung characteristics of asthma via growth factor-like effects(15). A vagally medi-
ated bronchoconstrictor effect of hyperinsulinemia has also been described(16). A study 
in healthy adults has found an association between insulin resistance and bronchial 
hyperresponsiveness(17). We however, found that only hypertension – as one of the five 
components of the metabolic syndrome – was associated with FEV1/FVC and further-
more, we did not test bronchial hyperresponsiveness.
General discussion 141
8
After we had found more circumstantial evidence that systemic inflammation might 
explain the relationship between asthma and obesity, we investigated whether this 
systemic inflammation also leads to local bronchial inflammation. As bronchial inflam-
mation is considered a key component of asthma, if bronchial inflammation in present 
in the morbidly obese asthma subject, it would argue for a causal relationship between 
obesity and asthma.
Whereas other studies tried to investigate this bronchial inflammation by bronchial 
lavage or bronchial brushes, it can be argued whether they truly investigated bronchial 
inflammation. There might be a difference in the inflammatory cell population within 
the airway epithelium (as investigated by lavage, brushes or bronchial biopsies) and 
that in submucosa (as investigated by bronchial biopsies). We therefore investigated in 
chapter 5 characteristics of bronchial biopsies from morbidly obese asthma patients 
and morbidly obese controls.
As we found in chapter 4 that increased numbers or circulating eosinophils could be 
a specific manifestation of the systemic inflammation associated with the metabolic 
syndrome, it could be expected that asthma in the morbidly obese is also an eosinophil 
driven disease as it is known to be in many lean atopic asthma subjects. However, there 
is large debate in literature about the nature of the inflammation in obese asthma sub-
jects. Asthma in the obese has been characterized as a specific phenotype, with a female 
predominance, late on-set and not eosinophilic(18).
We were surprised to find that despite evidence for systemic inflammation, which 
seemed to be related to the level of asthma control, there was no evidence for bronchial 
inflammation in the morbidly obese, characterized by increased numbers of eosinophils 
or neutrophils(5). Despite one part of the morbidly obese study population was diagnosed 
as having asthma, while the other part of the morbidly obese study population had no 
asthma, there was no difference in any of the components of bronchial inflammation 
studies with the exception of CD8 positive T-cells. Both groups had the same degree of 
obesity, had no differences in lung function, or prevalence of the metabolic syndrome. 
A good explanation why one group has asthma and the other not, despite the fact that 
there is no difference in bronchial inflammation remains a question to be elucidated.
Our data suggest that asthma in our cohort is not driven by a classical TH2-mediated 
mechanism and probably needs to be regarded as a distinct phenotype of the disease, 
not related to significant detectable inflammatory responses in the airway walls. Pos-
sibly asthma in the morbidly obese – as were the subjects of our studies –  constitutes a 
specific phenotype, which is distinct from asthma in obese subjects. Desai et al.(19), who 
investigated obese asthma subjects (mean BMI 36 kg/m2 versus mean BMI 44 kg/m2 in 
our study), did find an elevated bronchial submucosal eosinophil number as compared 
to lean controls and lean asthmatics. Others discuss that the lack of airway eosinophils 
could be altered trafficking of these cells from the vasculature or interstitium into the 
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airspace rather than a unique inflammatory phenotype per se(20). While others state that 
the location of the eosinophils within specific tissues may directly affect their function(21). 
Additionally, we also found no evidence for neutrophil-dominated bronchial inflamma-
tion, as has been shown in an obese asthma group by Scott(22).
Furthermore our study was the first to compare bronchial biopsies from morbidly 
obese asthma subjects to morbidly obese controls. Previous studies compared obese 
asthmatics with lean asthmatics, and found differences. It should be kept in mind that 
these differences can also be attributed to obesity rather than asthma.
As the classical Th2-mediated mechanism seems not to be present in the morbidly 
obese with asthma, other mechanisms could be active. Another cell type of interest 
are the macrophages. Blood monocytes and adipose tissue macrophages in obesity 
demonstrate a classical M1 activation. Lugogo et al compared macrophages of 42 obese 
subjects with asthma with 46 obese subjects without asthma, and found that alveolar 
macrophages in obese asthmatics demonstrate an exaggerated response to the proin-
flammatory effect of leptin(23). Furthermore, Fernandez has showed that in obese asth-
matics the efferocytosis (the process by which macrophages ingest and clear apoptotic 
cells) of blood monocytes and airway macrophages in obese asthmatics was 40% lower 
as compared to lean asthmatics. Although we found no differences in the number of 
macrophages in the bronchial tissue between morbidly obese asthmatics and morbidly 
obese controls, of course there could have been a difference in macrophage function. 
Further research should also focus on macrophages in the fat tissue, and whether these 
macrophages in the fat tissue also influence systemic inflammation and thereby bron-
chial inflammation.
TH17 cells, developmentally distinct from TH1 and TH2 cells, could also play a role in the 
relationship between obesity and asthma, as IL-17A – produced by TH17 cells, but also 
by other cell types - is required for the development of bronchial hyperresponsiveness 
in obese mice(24). Furthermore, Mathews et al. have recently shown that the increases in 
IL-17A precedes the development of bronchial hyperresponsiveness by several weeks in 
mice(25), suggesting that obesity and asthma are not two co-incidental diseases. Data on 
IL-17A in obese humans with asthma is rare, and it also was not a subject of our research.
Air pollution is now mentioned as a novel risk factor for the development of obesity(26) 
and asthma, and research is now focusing on bronchial inflammation caused by air 
pollution(27). Endocrine-disrupting chemical (EDC) are chemicals that can disrupt adipo-
genesis and energy balance. Air pollution can induce obesity via a systemic inflamma-
tory pathway that targets adipocytes(28). Many EDCs are highly lipophilic and therefore 
accumulate in the fat tissue, where they can release proinflammatory signals but also 
may cause adipocyte proliferation and differentiation. This seems quite plausible, and 
might explain the exploding prevalence of obesity in the last decades, other than excess 
caloric intake, sedentary lifestyle or genetic susceptibility. However, it is now also stated 
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that obese individuals are more vulnerable to develop asthma due to exposure to air 
pollutants than lean individuals. In a study with 148 children with persistent asthma, the 
association between indoor particulate matter less than 2.5 µm in mean aerodynamic 
diameter (PM2.5) and nitrogen dioxide (NO2) levels and respiratory symptoms were ex-
amined. Overweight children were more susceptible to pulmonary effects of PM2.5 and 
NO2(29). This does not answer whether it is asthma or obesity that made the children 
more susceptible to EDCs. In a mouse study by Shore et al, obese mice inhaled greater 
doses of air pollutant ozone in the lungs than normal weight mice because of higher 
breathing frequency, accompanied by greater airway hyperresponsiveness and greater 
cellular inflammation(27). This is not in line with our results of bronchial tissue inflamma-
tion, as discussed in chapter 5, where we found no difference in cellular inflammation 
between obese subjects with or without asthma. This might be explained by the fact 
that there might be an association between air pollutants and asthma or obesity, but 
this is not a causal relationship. Further research on air pollution is needed.
Since we found no difference in bronchial inflammation between obese asthma sub-
jects and obese controls, it can be argued that the definition of asthma as a syndrome 
characterized by airway hyper-responsiveness, inflammation and clinical symptoms, 
as presented in the GINA guidelines, is perhaps not applicable to the morbidly obese. 
In the present study, all asthma subjects had symptoms, reversible airway obstruction 
or increased bronchial hyper-reactivity. In contrast, in majority of patients no airway 
inflammation could be detected. This further strengthens the concept of a different 
asthma phenotype, whereas the phenotype observed in the present study has no 
distinct inflammatory changes in the airways. This phenomenon probably explains why 
these patients have such a poor response to anti-inflammatory medication. Weight loss 
seems to be the most important therapeutic goal, although further research on this 
subject is needed.
Bariatric surgery
Bariatric surgery is considered a definitive solution for morbidly obesity. In line with 
the worldwide epidemic of obesity, the number of bariatric surgery procedures being 
performed is increasing every year, with a 22-fold increase between 1996 en 2008(30). 
The prevention of complications of bariatric surgery is of great importance, especially 
since surgery is elective and complications are difficult to treat in this group of mor-
bidly obese patients. As we have shown in chapter 4 that morbidly obese subjects with 
the metabolic syndrome have a slight, but statistically significant, increase in airflow 
obstruction, we wondered whether subjects with more airflow obstruction or airflow re-
versibility, had more complications after bariatric surgery. In chapter 6  we have shown 
that subjects with complications within 30 days of bariatric surgery more often have 
airflow reversibility or airflow obstruction(6). Therefore, as symptoms are often unreliable 
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in the morbidly obese – as already discussed in chapter 2 - , pulmonary function tests 
should routinely be part of the preoperative risk assessment. Generally, laparoscopic 
bariatric surgery is safe, but randomized prospective studies are needed to investigate 
whether abnormal pulmonary functions tests could indeed serve as a guide in patient 
selection and optimization of the preoperative medical condition of patients undergo-
ing bariatric surgery, which could lead to additional improvement in the outcomes after 
bariatric surgery.
The current guidelines of the American Society of Metabolic and Bariatric Surgery state 
that spirometry as a preoperative test is indicated only in the presence of risk factors 
previously identified by other tests(31). A recent study by Clavellina et al in 602 patients, 
which investigated the relationship between spirometry results and the frequency of 
postoperative complications(32), supports our study results. They also found that us-
ing multivariate logistic regression analysis, an abnormal spirometry was a significant 
predictor of post-operative pulmonary complications in patients with respiratory symp-
toms and/ or obstructive sleep apnea syndrome (OSAS). However, they state that there 
was a significant number of asymptomatic patients that in spite of an abnormal spirom-
etry, did not develop respiratory complications(32), and therefore argue that spirometry 
should not be performed regularly before bariatric surgery. A large study of 158405 
patients in the USA, which focused on pulmonary complications of bariatric surgery, 
found that not only the metabolic syndrome, but also asthma is a risk factor for postop-
erative pulmonary complications(33). However, as discussed previously, the major pitfall 
of this article was that the asthma diagnosis was based on physician assessment and 
no spirometry was performed. As the metabolic syndrome is seen as a state of systemic 
inflammation, it is logical to speculate that subjects with (more) systemic inflammation 
have a higher change of complications of bariatric surgery. The abovementioned US 
study found that the metabolic syndrome is associated with complications of bariatric 
surgery, we although did not find such an association.
Interestingly, our study has shown that spirometry is not only useful in predicting 
pulmonary complications, but it might predict all complications of bariatric surgery. 
This it is in line with previous findings that FEV1 is associated with mortality(34). FEV1 
could possibly be a marker of general health or fitness. So abnormal spirometry does 
not only indicate obstructive pulmonary disease, but might also indicate poor general 
health. In this cohort we had no data on systemic or bronchial inflammation. It is purely 
speculative to say that the group with abnormal spirometry also had more systemic 
inflammation.
Only a randomized controlled intervention study which investigates whether therapy 
in subjects with abnormal spirometry could prevent complications of bariatric surgery, 
could answer whether spirometry should be standard in all bariatric subjects. Such a 
study has not yet been performed to our knowledge.
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After showing in chapter 5 that bronchial inflammation is absent in the morbidly obese, 
in contrast to systemic inflammation, we further explored the effects of weight loss by 
bariatric surgery. In chapter 7 we extensively looked at both clinical, physiological, sys-
temic and bronchial musical inflammatory parameters before and after bariatric surgery 
in morbidly obese asthma subjects and morbidly obese control subjects(35). Although 
we found no improvement in our primary endpoint FEV1/FVC, we did find improvement 
in asthma control, quality of life, medication use and PD20 methacholine. The significant 
improvement of R5-R20 (peripheral airway function) after bariatric surgery, which was 
associated with BMI, ACQ and PD20, suggests that peripheral airways play a major role in 
the relationship between obesity and asthma. Finally, bariatric surgery also decreased 
markers of systemic inflammation, and mast cell counts in bronchial submucosa of 
obese asthma subjects.
The fact that we did not find clear evidence that also bronchial inflammation is 
decreased concordantly with the systemic inflammation, is in contrast to the results 
of Arismendi et al(36). They showed not only that in a group of healthy obese subjects, 
systemic inflammation is not modified by sex, smoking status or metabolic syndrome, 
but also that  pulmonary inflammation, as measured by exhaled IL-8, IL-10 and 8-iso-
prostane, is increased in obese healthy subjects as compared to lean healthy subjects, 
and furthermore that this pulmonary inflammation in decreased after bariatric surgery. 
However, they did not include subjects with asthma. And as stated previously, the ques-
tion remains whether there are cellular differences with regard to inflammation between 
the submucosa and the epithelium.
Obesity is associated with increased oxidative stress. Exhaled 8-isoprostane, derived 
from free radical-catelyzed peroxidation of arachidonic acid, is a marker of oxidative 
stress. Oxidative stress is characterized by the presence of increased reactive oxygen 
species (ROS). ROS production contributes to increased mucus production and increased 
airway reactivity. Increased plasma 8-isoprostane levels have been noted in asthma, but 
were not present after adjusting for obesity(37). This suggests that the elevated plasma 
levels are a consequence of obesity rather than asthma.
Recently there is more recognition that bioenergetic failure is a common pathway 
rather than a outcome of disease, in obesity, metabolic syndrome and asthma(38, 39). Mito-
chondrial dysfunction seems to be related to the metabolic syndrome. Surplus nutrient 
supply overloads mitochondria(40), leading to overproduction of (ROS) and accumula-
tion of incompletely oxidized substrates. The damage of these ROS causes reduction in 
mitochondrial integrity, and triggers stress pathways that reduce insulin sensitivity(41). 
Together with the sedentary lifestyle, this appears to be the foundation of insulin resis-
tance. As fatty acid oxidation for energy can only happen in mitochondria, fats are not 
adequately metabolized, leading to intracellular accumulation and increased circulating 
lipids(41). This is the trias of obesity, hyperglycaemia and dyslipidemia, also known as the 
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metabolic syndrome. As hypersinsulinemia seems to be an independent risk factor for 
asthma(15), mitochondrial mechanisms important in the metabolic syndrome can also 
contribute to asthma. Although in mice models of allergic airway inflammation, mito-
chondrial dysfunction has been demonstrated(41), there is limited evidence for a causal 
role of mitochondrial dysfunction in human asthma. The exact role of oxidative stress in 
the relationship between asthma and obesity has yet to be elucidated, and should be 
focus of further research.
As previously discussed, we take the view that morbidly obese asthmatics are a distinct 
phenotype on its own, in contrast to obese asthmatics. It is also speculated that the 
obese asthma phenotype could be further divided into Th2-high (high serum IgE) obese 
asthmatics having pre-existing allergic asthma that is complicated by obesity, whereas 
Th2-low (low serum IgE) obese asthmatics develop asthma symptoms as a consequence 
of obesity. This subphenotyping is confirmed by the fact that airway hyperresponsive-
ness in Th2-low obese asthmatics improves after weight loss following bariatric surgery, 
in contrast to Th2-high obese asthmatics(42).
Traditionally asthma research has focused on the large airways. However, small airways 
are also an important site of airway inflammation and remodeling in asthma(43). There are 
only a few studies on small airways in (lean) asthma(44, 45), the list of small airway studies 
in subjects with obesity is even smaller(46). With impulse oscillometry (IOS) the resistance 
and reactance of the airways can be measured easily. Resistance at 20Hz is considered 
to reflect the large airways (R20) and resistance at 5Hz the total airways (R5). Small airway 
resistance can be calculated with the difference R5-R20. Reactance of the system at 5Hz 
(X5) is also assumed to reflect small airway function(47). Asthma symptoms correlate 
poorly with FEV1, and in a recent study by Van der Wiel et al(44), which also included some 
obese subjects, it was shown that also small airway dysfunction poorly associated with 
asthma symptoms. However, they showed that small airway dysfunction is associated 
with more severe bronchial hyperresponsivenss to methacholine.
As small airways are now subject of current research in obese asthmatics, Chapman et 
al. investigated the effect of bariatric surgery on small airways and the two phenotypes 
of obese asthma, and found that weight loss does not alter small airway responsiveness 
inTH2-high obese asthmatics, in contrast to TH2 low obese asthmatics where weight loss 
is associated with a reduction in small airway responsiveness(46). However, the patient 
numbers in this study are small (TH2-low, n=8; TH2-high, n=5). As our numbers are larger, 
this could explain why we did not find differences in  subjects with either high or low IgE.
Treatment of (morbidly) obese asthmatics has proven to be difficult, as they respond 
poorly to conventional asthma therapies such as inhaled corticosteroids (ICS)(48). As 
the conventional asthma therapies do not work, other researchers have investigated 
alternative options such as the effect of dietary weight loss(49-52). The study by Stenius et 
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al.(49) showed that a 14-week weight reduction program using a low calorie diet leads to 
sustained improvement in lung function and health status. The role of exercise as inter-
vention has not been studied extensively, although exercise or pulmonary rehabilitation 
could be of use especially in the morbidly obese asthma patient.  However, it is difficult 
to obtain sustained weight loss in the morbidly obese with calorie restriction and be-
havioral interventions. Bariatric surgery causes a larger and prolonged effect on weight 
loss. Previous studies have also shown that bariatric surgery improves asthma control 
and airway hyperresponsiveness(53). Some, however, state that the surgical technique is 
of influence on asthma related outcomes. A study of 257 patients with asthma showed 
after 1-year an overall reduction in asthma medication in all patients. Those who under-
went a laparoscopic gastric banding procedure were 37% more likely to show improve-
ment in self-reported asthma severity compared to those operated with the Roux-and-Y 
procedure(54). Gastric banding is however a procedure that has become less common, 
due to complications, and is not performed in the Sint Franciscus Gasthuis. As far as we 
know there are no studies comparing the effects on medication use between gastric 
sleeve resection and gastric Roux-and-Y bypass. In addition, bariatric surgery does not 
only influence asthma, it also improves asthma comorbidities such as gastroesophageal 
reflux disease (GERD) and obstructive sleep apnea.
Other treatment options discussed in literature of obese asthma patients could be the 
use of either metformin or statins. Metformin restores insulin sensitivity and promotes 
mitochondrial metabolism(55). In mice with diet-induced obesity, metformin attenuated 
allergen-induced eosinophilic inflammation(56). The beneficial effects of metformin were 
not found in a genetically obese mice model with intrinsic airway hyperresponsive-
ness(57). There is little data on the effect of metformin in human (obese) subjects with 
asthma. Further research is needed.
Statins which are classically prescribed for hyperlipidemia, have also found to have 
anti-inflammatory effect, and improve lung function(58). In a retrospective study of 165 
adult asthmatics it was found that patients on statins had significantly increased ACT 
scores as compared to those without statins(59). However, medication related interven-
tions were not part of our study.
All these findings together are underlining the importance of substantial weight 
reduction, in particular by bariatric surgery, which should be a cornerstone in the treat-
ment of morbidly obese asthma patients. Furthermore, I would like to advocate that 
asthma should also be considered as one of the comorbidities – just like diabetes and 
OSAS – that makes patients eligible for bariatric surgery from a BMI level of 35 kg/m2. 
Perhaps in future, morbidly obese asthmatic subjects will be sent more often to the sur-
geon, in addition to being sent to the pulmonologist, as “the surgeon can cure asthma 
in the morbidly obese”.
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FINAL REMARKS
The studies performed in this thesis illustrate the complicated interplay between obe-
sity and asthma. With the results of our studies and recent findings reported in literature, 
figure 2 from the introduction could be altered into:
 
Figure 1 Hypothesis explaining the obesity-asthma association
The studies from this thesis show the complexity of relation and interaction between 
obesity and asthma. The observed  epidemiological relationship between obesity and 
asthma does not prove causality, and cannot be completely explained by overdiagnosis 
of asthma, especially because also underdiagnosis of asthma exists within the obese 
population. The fact that in this population of morbidly obese we found an association 
between airway obstruction and eosinophils in the peripheral blood, particularly in 
those patients with the metabolic syndrome,  indicates a possible causal relationship 
between obesity and asthma. However, this was contradicted by the fact that we found 
no difference in bronchial inflammation, including eosinophils between morbid obese 
patients with and without asthma. Despite evidence for more systemic inflammation, 
analysis of bronchial biopsies did not provide further clues for a pathophysiological 
basis of the interaction between obesity and asthma. Besides the clear need for a rigor-
ous diagnosis of asthma in the morbidly obese, the question arises whether asthma in 
the morbidly obese is a distinct phenotype characterized by the absence of eosinophilic 
or neutrophilic inflammation. However, despite the absence of bronchial inflammation, 
substantial weight loss induced by bariatric surgery does improve lung function, quality 
of life and systemic inflammation in as both morbidly obese asthma patients as mor-
bidly obese controls. This indicates that weight loss is the cornerstone for treatment of 
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the morbidly obese asthma phenotype, and that this observation may provide further 
clues for understanding the relationship between obesity and asthma.
Further research is necessary to show whether the abovementioned effects of bariat-
ric surgery are also present after long term follow-up. Also research regarding the role 
of small airways in the morbidly obese asthma subject is necessary. Finally, the effect 
of pulmonary rehabilitation before bariatric surgery is an interesting topic for further 
research, and might reveal whether it decreases complications of bariatric surgery, and 
whether pulmonary rehabilitation on its own has any effect in the (morbidly) obese 
asthma patient.
Taken together, despite the fact that further research, especially directed at the role of 
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Historisch werd zwaarlijvigheid, ook wel obesitas genoemd, gezien als een teken van 
rijkdom en welvaart. Het is aannemelijk om te veronderstellen dat obesitas tegelijkertijd 
ontstond met de industriële revolutie. Dat obesitas ook kan leiden tot een scala aan an-
dere aandoeningen, werd al veel eerder onderkend: het was Hipprocrates die al schreef 
dat “zwaarlijvigheid niet alleen zelf een ziekte is, maar de voorbode van andere”(1). Obe-
sitas is momenteel een groot gezondheidsprobleem en ontwikkelt zich tot een wereld-
wijde epidemie. Obesitas wordt geclassificeerd middels de Body Mass Index (BMI), en is 
gedefinieerd als een abnormale of excessieve vetophoping die gezondheidsproblemen 
kan veroorzaken. De Wereld Gezondheid Organisatie voorspelt dat in 2015 ongeveer 
2,3 miljard volwassenen overgewicht (BMI 25-30 kg/m2) zullen hebben, en dat meer dan 
700 miljoen obees zullen zijn (BMI 30-40 kg/m2). Een BMI boven de 40 kg/m2 wordt ook 
wel morbide obesitas genoemd.
De afgelopen decades is het aantal patiënten met astma ook toegenomen(2, 3). Omdat 
de “epidemie” van obesitas gelijktijdig heeft plaats gevonden, suggereert dit een mo-
gelijke relatie tussen obesitas en astma(4, 5). Daarnaast hebben obese astma-patiënten 
een slechtere astma gerelateerde kwaliteit van leven(6), meer klachten ten gevolge van 
minder astma controle(7) en ook ernstiger ziekte(8). Het feit dat astma symptomen ver-
minderen na gewichtsverlies, ondersteunt de gedachte dat obesitas ook daadwerkelijk 
leidt tot astma, oftewel dat er een causale relatie bestaat(5). Het dilemma waar dit proef-
schrift antwoord op probeert te geven, is of de relatie tussen obesitas en astma causaal 
is, of dat obesitas en astma twee tegelijk voorkomende ziekten in dezelfde persoon zijn.
Diagnose van astma in morbide obese patiënten
Volgens de laatste Global Initiative for Asthma (GINA) definitie van 2014, is astma een 
ziekte die zich op meerdere manieren kan uiten (“heterogene ziekte”), en wordt meestal 
gekarakteriseerd door chronische luchtwegontsteking. Het wordt gedefinieerd door 
klachten zoals piepen, kortademigheid, benauwdheid en hoesten. Deze klachten zijn 
niet altijd aanwezig, maar komen en gaan zowel over de tijd als in intensiteit. Als ten 
tijde van klachten een longfunctie zou worden geblazen, zou dit een moeizame uitade-
ming laten zien omdat de luchtwegen vernauwd zijn, terwijl er geen afwijkingen zullen 
zijn als men geen klachten heeft. Dit wordt ook wel een “variabele expiratoire luchtweg 
obstructie” genoemd(9). De GINA richtlijn adviseert dat de diagnose van astma zowel 
gebaseerd moet zijn op de aanwezigheid van symptomen als objectieve metingen 
zoals variabele expiratoire luchtweg obstructie(9). Echter, in de dagelijkse praktijk en met 
name in de 1e lijn, is de diagnose astma voornamelijk gebaseerd op klachten; longfunc-
tieonderzoek (spirometrie of provocatietesten) worden niet altijd uitgevoerd(10). Omdat 
obese mensen meer klachten van kortademigheid hebben dan niet-obese mensen(11), 
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kan het gebeuren dat zij ten onrechte de diagnose astma krijgen (overdiagnose). Onver-
mijdelijk leidt elke overdiagnose tot ineffectieve behandeling(10), met verhoogde kans 
op bijwerkingen en hoge medische kosten(12).
De eerste suggestie dat er een relatie bestond tussen obesitas en astma was geba-
seerd op epidemiologische studies, waarbij er in grote groepen mensen gekeken werd 
hoe vaak een ziekte voorkwam. Echter, vele epidemiologische studies naar obesitas 
en astma hebben een huisarts-diagnose astma gebruikt, zonder bevestiging van de 
diagnose astma middels longfunctietesten. Dit betekent dat men kritisch moet zijn 
of de diagnose astma wel correct is, en het roept ook vraagtekens op bij de mogelijke 
causale relatie tussen obesitas en astma. Andere studies hebben namelijk al laten zien 
dat na uitgebreide testen de diagnose astma verkeerd was bij 30% van de door de 
huisarts gediagnosticeerde astma patiënten(13). Aan de andere kant is het missen van de 
diagnose astma (onderdiagnose) in de obese populatie ook een belangrijk aspect. Alle 
voorgaande studies betreffende overdiagnose selecteerden obese patiënten met waar-
bij de diagnose astma is vastgesteld(13-15), en namen daardoor de obese patiënten met 
ongediagnosticeerd astma niet mee in hun analyses. Daarom is er weinig bekend over 
onderdiagnose van astma bij obese personen. In hoofdstuk 2 hebben we laten zien dat 
zowel overdiagnose maar ook onderdiagnose van astma voorkomt in morbide obese 
patiënten. Dit bevestigt nogmaals dat bij morbide obese patiënten het stellen van de 
diagnose astma op basis van alleen symptomen onbetrouwbaar is, en dat longfunctie-
testen een essentieel onderdeel zijn van de diagnostiek naar astma in de morbide obese 
populatie(16). Echter, als gevolg van het selectieproces en de inclusiemethoden van onze 
studie van hoofdstuk 2, kunnen we geen uitspraak doen over de frequentie van overdi-
agnose danwel onderdiagnose van astma in de totale morbide obese populatie.
Bronchiale en systemische inflammatie bij morbide obese patiënten
Omdat overdiagnose van astma niet geheel de associatie tussen obesitas en astma kan 
verklaren, zijn we op zoek gegaan naar andere verklaringen. In hoofdstuk 3 werden 
alle tot dan toe bekende verklaringen besproken, zoals dieet, genetica, andere ziekten 
die tegelijkertijd spelen in een patiënt (comorbiditeiten), veranderde longfunctie ten 
gevolge van de andere lichaamsbouw (centrale adipositas) en ontsteking. Zoals al 
eerder gezegd is chronische luchtwegontsteking een essentieel onderdeel van astma. 
Luchtwegontsteking wordt ook wel bronchiale inflammatie genoemd. Er zijn verschil-
lende vormen van ontsteking, oftewel inflammatie, zoals onder andere “systemische 
inflammatie”. Hiermee wordt een ontsteking bedoeld die zich afspeelt in het gehele 
lichaam (“het systeem”), en die zich verspreid door het lichaam via het bloed.
In hoofdstuk 3 werd als een mogelijke nieuwe verklaring voor de relatie tussen obesi-
tas en astma het metabool syndroom gesuggereerd(17). Het metabool syndroom is een 
combinatie van ziekten die vaak voorkomt bij mensen met overgewicht. We spreken 
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van het metabool syndroom als patiënten 3 van de volgende 5 problemen hebben; 
suikerziekte (diabetes mellitus), hoge bloeddruk (hypertensie), hoog cholesterol (hyper-
trygliceridemie), te laag “goed cholesterol” (verlaagd HDL cholesterol) of een te grote 
buikomtrek (centrale adipositas).
De mechanismen die ten grondslag liggen aan de relatie tussen het metabool 
syndroom en astma zijn nog onduidelijk. We weten dat personen met obesitas een 
milde chronische systemische inflammatie hebben, wellicht dat deze milde chronische 
systemische inflammatie de relatie tussen obesitas en astma verklaard. De hypothese is 
dat deze milde systemische inflammatie, via het bloed “overstroomt” naar de longen, en 
aldaar de voor astma zo typische chronische luchtweginflammatie veroorzaakt.
Om te onderzoeken of het metabool syndroom inderdaad de relatie tussen obesitas 
en astma verklaart, hebben we in hoofdstuk 4 de relatie tussen luchtwegobstructie 
(FEV1/FVC) – een essentieel onderdeel van de diagnose van astma – en het metabool 
syndroom onderzocht. We hebben onder andere gekeken naar eosinofielen; dit zijn een 
specifiek soort ontstekingscellen, die vaak verhoogd zijn bij patiënten met allergieën en 
astma. Deze studie liet een klein, maar statistisch significant, verschil zien in eosinofielen 
en luchtwegobstructie (FEV1/FVC) tussen patiënten met en zonder het metabool syn-
droom(18). Ondanks dat het verschil maar gering is, kan het wel onze hypothese  - dat het 
metabool syndroom mogelijk longfunctiestoornissen veroorzaakt, door de  systemische 
inflammatie, en met name, door bloed eosinofielen - ondersteunen. Dit zou een aanwij-
zing kunnen zijn voor een causale relatie tussen obesitas en astma, en dan wellicht via 
het metabool syndroom.
Nadat we indirect bewijs hadden gevonden dat systemische inflammatie mogelijk de 
relatie tussen astma en obesitas zou kunnen verklaren, hebben we onderzocht of deze 
systemische inflammatie ook daadwerkelijk leidt tot lokale bronchiale inflammatie. 
Zoals al eerder vermeld, is astma een chronische ontsteking van de luchtwegen. Typisch 
allergisch astma wordt gekarakteriseerd door de aanwezigheid van een allergie, een 
verhoogd aantal eosinofielen in het slijm van de luchtwegen en verhoogd uitgeademd 
stikstofoxide (“TH2-mechanisme”). Astma is echter een heterogene ziekte, wat betekent 
dat er verschillende vormen van astma zijn. Voor elk van deze verschillende vormen 
van astma, ook wel astma fenotypes genoemd, zijn er verschillende onderliggende 
ziekteprocessen die mogelijk deels op een andere manier behandeld zouden moeten 
worden(9). Astma met obesitas is een van deze herkenbare fenotypes, meestal gekarak-
teriseerd door veel symptomen, die pas tot uiting komen op volwassen leeftijd. Er is in 
de literatuur enige discussie over welke ontstekingscellen betrokken zijn bij de lucht-
wegontsteking bij obese astma patiënten. In tegenstelling tot de typisch allergische 
astma patiënten, is er vaak géén sprake van een verhoogd aantal eosinofielen, maar 
wordt er gedacht dat de neutrofielen de inflammatie veroorzaken. Terwijl de ene onder-
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zoeksgroep meer neutrofielen in het slijm van de luchwegen laat zien(19), laten andere 
studies geen relatie zien tussen obesitas en neutrofiele luchtweginflammatie(20, 21). Er zijn 
echter verschillende manieren om de cellen betrokken bij de luchtwegontsteking te on-
derzoeken. Andere studies hebben luchtwegontsteking onderzocht door het spoelen 
van de longen met vocht (“bronchiale lavage”) of het maken van een uitstrijkje van de 
luchtwegen (“bronchiale brushes”). Daarom kan de vraag worden gesteld of zij werkelijk 
luchtwegontsteking hebben onderzocht. Er kan namelijk een verschil zijn in de ontste-
kingscellen aangetroffen in het slijmvlies van de luchtwegen (“luchtweg epitheel”; zoals 
onderzocht met lavage, brushes of bronchiale biopten) en de cellen van de wanden van 
de luchtwegen zelf (“submucosa”). Door middel van het bestuderen van stukjes weefsel 
die worden weggenomen uit de wand van de luchtwegen (“bronchiale biopten”), kun-
nen de ontstekingscellen in de wanden van de luchtwegen worden onderzocht.
We hebben in hoofdstuk 5 de karakteristieken van bronchiale biopten van morbide 
obese astma patiënten en morbide obese controles onderzocht. Tot onze verrassing von-
den we geen bewijs voor méér luchtwegontsteking (verhoogde aantallen eosinofielen 
of neutrofielen) in morbide obese astma patiënten in vergelijking met morbide obese 
patiënten zonder astma. Dit ondanks dat we wel bewijs hadden voor meer systemische 
inflammatie in morbide obese astma patiënten, waarbij patiënten met meer astma-
klachten ook meer systemische inflammatie hadden(22). Onze data suggereren dat astma 
in ons cohort niet wordt aangestuurd door het klassieke TH2-gemedieerde mechanisme 
waarbij eosinofielen een belangrijke rol spelen, en wellicht gezien moet worden als een 
specifiek fenotype van de ziekte zonder significant waarneembare ontsteking in de 
luchtwegen. Wellicht is het zelfs zo dat astma in morbide obese patiënten een specifiek 
fenotype is, dat onderscheiden moet worden van astma in obese patiënten.
Bariatrische chirurgie
Onder bariatrische chirurgie worden alle operaties verstaan die tot doel hebben om 
het gewicht te verminderen. Bariatrische chirurgie wordt gezien als een definitieve 
oplossing voor morbide obesitas, omdat het gewichtsverlies permanent is. Dit in tegen-
stelling tot diëten, die vaak een tijdelijke oplossing bieden. Bariatrische chirurgie leidt 
tot gewichtsverlies middels twee mechanismen: minder opname van voedingsstoffen 
(malabsorptie) en een kleinere hoeveelheid voedsel die kan worden gegeten (restrictie). 
De sleeve gastrectomy, waarbij het grootste deel van de  maag wordt verwijderd, is een 
restrictieve methode. Bij de gastric bypass operatie wordt een klein zakje gemaakt van 
de maag, gescheiden van de rest van de maag, en tevens aangesloten op de dunne 
darm. Dit is een combinatie van zowel een restrictieve als malabsorptieve procedure.
Tegelijkertijd met de obesitas epidemie, is ook het aantal bariatrische chirurgie pro-
cedures toegenomen, met een 22-voudige stijging tussen 1996 en 2008(23). Bij ongeveer 
5% zullen er complicaties optreden. In een grote studie werd aangetoond dat longont-
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steking en longfalen, ondanks dat deze niet vaak voorkomen, wel voor één-vijfde van de 
morbiditeit zorgen. Daarnaast zijn juist deze complicaties geassocieerd met de hoogste 
kans op overlijden(24) en de hoogste kosten(25). Omdat bariatrische chirurgie niet wordt 
verricht vanwege een acuut levensgevaar, maar een electieve procedure is in relatief 
gezonde patiënten, is preventie van complicaties van bariatische chirurgie van groot 
belang.
Huidige richtlijnen stellen dat longfunctietesten voor de operatie niet standaard 
nodig zijn bij patiënten zonder bewijs voor longziekten(26). In hoofdstuk 2 hebben we 
reeds laten zien dat symptomen passend bij luchtwegziekten vaak onbetrouwbaar 
zijn in morbide obese patiënten, maar ook dat kortademigheid soms ten onrechte 
wordt toegewijd aan obesitas in plaats van astma (onderdiagnose). Dit alles tezamen 
was de reden om in een cohort te kijken naar de relatie tussen longfunctiestoornissen 
en complicaties van bariatrische chirurgie. In hoofdstuk 6 hebben we laten zien dat 
patiënten met complicaties binnen 30 dagen na bariatrische chirurgie vaker luchtweg-
reversibiliteit of luchtwegobstructie hebben(27). Wij zijn dan ook van mening dat, juist 
omdat symptomen passend bij luchtwegziekten vaak onbetrouwbaar zijn in de mor-
bide obese populatie, longfunctietesten een routinematig onderdeel zouden moeten 
zijn van de pre-operatieve risico inschatting.
Zover wij weten zijn er zes prospectieve studies gepubliceerd die hebben gekeken naar 
het effect van bariatrische chirurgie bij obese astma patiënten(28-33). Deze zes studies con-
cluderen dat luchtwegfunctie en astma controle sterk verbeteren met gewichtsverlies 
na bariatrische chirurige bij obese astma patiënten. Echter, de aantallen onderzochte 
patiënten in deze zes studies waren maar klein. Daarnaast hadden ze of geen (follow-
up) van een controle groep van niet-astma patiënten na bariatrische chirurgie of geen 
controle groep van obese astma patiënten die geen bariatrische chirurgie ondergingen.
In hoofdstuk 7 hebben we uitgebreid gekeken naar zowel klachten als allerlei klini-
sche parameters, systemische en bronchiale ontsteking voor en na bariatrische chirurgie 
in morbide obese astma patiënten en morbide obese controles(34). Ondanks dat we geen 
verbetering vonden in luchtwegobstructie (onze primaire uitkomstparameter FEV1/
FVC), vonden we wel verbetering in astma-controle (gemeten met de ACQ vragenlijst), 
kwaliteit van leven, medicatie-gebruik en bronchiale hyperreactiviteit (longen die 
te sterk reageren op prikkelende stoffen, uitgedrukt middels PD20 metacholine). De 
significante verbetering in kleine luchtwegen functie (R5-R20) na bariatrische chirurgie, 
welke geassocieerd was met BMI, ACQ en PD20, suggereert dat de kleine luchtwegen een 
grote rol spelen in de relatie tussen obesitas en astma. Tenslotte daalden na bariatrische 
chirurgie ook de markers van systemische ontsteking, en het aantal mestcellen (een 
type ontstekingscellen) in de luchtwegen van obese astma-patiënten. Tezamen bena-
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drukken deze resultaten dat door bariatrische chirurgie geïnduceerd gewichtsverlies de 
hoeksteen van de behandeling van morbide obese astma patiënten zou moeten zijn.
De studies uit dit proefschrift laten zien dat de interacties tussen obesitas en astma een 
complex karakter hebben. De epidemiologische relatie tussen astma en obesitas bewijst 
geen causaliteit, en kan niet geheel verklaard worden door overdiagnose van astma, 
zeker omdat ook onderdiagnose van astma voorkomt binnen de obese populatie. Het 
benadrukt nogmaals de noodzaak tot een strikte diagnose van astma bij morbide obese 
personen. Het feit dat we een relatie vonden tussen luchtwegobstructie en eosinofielen 
in het perifere bloed, met name bij patiënten met het metabool syndroom, wijst weer 
op een mogelijke causale relatie tussen obesitas en astma. Dit werd echter weer tegen-
gesproken door het feit dat we geen verschil in bronchiale inflammatie vonden tussen 
morbide obese patiënten met of zonder astma. Ondanks dat we wel aanwijzingen 
vonden voor meer systemische inflammatie, vonden we dus geen pathofysiologische 
verklaring in de bronchus biopten waarom deze patiënten “astma” hebben.  Daarmee 
rijst de vraag of astma bij morbide obese populatie een specifiek fenotype is, zonder 
eosinofiel of neutrofiel gedreven inflammatie. Echter, ondanks de afwezigheid van 
bronchiale inflammatie, lijkt substantieel gewichtsverlies door bariatrische chirurgie 
longfunctie, kwaliteit van leven en systemische inflammatie te verbeteren bij zowel 
morbide obese astma patiënten als morbide obese controles. Dit houdt in dat gewichts-
verlies de hoeksteen van de behandeling van het morbide obese astma fenotype is. En 
deze temporale relatie is weer een aanwijzing voor een causale relatie tussen obesitas 
en astma.
Een goede verklaring waarom de ene morbide obese patiënt wel “astma” heeft en de 
ander niet, hebben we nog niet gevonden. Ondanks onze eerdere aanwijzingen voor 
een mogelijke rol voor het metabool syndroom, konden we deze niet terugvinden in 
beide studies met bronchusbiopten. Daarnaast kan het zijn dat obesitas een factor is die 
astma verergert, maar niet veroorzaakt. Wellicht dat de kleine luchtwegen hier toch een 
grotere rol in spelen. Middels longfunctieonderzoek hebben we hier wel aanwijzingen 
voor gevonden. Met name centrale adipositas – oftewel de appelvorm in tegenstelling 
tot de peervorm – zou compressie kunnen geven op de kleine luchtwegen.
Omdat gewichtsreductie een belangrijk onderdeel van de behandeling is, zou mijns 
inziens astma, net als hypertensie of diabetes mellitus, een van de ziekten moeten wor-
den waarbij bariatrische chirurgie al geïndiceerd is vanaf een BMI van 35 kg/m2. Nader 
onderzoek is nodig om aan te tonen of de bovengenoemde effecten van bariatrische 
chirurgie ook blijven bestaan na langere follow-up. Ook onderzoek naar de rol van de 
kleine luchtwegen bij morbide obese astma patiënten is noodzakelijk. Tenslotte, is het 
effect van longrevalidatie voor bariatrische chirurgie een interessant onderwerp van 
verder onderzoek, en kan het mogelijk tonen of longrevalidatie het aantal complicaties 
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na bariatrische chirurgie kan verlagen, en aantonen of longrevalidatie überhaupt enig 
effect heeft bij (morbide) obese astma patiënten.
Alles tezamen genomen, ben ik ondanks het feit dat nader onderzoek naar met name 
de rol van de kleine luchtwegen nodig is, van mening dat er een causale relatie bestaat 
tussen obesitas en astma.
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%EWL: percentage excess weight loss
ACQ: Asthma Control Questionnaire
AQLQ: Asthma Quality of Life Questionnaire
ASA: American Society of Anesthesiologists
BHR: bronchial hyperresponsiveness
BMI: Body Mass Index
COPD: chronic obstructive pulmonary disease
CRP: C-reactive protein
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eNO: exhaled Nitric Oxide
ERV: expiratory reserve volume
ESS: Epworth Sleepiness Scale
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HDL: High-density lipoprotein




NCEP-APT III: National Cholesterol Education Program’s Adult Treatment Panel III report
OSAS: Obstructive Sleep Apnea Syndrome
RV: Residual volume
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